SIGA rockt mit Pocken-Medikament! - 500 Beiträge pro Seite

[erbla]

+160%!!!

[Buddah]

Wahnsinn!
http://finance.yahoo.com/q?s=SIGA

[erbla]

Antwort auf Beitrag Nr.: 24.700.917 von Buddah am 18.10.06 14:25:44

+210%!!!

[mrsun]

hallole
konnte grade noch mein vk limit nach oben korigieren,hätte mich sonst glatt rausgekauft.

wooooooooooow

[bauspara]

Antwort auf Beitrag Nr.: 24.700.980 von erbla am 18.10.06 14:28:57

fuck ich hab kein fill bekommen!

wollt bei 4.99 und 5.55

[Buddah]

wer hat hier denn heute Mittag (in Deutschland) gekauft?
Glückwunsch! sind beide über 100& vorne...

[erbla]

Antwort auf Beitrag Nr.: 24.701.110 von Buddah am 18.10.06 14:35:18

Bin unter pari in F im Verkauf, wer welche haben will, nur zu.

[Buddah]

TOP INSTITUTIONAL HOLDERS
DRESDNER BANK AG
http://finance.yahoo.com/q/mh?s=SIGA
na,wenigstens sind ein paar Deutsche dabei!

[mrsun]

Antwort auf Beitrag Nr.: 24.701.110 von Buddah am 18.10.06 14:35:18

bin schon seit anfang oktober drin,leider zu hoch bei 1,5€,aber geduld zahlt sich doch immer aus

[Buddah]

Der Makler stellt gar kein ASK rein!was willst Du?

[mrsun]

ich hab mich mal auf 12$ zurückgezogen,aber ich glaub ich muß noch weiter zurück

[erbla]

Antwort auf Beitrag Nr.: 24.701.219 von Buddah am 18.10.06 14:40:54

Ca. 6% unter pari.

[Buddah]

verzeih mir erbla, aber ich tue mich sehr schwer bei ca.200% noch draufzuspringen.Wie sagte Kostolany so schön:"„Einer Straßenbahn und einer Aktie darf man nie nachlaufen. Nur Geduld: Die nächste kommt mit Sicherheit.“
Glückwunsch euch!

gruss B.

[erbla]

Antwort auf Beitrag Nr.: 24.701.548 von Buddah am 18.10.06 14:56:03

Vielleicht hat ja jemand die Möglichkeit, in die US-Vorbörse zu verkaufen, für den wär das sicher interessant.

[Buddah]

Antwort auf Beitrag Nr.: 24.701.548 von Buddah am 18.10.06 14:56:03

zumal ich erst kürzlich bei CELL THERAPEUTICS INC mitten ins Up-Gap gekauft habe.und statt die Verluste sofort zu realisieren zu lange gezögert habe.siehe mitte Sep.:

[mfierke]

kann man leider nur zuschauen

[erbla]

Antwort auf Beitrag Nr.: 24.701.614 von Buddah am 18.10.06 14:59:20

CTIC hab ich auch übelst draufgezahlt.

[Buddah]

Antwort auf Beitrag Nr.: 24.701.763 von erbla am 18.10.06 15:05:28

war allerdings auch eine Sauerei.Erst der Novartis Deal,dann die Platzierung...

[erbla]

Antwort auf Beitrag Nr.: 24.701.810 von Buddah am 18.10.06 15:07:42

Sauerei ist das richtige Wort. Man hätte es sich ja denken können, als die an dem ersten Tag bei der Meldung bei glaub ca. +/-0 geschlossen hat. Da wussten wieder einige, was am nächsten Tag noch nachkommt.

[Buddah]

Antwort auf Beitrag Nr.: 24.701.881 von erbla am 18.10.06 15:11:32

stimmt!

[mrsun]

halb fünf vorbei,und die hälfte der firma hat den besitzer gewechselt,im schnitt zu 5$
wahnsinn

[spekulativ]

was für ein schöner tag

gruß spekulativ

[mrsun]

gleich ist die ganze firma einmal gehandelt
dann ist alles möglich,vielleicht auch kursaussetzung
ich hab mich schon mal in den dreistelligen bereich zurück gezogen
sicher ist sicher

[whyso]

Das sagt schon viel aus...

[whyso]

-Siga smallpox treatment offers 100% protection-


"We are particularly pleased because the amount of virus used in this study is equivalent to the level present in late-stage disease in humans, which we believe signals that SIGA-246 can be used to prevent disease in humans," said Dr Dennis Hruby, Chief Scientific Officer of Siga. "This test in non-human primates is as close as anyone can get to the real thing because there has not been any natural occurrence of smallpox since 1977."

Smallpox is considered one of the most significant biowarfare threats. Smallpox is readily transmitted between humans, it has significant mortality rates and the population is no longer vaccinated against it. At this time, there is also no approved treatment for smallpox.

Siga previously announced that SIGA-246 has been shown to be safe to administer to humans as a once-a-day pill. In December 2005, the FDA granted "fast-track" status to SIGA-246.

[mrsun]

SIGA Announces $9.0 Million Private Placement
SIGA Technologies, Inc. (NASDAQ: SIGA) announced today that on October 18, 2006 it entered into a Securities Purchase Agreement for the issuance and sale to institutional investors of 2,000,000 shares of the company's common stock at $4.54 per share and warrants to purchase 1,000,000 shares of the company's common stock. The warrants are exercisable at any time and from time to time through and including the seventh anniversary of the closing date at an exercise price equal to 110% of the closing price of the company's common stock on October 18, 2006.

The sale of common stock and warrants to purchase common stock was placed by, Empire Financial Group (EFH: AMEX) and The Shemano Group, institutional brokerage firms in San Francisco, CA.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). SIGA's product development programs also emphasize the increasingly serious problem of drug resistant bacteria.

For more information about SIGA, please visit SIGA's Web site at www.siga.com.

Forward-looking Statements

This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products and (f) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.


SIGA Technologies, Inc.
Tom Konatich, 212-672-9100
Chief Financial Officer & Acting CEO



Source: Business Wire (October 19, 2006 - 7:53 AM EST)

News by QuoteMedia
www.quotemedia.com

[whyso]

Antwort auf Beitrag Nr.: 24.721.283 von mrsun am 19.10.06 15:03:14

Dann haben sie genug Geld um das ganze alleine durchzuziehen...

Gelegenheit mmacht Diebe

[mrsun]

wieso alleine?ich glaub hier weiß keiner so richtig bescheid
dann schau mal hier:http://www.pharmathene.com/pdf/news250906.pdf

[whyso]

Antwort auf Beitrag Nr.: 24.722.796 von mrsun am 19.10.06 15:58:34

@MR.Sun-lesen sie folgende Schlagzeile aus dem Hause SIGA von 4th Oct

SIGA Terminates Merger Agreement with PharmAthene, Inc.

Last Update: 5:10 PM ET Oct 4, 2006


NEW YORK, Oct 04, 2006 (BUSINESS WIRE) -- SIGA Technologies, Inc. (SIGA : siga technologies inc com
News , chart, profile, more
Last: 4.02-0.52-11.45%

12:49am 10/20/2006

Delayed quote dataAdd to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
SIGA4.02, -0.52, -11.5%) disclosed today that it had terminated its Agreement and Plan of Merger with PharmAthene, Inc., pursuant to the terms of that agreement.
In reaching its decision, the SIGA Board of Directors considered many factors, including recent positive scientific data and the receipt of approximately $27 million in grants for its smallpox and arenavirus programs over the last several months, which amount includes a grant of $16.5 million from the National Institutes of Health also announced today.
Donald Drapkin, Chairman of the Board of SIGA, commented, "SIGA is excited about its future and committed to the development and successful completion of its lead product candidate, SIGA-246, a smallpox antiviral treatment, as well as its other anti-viral and anti-infective programs."
About SIGA Technologies, Inc.
SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA has the potential to become a significant force in the discovery of vaccine and pharmaceutical agents to fight emerging pathogens. SIGA's product development programs emphasize the increasingly serious problem of drug resistant bacteria. In addition to smallpox, SIGA has antiviral programs targeting other Category A viral pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg).
For more information about SIGA, please visit SIGA's Web site at www.siga.com.

http://www.marketwatch.com/News/Story/Story.aspx?guid=%7B809…

The want to go it alone... und haben jetzt 9 Mio$ zusätzliches Kapital in der Kriegskasse (und auch ein Grant von 16,1 Mio $ von der NIH (US Regierung) bekommen
http://www.marketwatch.com/News/Story/Story.aspx?guid=%7B022…

Das könnte ein Acor nummer 2 werden!

We will see in time,
Whyso

[mrsun]

Antwort auf Beitrag Nr.: 24.733.436 von whyso am 20.10.06 08:21:50

selbst wenn die das ding alleine durchziehen wollen,sind das dann nur noch peanuts,denn als hauptpreis gibts PROJEKT BIOSHIELD

http://www.hhs.gov/ophep/ophemc/

deshalb einfach nur warten auf viel grün und viel glück

[whyso]

Antwort auf Beitrag Nr.: 24.737.207 von mrsun am 20.10.06 11:12:45

@Mrsun
LESENSWERT...http://www.investologyinc.com/reports/paid/SIGA%20052305.pdf

Viele Grüße,
Whyso

[mrsun]

Antwort auf Beitrag Nr.: 24.739.807 von whyso am 20.10.06 13:12:51

na,lässt sich gut lesen
dann war ich meinem ersten,persönlichen kursziel von 12$ gar nicht so weit entfernt.
zum vergleich nur mal so ein anderer partner von pharmathene
Mon, Oct 16, 2006

6:00 AM Medarex and PharmAthene Announce Phase I Results of Anthrax Therapeutic Valortim(TM) - PR Newswire

und die haben schon lange 12$ unterm kiel

[amorphis]

Antwort auf Beitrag Nr.: 24.739.807 von whyso am 20.10.06 13:12:51

whyso...wußte gar nicht das du auch bei siga investiert bist...

[whyso]

Antwort auf Beitrag Nr.: 24.748.908 von amorphis am 20.10.06 19:14:55

Dabei ist relativ...bin noch im "Aufbau befindlich"

[Joe_Trader]

Antwort auf Beitrag Nr.: 24.810.414 von whyso am 23.10.06 23:42:17

Fehlt der Nachzünder

joe

[goyauno]

Antwort auf Beitrag Nr.: 24.817.889 von Joe_Trader am 24.10.06 13:26:14

hier hast du deine zündung

Great Article on SIGA in Oregon Newspaper (3 Ratings) 33 minutes ago Congratulations SIGA shareholders. Hold and/or accumulate shares over the next year, and watch your net worth skyrocket.

Here's the link: http://www.gazettetimes.com/articles/200...

And here's part of the article--emphasis (in all caps) is mine:

Siga Technologies finds quick payoff from test of smallpox remedy

By BENNETT HALL
Gazette-Times business editor

It’s been a long and bumpy road, but the finish line may be in sight for Siga Technologies in its journey toward profitability.

Like many — if not most — small drug-discovery companies, Siga has burned through millions of dollars and posted year after year of losses as it tried to bring a developmental treatment to market. After a successful animal trial announced last week, however, the company could be on the verge of scoring a major coup with the first effective treatment for smallpox.

“In the biodefense area, smallpox is the number one concern, and we would expect this is going to be our big product,” said Dennis Hruby, Siga’s chief scientific officer and a microbiology professor at Oregon State University.

Smallpox was eradicated in nature 30 years ago but is considered a potential terrorist threat, and no proven treatment for the deadly virus exists. The Defense Department and other federal agencies funded the latest test, conducted on monkeys at a secure Centers for Disease Control facility in Atlanta.

Siga claims its drug, a once-daily pill called Siga-246, showed “100 percent protection” against the smallpox virus, both before and after exposure. The drug previously passed a human safety trial.

Additional tests are needed before the company can request approval from the Food & Drug Administration, but the Defense Department is footing the bill with a $16.5 million grant. . . .

“Siga’s a significantly different company today than it was in February and March,” Konatich said by phone from the company’s New York headquarters Friday. “We will be lobbying and negotiating with various agencies of the federal government for a sale of the drug.”

Konatich declined to speculate on when a deal to supply the drug might be reached or what it might be worth to Siga. But he did say that VARIOUS INDUSTRY ESTIMATES MAKE IT CLEAR THAT THE POTENTIAL MARKET FOR SMALLPOX TREATMENTS IS A LUCRATIVE ONE.

“IT'S IN THE HUNDREDS OF MILLIONS OF DOLLARS, IF NOT MORE,” he said.

OTHER POTENTIAL MARKETS AWAIT OVERSEAS, particularly in Europe. Hruby has been invited to Geneva to make a presentation to the World Health Organization’s advisory council, which he hopes will help spread the word about Siga’s research.

Hruby said Siga-246 can treat monkeypox and related viral diseases, and the firm is ALSO PURSUING DRUG CANDIDATES FOR A RANGE OF OTHER EXOTIC VIRUSES.

“There’s two things: There’s biodefense, and there’s emerging diseases,” Hruby said. “Hopefully, we’ll never need it for biodefense. But it’s nice to have a drug like this on the shelf.”


Sentiment : Strong Buy

[Joe_Trader]

Antwort auf Beitrag Nr.: 24.819.507 von goyauno am 24.10.06 14:24:15

der start der nachzündung sollte aber nicht zu lange auf sich warten lassen ,sonst bringt es nichts

joe

[whyso]

Antwort auf Beitrag Nr.: 24.821.686 von Joe_Trader am 24.10.06 15:49:23

http://tools.thestreet.com/tsc/quotes.html?pg=qcn&symb=SIGA

[Joe_Trader]

Mandatory Anthrax Shots to Return

By Christopher Lee
Washington Post Staff Writer
Tuesday, October 17, 2006; Page A03

The Defense Department will resume mandatory anthrax vaccinations for more than 200,000 troops and defense contractors within 60 days, a Pentagon official said yesterday, rejecting the concerns of some veterans and service members who say that the vaccine has not been proved safe or effective.

The vaccinations will be required for most military units and civilian contractors assigned to homeland bioterrorism defense or deployed in Iraq, Afghanistan or South Korea, said William Winkenwerder Jr., a physician and the assistant secretary of defense for health affairs. As troops rotate in and out of those regions, the number receiving vaccinations will grow considerably, he said.

Biotechnology

Researchers and regulators are reshaping the landscape of science, medicine and health, engendering hope -- and disquiet -- for the future of humanity.

* Essay: Cooking With Clones? The Possibilities Are Many.
* Gov't Panel Recommends Shingles Vaccine
* ImClone Names Icahn Chairman; Shares Up
* Actors, Athletes to Be in Stem-Cell Ad
* Michael J. Fox ignites stem-cell debate
More News

Who's Blogging?
Read what bloggers are saying about this article.

* Drudge Retort: califchris's blog
* Armchair Generalist
* Multiple Sclerosis Fact Sheet


Full List of Blogs (12 links) »

Most Blogged About Articles
On washingtonpost.com | On the web

Save & Share Article What's This?
Digg
Google

del.icio.us
Yahoo!

Reddit

A lawsuit filed by six former or current service members had blocked the mandatory vaccinations since October 2004, when U.S. District Judge Emmet G. Sullivan ruled that the Food and Drug Administration had erred in approving the vaccine in 2003 without seeking public comment and conducting a full review.

But the FDA then held a 90-day comment period to overcome that hurdle and granted the vaccine final approval last December, clearing a legal path for the Pentagon to resume the controversial program.

"The FDA went out again . . . and came to the very unambiguous and clear conclusion that the vaccine was safe and it was effective against all forms of exposure," Winkenwerder said. "In our view, that has definitively settled the question."

But Mark Zaid, an attorney for the six plaintiffs, said yesterday that Sullivan's ruling and the Pentagon's remedy both turned on procedural technicalities. The plaintiffs plan to file a new lawsuit challenging the government's contention that human studies from the 1950s and more recent studies in animals demonstrated the safety and efficacy of the vaccine.

"It is an unnecessary, unproven and potentially unsafe vaccine," Zaid said. "Everyone is concerned as to their health, and the fact is that there is no scientific evidence that the vaccine works in humans. . . . I think this program is nothing more than a glorified public relations campaign to demonstrate that they are doing something."

Anthrax is a deadly infectious disease caused by the spore-forming bacterium Bacillus anthracis . A month after the Sept. 11, 2001, attacks, letters tainted with anthrax infected people in Connecticut, Florida, New Jersey, New York and the District. The unsolved attacks killed five people, sickened 17 and caused about 10,000 to be put on antibiotics.

Although the previous anthrax attacks occurred on U.S. soil, Winkenwerder said troops overseas are believed to be a higher risk, and military personnel in the United States do not have to receive the six shots.

"I have not been vaccinated because I'm not in any of the targeted groups," Winkenwerder said. "If I was, I would receive the vaccine without hesitation."

The Clinton administration began the mandatory vaccinations in 1997. Over the next few years, hundreds of active-duty service members refused to take the vaccine, and more than 100 were court-martialed as a result. Winkenwerder said that 27 people refused the vaccine and left the military in 2003, and that 10 did so in 2004. A voluntary vaccination program that Sullivan allowed last year saw participation rates of 50 percent, Winkenwerder said. In all, more than 1.2 million military and civilian personnel have received the vaccine.

Some who received vaccinations for anthrax and smallpox around the time of the 2003 invasion of Iraq have complained of fatigue, migraines, pain and diseases such as multiple sclerosis.

Winkenwerder said that, as with any vaccine, some who receive the shots develop adverse reactions, but that there is no evidence to indicate a particular problem with the anthrax vaccine.

But as recently as this spring, the Government Accountability Office, the investigative arm of Congress, said questions remain about the vaccine. "The long term safety of the licensed vaccine has not been studied," the agency said in a May 9 report. ". . . Also, there is some evidence that the current anthrax vaccine may have diminished efficacy against certain virulent strains of anthrax."

Barbara Loe Fisher, president of the National Vaccine Information Center, said her nonprofit advocacy group is adding more information to its Web site about the research and development of biological defense vaccines.

"The DOD has a moral duty to fully disclose anthrax vaccine risks, as well as benefits, to soldiers and allow them to make an informed, voluntary decision," she said in a statement.

http://www.washingtonpost.com/wp-dyn/content/article/2006/10…

----------------------------------------------
joe

[Joe_Trader]

October 25, 2006: The U.S. Department of Defense will resume mandatory anthrax vaccinations by the end of the year. Over 200,000 military personnel (and some contractors and Department of Defense civilians) will be vaccinated. Most of these will be members of biological weapon defense units, or those serving in the Middle East or Korea. Court challenges to such vaccinations had caused the Department of Defense to fall back on voluntary compliance. But only about half the people who needed the vaccinations got them voluntarily. So, after slogging through the courts for over a year, the mandatory vaccinations were restored.



Giving anthrax and smallpox vaccinations to troops caused some controversy, and a court injunction, despite the fact that thousands of medical and agricultural workers regularly get anthrax vaccinations, and that until the 1970s, nearly everyone was vaccinated for smallpox. The controversy arose from the fact that, with any vaccination, a small percentage (usually a fraction of one percent) of those receiving the vaccination will get sick. A few people will even die. But when your chance of exposure to much more lethal diseases like anthrax and smallpox is high, the small vaccination risk is considered a reasonable trade off. The Department of Defense vaccination program is to protect troops against the possible terrorist use of biological weapons. The problem here is that there is no agreement on how likely that is to happen. Thus the real risk of adverse reaction to a vaccination looms larger than the threat of catching the disease itself. Out of 750,000 troops originally vaccinated for anthrax, about 30 refused, and were all punished for disobeying orders. It was from this group that the legal actions originated. The scientific community finally convinced the courts that giving the troops anthrax vaccinations was a safe and sound thing to do.

Another 625,000 troops have been vaccinated for smallpox, with no refusals.

----------------------------------------------------

[Joe_Trader]

http://www.strategypage.com/htmw/htchem/articles/20061025.as…


joe

[Joe_Trader]

tja , infos sind aus dem yahoo board.

ob es auswirkungen bezügl. der presseberichte für/auf siga hat ??

[Joe_Trader]

das posting fand ich interessant.
http://messages.finance.yahoo.com/Healthcare/Biotechnology_a…

joe

[whyso]

Watch this space



und die Siga Blogs stellen die wahre Möglichkeiten hinter dieser Biotechperle mittlerweile etwas genauer dar

http://www.thestreet.com/_mktw/newsanalysis/investing/103166…

Good trades & steady hands mit SIGA,
Whyso

[mrsun]

hallo whyso

hab versucht mal´n bisschen mehr über siga und pharmathene raus zu finden.der artikel ist zwar schon etwas älter aber interessant.

http://www.nyba.org/news/member_news/mar142006_4.shtml

weiterhin viel grün

[mrsun]

auch schon´n paar tage alt aber gut

http://www.kval.com/news/4448787.html

[whyso]

Dr. Huggins commented, "This drug holds great promise as a therapy for poxvirus infections." Donald Drapkin, Chairman of SIGA, added, "Smallpox is one of the great biowarfare threats, and SIGA-246 demonstrates SIGA's leadership in efforts to counteract that threat."

Smallpox is considered one of the most significant biowarfare threats. The CDC classifies variola, the virus that causes smallpox, as a "Category A" (highest level threat) bioterrorism agent. Smallpox is readily transmitted between humans, it has significant mortality rates and the population is no longer vaccinated against it. Mass immunizations of the general population using the current live vaccine are not recommended, as there are known complications affecting some individuals, which may include encephalitis, myocarditis, and death. Immunocompromised individuals receiving this vaccine are at particular risk from a systemic infection. At this time, there is also no approved treatment for smallpox.


Virus Behandlung "History in the making"
Good trades & steady hands,
Whyso

[mrsun]

Form 10-Q ist draußen

[whyso]

Hi Mr.Sun!

schau dir die jetzt folgende Link näher an:
http://www.fbo.gov/spg/USAF/AFDW/11CONS/Awards/FA7014%2D07%2…

Tja, noch ein 1Million dollar Kontrakt an land gezogen mit der US Army...und ich habe das gefühl das ist nur die Spitze des Eisbergs gewesen

Schönes Wochenende,
Whyso

[mrsun]

Antwort auf Beitrag Nr.: 25.107.748 von whyso am 03.11.06 17:28:08

hallo whyso
super recherchiert,bin auch der meinung daß hier noch viel kommen wird,auch wenn wir die 3§ noch ein weilchen sehen werden.
ich denke hier wird im moment kräftig eingesammelt,bevor es zum nächsten abflug kommt.
als bonus hier noch ein anderes unternehmen das kurz vor nasdaq listing steht und um 1§ rangiert.
ZixIt Corp. ticker symbol ZIXI
ist auch in DE gelistet,wird aber nichts verkauft,will in USA gekauft werden.

schönes wochenende

[amorphis]

das was kommt ist def klar!das volumen was wir hier hatten...das kam nicht von ungefähr!

[whyso]

Ein 15$ stock, heute für 2,90 €in Frankfurt zu haben...

http://www.investologyinc.com/reports/paid/SIGA%20052305.pdf

Time will tell,
Whyso

[mrsun]

Antwort auf Beitrag Nr.: 25.196.594 von whyso am 07.11.06 17:17:45

hi whyso
Ausbruchversuch heute,oder bald News?!! Was denkst Du!

[whyso]

Antwort auf Beitrag Nr.: 25.197.413 von mrsun am 07.11.06 17:51:48

Das Gericht "brödelt vor sich hin" in der Siga Küche z.Zt

Aber heute haben wir die ersten Hinweisse wieder bekommen/ gesehen/erlebt seit der rasante Anstieg das "interessierte parties" hier an die seitenline standen, und weiterhin stehen

Watch that old Pie-chart:





http://thomson.finance.lycos.com/lycos/iwatch/cgi-bin/iw_act…

Steigende Grüße,
Whyso

[whyso]

Antwort auf Beitrag Nr.: 25.197.413 von mrsun am 07.11.06 17:51:48

"Ausbruchversuch heute,oder bald News?!! Was denkst Du"

...beides

[mrsun]

Antwort auf Beitrag Nr.: 25.198.386 von whyso am 07.11.06 18:41:23

In den Ami-boards wird kaum kenntnis genommen,und man findet kaum Hinweise.
Selbst auf Infiniti steht nichts über denn Air Force Deal,und die hatten seit 27.Sept bis gestern,SIGA auf Stocks to Watch.

[mrsun]

uuups,und die 4$ waren wieder da

[mrsun]

Unser Big Brother wird auch immer beliebter
http://www.pharmathene.com/pdf/news06NOV2006.pdf

und was macht Medarex
Tue, Nov 07, 2006
6:01 AM Medarex and PacMab Announce Therapeutic Antibody Co-Development Agreement - PR Newswire

muss zwar nichts bedeuten,aber vielleicht doch

[amorphis]

SIGA Technologies Inc.
07.11.06 22:00 Uhr

4,27 USD

+27,46 % [+0,92]


was fürn volumen zuletzt....

[mrsun]

das Ding geht weiter,look quotemedia

[amorphis]

https://secure.reuters.com/ecommerce/Catalog/ReportDetail.as…

The fundamental factors that we factor into our analysis and valuation have considerably strengthened
for SIGA in recent weeks as a number of important developments took place:

- The proposed merger with PharmAthene has been cancelled thus removing the related uncertainties
and unknowns that complicated or prevented a complete analysis of SIGA.

- SIGA-246 fully protected monkeys from a variant of the smallpox virus that it prevented from
becoming infective by blocking the action of a viral enzyme that is necessary for the assembly of an
envelope protein (p37) without which the virus is unable to get out of the host (invaded) cells. As a
result, the virus becomes trapped inside the cell and is unable to spread to other cells; the virus is no
longer infective! This specific viral enzyme is also present in the smallpox virus against which SIGA-
246 should also protect. Moreover, the studies in monkeys confirmed the results of earlier studies in
rodents in which SIGA-246 fully protected rodents against all varieties of the poxvirus that were
tested. SIGA-246 has thus successfully completed both of the efficacy tests required under the “twoanimal
rule.”

- SIGA-246 appeared safe and to be well tolerated in a Phase I trial on healthy volunteers that was
completed in June 2006.

- The Company is now preparing to submit the Phase I trial results to the FDA as part of seeking
authorization to proceed with the Phase III trials that are necessary for obtaining the data for
statistical proof of efficacy and safety that is required by the FDA.

- The Company has recently obtained close to $21 million in additional funding for completing the
development of SIGA-246 and submitting an NDA for it to the FDA.

Factoring the above developments into our valuation model for SIGA and using conservative
assumptions, we now estimate at 80% (up from our previous 35% - see our December 9, 2005 update)
the probability that it will be approved in early 2008 and will generate revenues of $400 million and
fully diluted EPS of $1.30 in FY09.

Assuming this stock will have a P/E of 10 by the end of FY09, its price will then be $13.00 (fully
diluted). To calculate a 12-month Price Target for SIGA, we discount back by two years its future
value of $13.00 in FY09 using an annual discount factor of 0.129 that combines the current 3-year,
risk-free 4.80 % Treasury yield (source: Bloomberg.com - October 20, 2006) and a 100% - 80% or
20% risk factor. The resulting 12-month Price Target is $10.20. Discounting back by three years,
we calculate a risk-adjusted Present Value of $ 9.04 for this stock, up from our previous $4.50 (see
Dec 9, 2005 update) for this stock that has traded in the $2.00 to $5.50 range in recent days.

Conclusion
We believe that SIGA may begin selling its first product, the smallpox antiviral SIGA-246 and
achieve EPS of $1.30 on revenues of $406 million in FY09.
We raise our rating on SIGA to Buy from Neutral and our 12-month Price Target to $10.20 from
our previous No Price Target.

[whyso]

Good Reading links (and combination) work:

ttp://triad.bizjournals.com/triad/stories/2006/10/02/story1.…

Sigas Personal:
http://www.siga.com/1d_MgmtPersonnel.html

In my humble opinion they are cooking a real "big goose" here,

Good trades & steady hands,
Whyso

[e-mail], bis ende November will man die gesamte Army Aufträge angeblich genannt haben ((((N.B. ich habe hierfür keine "nenneswerte" Quelle den ich hier angeben könnte )))))

[whyso]

Jeder spricht mal von "Deep pocket" Investors...ein solches gibt es tatsächlich im Fall -SIGA- Please welcome Mr.Perlemann

PERELMAN SCORING ON DESIGNER DRUGS-By PAUL THARP

October 19, 2006 -- Buyout billionaire Ron Perelman's companies picked up a tidy paper profit of $32.7 million on their stakes in a small biotech company which reported a breakthrough for an overnight antidote to smallpox bioweapons.

While best known for controlling cosmetics giant Revlon, Perelman is deep into designer drugs - one that'll prevent Alzheimer's, and three others that'll shield users from even the most vile bioweapons.

Shares in SIGA Technologies soared 130 percent after it said tests on monkeys exposed to smallpox were cured completely in 24 hours, the first drug to demonstrate 100 percent protection against the sometimes fatal disease.

Currently, SIGA is testing the drug on healthy human volunteers at a research facility in Hackensack, N.J., giving them a single dose daily.

Shares jumped $2.57 to $4.54. Perelman controls 44 percent of the stock through several entities.

Just a month ago, Perelman separately raked in big profits on his Alzheimer's cure project after Pfizer paid $155 million to Perelman's other biotech firm, TransTech Pharma, to develop a blocker to the ailment. Perelman has bankrolled the project since 2000. Perelman, 63, and in reported good health, is also in the process of merging his two biotech outfits with a third biotech firm, PharmAthene, whose lead product, Valortim, is a protective vaccine against weapons-grade anthrax. PharmAthene recently gobbled up another small firm, Nexia, that developed Protexia, an antidote to weapons-grade nerve gas.

His SIGA firm also has developed a product to fight vicious hemorrhagic viruses that can cause organs and brains to rupture within hours, such as the Ebola virus.

SIGA has burned through more than $20 million in the past two years, but has offset the losses by collecting more than $39 million in grants from the U.S. Army and National Institutes of Health to develop the defenses to biowarfare. Perelman and other investors have poured about $58 million into SIGA in the past several years.

The Pentagon is poised to write more than $6 billion in checks to companies that develop defenses to the military's five most dreaded bioweapons: inhalable anthrax, nerve gas, smallpox, botulism toxins and hemorrhagic viruses.

Friends say Perelman 15 years ago helped bankroll the first cure to a certain form of breast cancer affecting about a quarter of women, but he didn't make a dime on it.

He personally spent $1 million a year to help a Hollywood friend - Dr. Denny Slamin, the personal physician to the late NBC chief Brandon Tartikoff - develop Herceptin.

The drug today makes millions, but Perelman let UCLA retain the license to help support a breast cancer center. [e-mail]

http://www.nypost.com/seven/10192006/business/perelman_scori…

Ich behaupte mal wir haben es hier mit (im frühen Stadion befindlichen) "Acor" zu tun:


Gelegenheit macht Diebe,
Whyso

[goyauno]

Press Release Source: SIGA Technologies, Inc.


SIGA Passes Another Milestone with Smallpox Drug SIGA-246
Thursday November 9, 1:17 pm ET


NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) announced today the successful results of two independent primate trials of its smallpox drug SIGA-246. Last month, SIGA announced that SIGA-246 provides complete protection against human smallpox virus in nonhuman primates. The current trials involve infection with high doses of monkeypox virus, which may be lethal in primates if left untreated. SIGA-246 again afforded complete protection against disease symptoms. As with the primate trial last month and the human safety trial announced earlier this year, the current trials also demonstrate that SIGA-246 should be safe as well as effective.
ADVERTISEMENT


The first monkeypox virus study was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) and conducted at the Lovelace Respiratory Research Institute in Albuquerque, NM. In this study, all monkeys in the two groups receiving SIGA-246 (different dosages) were completely protected from disease.

The second study was conducted at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and was funded by the Department of Defense's Defense Threat Reduction Agency under the supervision of Dr. John Huggins, Chief of the Viral Therapeutics Branch. In the second study, two groups of nonhuman primates received SIGA-246 orally starting either one day post-infection or three days post-infection. Again both treatment groups were completely protected from disease.

"Taken together with the recent breakthrough results from the smallpox virus study, the data continue to support the use of SIGA-246 as the first drug available to prevent and treat disease caused by pathogenic poxviruses without significant side effects," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA. He added, "These are very important results for two reasons. First, in many respects monkeypox infections in non-human primates are more aggressive than infection with smallpox virus (normally a human pathogen), so protection by SIGA-246 represents a higher hurdle. Second, SIGA will likely use SIGA-246's performance against monkeypox infection in monkeys, along with the results in all of the several animal species tested to date, to satisfy FDA's efficacy requirements, so success here bodes well."

SIGA previously announced that SIGA-246 has been shown to be safe to administer to humans as a once-a-day pill. SIGA-246 has also demonstrated 100% disease protection in several mouse models of infection, which results SIGA will use, along with results from additional tests yet to be completed, to fulfill the U.S. Food and Drug Administration's "Animal Efficacy Rule." In December 2005, the FDA granted "fast-track" status to SIGA-246.

The Department of Homeland Security has designated smallpox a "material threat" to our national security, so SIGA-246 will be eligible for purchase for the Strategic National Stockpile under Project Bioshield.

In addition to smallpox, SIGA has antiviral programs targeting other Category A viral pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and LCM), flaviruses (Dengue), and the filoviruses (Ebola and Marburg), each of which presents a substantial, unmet medical need.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA is a leading company in the discovery of pharmaceutical agents to fight emerging pathogens. SIGA leverages its proprietary technologies through multiple strategic partners, including the National Institutes of Health and TransTech Pharma, Inc. For more information about SIGA, please visit SIGA's Web site at www.siga.com.

About the National Institute of Allergy and Infectious Diseases (NIAID)

NIAID, an institute within the U.S. National Institutes of Health, conducts and supports research to study the causes of allergic, immunologic and infectious diseases, and to develop better means of preventing, diagnosing and treating these illnesses. NIAID is headquartered in Bethesda, Maryland.

About the Defense Threat Reduction Agency

The Defense Threat Reduction Agency (DTRA) is an agency of the U.S. Department of Defense that safeguards America and its allies from weapons of mass destruction by providing capabilities to reduce, eliminate, and counter the threat, and mitigate its effects. DTRA headquarters is located at Fort Belvoir, Virginia, and it also operates field offices worldwide. The DTRA has identified an orthopox therapeutic as a critical need in its ongoing threat reduction efforts.

About the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a critical role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Material Command.

The information contained in this press release does not necessarily reflect the position or policy of the U.S. government, and no official endorsement should be inferred.

Forward-looking Statements

This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products and (f) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.



Contact:
SIGA Technologies, Inc.
Thomas N. Konatich, 212-672-9100
Chief Financial Officer & Acting CEO

--------------------------------------------------------------------------------
Source: SIGA Technologies, Inc.

[mrsun]

na also

The Department of Homeland Security has designated smallpox a "material threat" to our national security, so SIGA-246 will be eligible for purchase for the Strategic National Stockpile under Project Bioshield

oder anders ausgedrückt
´´das Ding geht glatt,sagte der Henker und seifte den Strick ein´´

[whyso]

Getting ready for Take off...



Gestern wurde SIGA 13.980 mal gehandelt an der Nasdaq & hat ein Handelsgegenwert von 28,79 Mio USD generiert...diese Tatsache sollte Langsam aufhorchen lassen

In addition to smallpox, SIGA has antiviral programs targeting other Category A viral pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and LCM), flaviruses (Dengue), and the filoviruses (Ebola and Marburg), each of which presents a substantial, unmet medical need.


Naja, mal sehen sagt der Blinde!
Whyso

[goyauno]

Friday, November 10, 2006
Last modified Sunday, October 22, 2006 10:25 PM PDT


CASEY CAMPBELL/Gazette-Times
At Siga Technologies’ Corvallis research labs, Eric Stavale works on a possible treatment for the Dengue virus. Siga got a big cash infusion last week after announcing progress on an experimental smallpox treatment.

Healthy development



Siga Technologies finds quick payoff from test of smallpox remedy

By BENNETT HALL
Gazette-Times business editor

It’s been a long and bumpy road, but the finish line may be in sight for Siga Technologies in its journey toward profitability.


Like many — if not most — small drug-discovery companies, Siga has burned through millions of dollars and posted year after year of losses as it tried to bring a developmental treatment to market. After a successful animal trial announced last week, however, the company could be on the verge of scoring a major coup with the first effective treatment for smallpox.

“In the biodefense area, smallpox is the number one concern, and we would expect this is going to be our big product,” said Dennis Hruby, Siga’s chief scientific officer and a microbiology professor at Oregon State University.

Smallpox was eradicated in nature 30 years ago but is considered a potential terrorist threat, and no proven treatment for the deadly virus exists. The Defense Department and other federal agencies funded the latest test, conducted on monkeys at a secure Centers for Disease Control facility in Atlanta.

Siga claims its drug, a once-daily pill called Siga-246, showed “100 percent protection” against the smallpox virus, both before and after exposure. The drug previously passed a human safety trial.

Additional tests are needed before the company can request approval from the Food & Drug Administration, but the Defense Department is footing the bill with a $16.5 million grant.

The news of a successful test triggered a financial windfall for Siga, which employs 50 people at its Corvallis research labs.

On Wednesday, the day the test results were announced, the company’s stock price more than doubled, shooting up to $4.54 a share after languishing at around $1 for most of the last year.

On Thursday, the company completed a $9 million private stock placement with some of its longtime institutional investors. Five hedge funds — Iroquois Master Fund, Cranshire Capital, Omicron Master Trust, Rockmore Investment Master Fund and Smithfield Fiduciary — bought the issue, consisting of 2 million shares of common stock at $4.54 a share. They also received warrants for an additional 1 million shares exercisable at $4.99 a share.

“It gave us the opportunity to bring in some cash quickly at a nice price,” said chief financial officer and acting CEO Tom Konatich, who’s been with the biotech firm for eight years. “Our balance sheet right now is about as strong as it’s been during my tenure.”

The stock placement caps a resurgence for Siga, which had entered a merger agreement last spring with an East Coast biotech company and faced delisting from the Nasdaq exchange this summer as its market capitalization slipped.

Now, with its cash reserves recharged and a smallpox drug marching toward approval, the merger is off and Siga is on the rebound.

“Siga’s a significantly different company today than it was in February and March,” Konatich said by phone from the company’s New York headquarters Friday. “We will be lobbying and negotiating with various agencies of the federal government for a sale of the drug.”

Konatich declined to speculate on when a deal to supply the drug might be reached or what it might be worth to Siga. But he did say that various industry estimates make it clear that the potential market for smallpox treatments is a lucrative one.

“It’s in the hundreds of millions of dollars, if not more,” he said.

Other potential markets await overseas, particularly in Europe. Hruby has been invited to Geneva to make a presentation to the World Health Organization’s advisory council, which he hopes will help spread the word about Siga’s research.

Hruby said Siga-246 can treat monkeypox and related viral diseases, and the firm is also pursuing drug candidates for a range of other exotic viruses.

“There’s two things: There’s biodefense, and there’s emerging diseases,” Hruby said. “Hopefully, we’ll never need it for biodefense. But it’s nice to have a drug like this on the shelf.”

Bennett Hall is the business editor for the Gazette-Times. He can be reached at 758-9529 or [e-mail].

[goyauno]

Press Release Source: SIGA Technologies, Inc.


SIGA Announces $2.3 Million in New Contracts with the U.S. Air Force
Friday November 10, 7:30 am ET


NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) today announced receipt of two contracts from the U.S. Air Force for a total of $2.3 million. SIGA received a one-year, $1.4 million contract with the Air Force Medical Service for the development of counter-measures against important potential biowarfare pathogens, the Dengue viruses, and other water-related viral agents. SIGA also received a one-year, $900,000 contract to aid the USAF Special Operations Command (USAFSOC) in its development of specific anti-viral agents, focusing on orthopoxvirus targets distinct from the target that is the focus of SIGA-246, the Company's lead smallpox drug.
ADVERTISEMENT





"We appreciate the opportunity to continue the development of these critical biological defense capabilities with our colleagues from the Air Force," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA.

Dengue fever and Dengue hemorrhagic fever are acute febrile mosquito-borne diseases caused by one of four closely related virus serotypes of the genus Flaviviridae. The two diseases affect tens of millions of people worldwide every year and present a biodefense threat in the U.S. Currently, there is no approved drug or vaccine against Dengue, leaving troops vulnerable overseas and in areas affected by flooding.

SIGA recently announced a breakthrough in its SIGA-246 program with the successful completion of a preliminary primate trial in which the drug completely prevented smallpox disease.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg).

For more information about SIGA, please visit SIGA's Web site at www.siga.com.

Forward-looking Statements

This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products and (f) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.



Contact:
SIGA Technologies, Inc.
Mr. Tom Konatich, 212-672-9100
CFO/Acting CEO

--------------------------------------------------------------------------------
Source: SIGA Technologies, Inc.

[whyso]

Nochmal 2,3 Mio$

SIGA Announces $2.3 Million in New Contracts with the U.S. Air Force....


NEW YORK, Nov 10, 2006 (BUSINESS WIRE) -- SIGA Technologies, Inc. (SIGA : siga technologies inc com
News , chart, profile, more
Last: 3.96+0.07+1.80%

7:04am 11/10/2006

SIGA3.96, +0.07, +1.8%) today announced receipt of two contracts from the U.S. Air Force for a total of $2.3 million. SIGA received a one-year, $1.4 million contract with the Air Force Medical Service for the development of counter-measures against important potential biowarfare pathogens, the Dengue viruses, and other water-related viral agents. SIGA also received a one-year, $900,000 contract to aid the USAF Special Operations Command (USAFSOC) in its development of specific anti-viral agents, focusing on orthopoxvirus targets distinct from the target that is the focus of SIGA-246, the Company's lead smallpox drug.
"We appreciate the opportunity to continue the development of these critical biological defense capabilities with our colleagues from the Air Force," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA.
Dengue fever and Dengue hemorrhagic fever are acute febrile mosquito-borne diseases caused by one of four closely related virus serotypes of the genus Flaviviridae. The two diseases affect tens of millions of people worldwide every year and present a biodefense threat in the U.S. Currently, there is no approved drug or vaccine against Dengue, leaving troops vulnerable overseas and in areas affected by flooding.
SIGA recently announced a breakthrough in its SIGA-246 program with the successful completion of a preliminary primate trial in which the drug completely prevented smallpox disease.
About SIGA Technologies, Inc.
SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg).
For more information about SIGA, please visit SIGA's Web site at www.siga.com.

http://www.marketwatch.com/News/Story/Story.aspx?guid=%7B96A…

Es wird täglich besser im sachen SIGA Ausgangslage, die ersten -(ernst gemeinte takeover offers)- sind bestimmt nicht mehr weit fern!!!

Der heutige Handel stateside könnte zukunftsweisend ausfallen!

Schönes weekend (& nächste Woche wieder stärker UP),
Whyso

[whyso]

Antwort auf Beitrag Nr.: 25.258.719 von goyauno am 10.11.06 13:37:09

Great minds think alike....

Praktisch Zeitgleich reingestellt!

Good trades für dich & deinem wünscht dir,
Whyso

[goyauno]

Antwort auf Beitrag Nr.: 25.258.882 von whyso am 10.11.06 13:45:18

wie wahr, wie wahr,.......

weiterhin viel Erfolg und ein gutes händchen mir GNTA & SIGA wünsche ich Dir!!!!

hasta luego, y mucha suerte

goyauno (carlitos)

[Papierhecht]

Hallöle!

Bin seit vorgestern auch mit von der Partie, nachdem SIGA kurz im SIGM thread erwähnt wurde. Dafür habe ich es glücklicherweies übers Herz gebracht mich von GNTA zu verabschieden - was findet ihr nur an der, mir scheint genta im Gegensatz zu SIGM und SIGA reines Gezocke zu sein, während die beiden ein enormes Potential besitzen. ("It´s in the hundreds of millions of dollars, if not more" - Konatich...)

Grüßle

der Hecht

[amorphis]

Antwort auf Beitrag Nr.: 25.318.252 von Papierhecht am 12.11.06 05:14:04

papierhecht...nicht jedes potential ist für jeden als solches ersichtlich...gnta wird noch rocken, habe weder bei der emea noch bei der fda bedenken...greez

[whyso]

Antwort auf Beitrag Nr.: 25.339.207 von amorphis am 12.11.06 17:41:27

"habe weder bei der emea noch bei der fda bedenken"

dito Amorphis ...

und hier ein paar "SIGA arguments" um dabei zu bleiben:

1)Gap 1/2 filled & from a tech. standpoint that is enough.

2)The week hands have been forced out & now the buying will start to over take the low volume selling that may be left.

3)Watch this video if you have not:
http://www.kval.com/news/4448787.html

4)Hedge funds paid more for long positions than the current price : On Thursday, the company completed a $9 million private stock placement with some of its longtime institutional investors. Five hedge funds — Iroquois Master Fund, Cranshire Capital, Omicron Master Trust, Rockmore Investment Master Fund and Smithfield Fiduciary — bought the issue, consisting of 2 million shares of common stock at $4.54 a share. They also received warrants for an additional 1 million shares exercisable at $4.99 a share.

The above says "bought" & that means a long position.

5)18-Oct-06 4.95 5.50 4.35 4.54 39,349,000 4.54 The volume over $5 was huge and it traded to 5.50 the second leg is most often well over the first folowed buy huge increase in the following days. The profit taking by weak reatail investors & low holders first takes the stock price down to test lows. This has been done: see #1

6)Probable first pop to: 4.54 area to 4.80 then followed buy heavy after hours run well over % & maybe 6. Then the following pre-market new highs and a round of new profit taking before a close that is higher than pre-market. That was the model LMRA followed.


Now below are just some points of interest:

When SIGA's next quarterly report comes out it should beat estimates because of the the private stock placement sales creating a $9 million income not expected. Early November the release should be due. SIGA should have a nice "buy the rumor" pre-earnings run.

SIGA platform now validated. SIGA's other drug studies certain to do well based on the proven platform.

SIGA said the Department of Homeland Security has designated smallpox a "material threat" to national security, so Siga-246 "will be eligible for purchase for the Strategic National Stockpile under Project Bioshield."

If you watched the video project bioshield allows the government to purchase the drug before the FDA says o.k. so that can happen now.

Siga pulled out of merger deal with PharmAthene Inc., SIGA citing positive scientific data & the receipt of around $27 million in grants for its smallpox & arenavirus programs over the last several months.

That deal was pulled out of so SIGA could enjoy its profits without sharing so its an indication of whats coming.

Institutional ownership up SIGA # 2 only behind ACOR & ahead of AMLR & LMRA take look:
http://moneycentral.msn.com/investor/fin

They did not buy to lose money.

SIGA has a bigger blockbuster story in my opinion in its new form of anti-biotics. Think about the drug resistant strains from over use of traditional anti-biotics. SIGA's anti-biotics will solve this problem. If SIGA pulls this off they will have the number 1 anti-biotic in the world & the "super germs" the name often given to drugs that resist current anti-biotics will perish. Think about sales from that no drug company can match that type drug in sales.

Cangene Corp., in 2003 secured a large multi-year contract from the U.S. government to supply a vaccine to prevent an adverse reaction to smallpox vaccinations. (large "multi year contract" see that part?)

That statement shows why we are at risk today for an attack because it tells us about the reasons we are not vacinated today: "adverse reaction" If you read up those adverse reactions can be death. Thank you SIGA for eliminating that "adverse effect".

With SIGA we won't need vacines at all in an outbreak just oral drug with no "adverse reaction" like that known.

Übrigens Bioshield wird kanppe 6 billion $ wert sein, und die Siga Adresse ist bereits bekannt und geschätzt (schon weit vor die 100% Test Ergebnisse im Bereich der Smallpox)

Tief durchatmen, Siga wird kommen!...
Whyso

[whyso]

important potential biowarfare pathogens, the Dengue viruses, and other water-related viral agents. SIGA also received a one-year, $900k contract to aid the USAF Special Operations Command in its development of specific anti-viral agents, focusing on orthopoxvirus targets distinct from the target that is the focus of SIGA-246, the co's lead smallpox drug.

http://news.moneycentral.msn.com/ticker/article.asp?Feed=Bco…

[amorphis]

http://www.sec.gov/Archives/edgar/data/1010086/0001169232060…

[amorphis]

http://today.reuters.com/news/articleinvesting.aspx?view=CN&…

leute...zählt 1 und 1 zusammen...und...siehe da...was seht ihr???

[amorphis]

14.11.06 17:50 Uhr

4,07 USD

+4,09 % [+0,1598]


die richtung stimmt so langsam...

[whyso]

Der springende Satz:

said on Tuesday it had been unexpectedly dropped from consideration by the U.S. government for a new smallpox vaccine contract that analysts believe could be worth up to $1 billion

[mrsun]

Antwort auf Beitrag Nr.: 25.398.649 von whyso am 14.11.06 23:26:54

hi whyso,auch noch wach?!
Die 4$ wollen einfach halten,nicht schlecht

aus i-hub

From Wall Street Reporter today:

SIGA Technologies (NASDAQ: SIGA) has cultivated a “dominant” position in the field of countermeasures against various biological threats, says acting CEO Thomas N. Konatich. The company’s smallpox program has a demonstrated safety profile and efficacy in primate models and as such “is sort of the gold standard of protection” at the moment, Mr. Konatich says. Other programs are in the pipeline. Between grants, contracts, and a recent $9 million private placement, the company is adequately funded to meet near-term development goals. According to Dr. Dennis E. Hruby, chief scientific officer, target markets have “a great likelihood” of being global in scale.

Click to Listen:http://www.wallstreetreporter.com/profile.php?id=21271

[whyso]

Antwort auf Beitrag Nr.: 25.398.959 von mrsun am 14.11.06 23:36:27

Hi Mr Sun-yepp Hellwach,h habe ein leckeren 98' Sangiovese heute Abend gekillt, und die latest News im Umfeld Siga etwas verarbeitet

A new candidate comes...



...and the other one goes!

Viele Grüße & UP
Whyso

[mrsun]

Antwort auf Beitrag Nr.: 25.399.947 von whyso am 14.11.06 23:59:20

yeep-dann dürfte bald siga-246,zur Grundausstattung eines jeden Health-Center in USA gehören.

Gut´s Nächtle

[Papierhecht]

Antwort auf Beitrag Nr.: 25.398.649 von whyso am 14.11.06 23:26:54

hehe, genau den gleichen Satz aus Amorphis´ angegebenen Link wollte ich auch zitieren...
nice one amorphis

[goyauno]

es hat bereits gezündet!!!!

Press Release Source: SIGA Technologies, Inc.


SIGA Technologies Presents Its Smallpox Drug (SIGA-246) to the World Health Organization (WHO)
Thursday November 16, 7:30 am ET


NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) announced that, on November 16, 2006, its Chief Scientific Officer, Dr. Dennis E. Hruby, will make a presentation on the progress of SIGA-246 to the World Health Organization's Smallpox Advisory Committee on Variola Virus Research. Dr. Hruby is attending by invitation and will serve as a temporary advisor to the Committee which is meeting in Geneva, Switzerland. This is the second year in a row that Dr. Hruby has been invited to make a presentation to the WHO on the development status of SIGA's smallpox antiviral drug (SIGA-246). "Given the central role of the WHO in safeguarding the health and well-being of the global citizenry, we appreciate the opportunity to update them on the recent significant advancements in developing SIGA-246 since we introduced the compound to the WHO last year," commented Dr. Hruby.
ADVERTISEMENT


In October 2006, SIGA announced that SIGA-246 completely protected non-human primates from lethal doses of smallpox (variola virus). SIGA-246 is the first drug ever to demonstrate 100% protection against human smallpox virus in a primate trial, which was conducted at the federal Centers for Disease Control and Prevention (CDC). Recently, SIGA also announced that oral dosing with SIGA-246 completely protected non-human primates from lethal doses of monkeypox virus even when treatment started 3 days after infection and at doses equivalent to the potential human dose. Monkeypox virus is closely related to human smallpox virus and causes a similar disease in both monkeys and humans. "These monkeypox studies are important in that the disease in non-human primates recapitulates smallpox disease seen in humans, and this model will be used as one of the definitive animal models the FDA will use to evaluate this drug. These results also confirm that SIGA-246 can be used both to treat smallpox and in the event of a monkeypox or related outbreak, such as the multi-state monkeypox outbreak in June 2003," stated Dr. Hruby. These primate trials and the human safety trial announced earlier this year demonstrate that SIGA-246 should be a safe and effective antiviral.

Smallpox virus is considered one of the most significant threats for use as a biowarfare agent due to the fact that since 1972 people in the United States have not been vaccinated against it. Smallpox is very easily transmitted from person to person, and has high mortality rates (30-60%) with 90% morbidity. Weaponized smallpox virus may have an incubation period as short as 3-7 days. It is classified as a Category A agent by the CDC. Mass immunizations of the general population using the current live vaccines are not recommended. Available vaccines are known to cause complications in certain individuals, including encephalitis, myocarditis, disseminated vaccinia virus infection, and death. At present there is no treatment for smallpox that can be safely administered to the general population without significant risk of adverse reactions.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg).

For more information about SIGA, please visit SIGA's Web site at www.siga.com.

Forward-looking Statements

This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products and (f) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.



Contact:
SIGA Technologies, Inc.
Tom Konatich, Chief Financial Officer & Acting CEO
212-672-9100

--------------------------------------------------------------------------------
Source: SIGA Technologies, Inc.

[amorphis]

http://www.wallstreetreporter.com/profile.php?id=21271

[whyso]

Ein mögliche Billion$$$ Marktplatz...und Hrubys Kommentar dazu:

"These monkeypox studies are important in that the disease in non-human primates recapitulates smallpox disease seen in humans, and this model will be used as one of the definitive animal models the FDA will use to evaluate this drug. These results also confirm that SIGA-246 can be used both to treat smallpox and in the event of a monkeypox or related outbreak, such as the multi-state monkeypox outbreak in June 2003," stated Dr. Hruby. These primate trials and the human safety trial announced earlier this year demonstrate that SIGA-246 should be a safe and effective antiviral."

[mrsun]

http://www.labor-spiez.ch/de/dok/fa/pdf/Affenpoken_d.pdf

[mrsun]

www.sec.gov/Archives/edgar/data/1010086/000116923206004592/0001169232-06-004592.txt

[mrsun]

Annan warns of "catastrophic" biotech danger
Sat Nov 18, 2006 6:04am ET


Science News
Calls for climate change action at Asia-Pacific summit
U.N. climate pact unlikely until after Bush: experts
Cosmonaut to tee up for monster orbital golf shot
More Science News... Email This Article | Print This Article | Reprints [-] Text [+]
ST. GALLEN, Switzerland (Reuters) - U.N. Secretary-General Kofi Annan warned that potential dangers from the rapidly growing biotechnology industry were increasing exponentially and urged creating global safeguards.

Annan, speaking on Saturday in the Swiss university town, warned of "catastrophic" results if recent advances in biotechnology, including gene manipulation and work with viruses, fell into the wrong hands.

"As biological research expands, and technologies become increasingly accessible, this potential for accidental or intentional harm grows exponentially," he said in the text of a speech.

"Even novices working in small laboratories will be able to carry out gene manipulation."


Game Console Wars
The video game industry's own clash of the titans reboots this week with the midnight launch of Sony's PlayStation 3 and Sunday's debut of Nintendo's Wii.

Full coverage
Annan's warning comes after he called in May for a global forum on biological terrorism, saying current treaties were too weak and governmental and commercial initiatives too scattered.

Annan likened the current consensus-building phase over life-sciences rules to the debate around nuclear technology in the 1950s that preceded the creation of the International Atomic Energy Agency and the Nuclear Non-Proliferation Treaty.

"We lack an international system of safeguards to manage those risks. Scientists may do their best to follow rules for responsible conduct of research. But efforts to harmonize these rules on a global level are outpaced by the galloping advance of science itself," he said.

Annan was speaking at an event where he received the Max Schmidheiny Freedom Prize.


© Reuters 2006. All Rights Reserved.


http://today.reuters.com/news/articlenews.aspx?type=scienceN…

[goyauno]

http://www.gazettetimes.com/articles/2006/10/23/news/busines…



Sunday, November 19, 2006
Last modified Sunday, October 22, 2006 10:25 PM PDT


CASEY CAMPBELL/Gazette-Times
At Siga Technologies’ Corvallis research labs, Eric Stavale works on a possible treatment for the Dengue virus. Siga got a big cash infusion last week after announcing progress on an experimental smallpox treatment.

Healthy development



Siga Technologies finds quick payoff from test of smallpox remedy

By BENNETT HALL
Gazette-Times business editor

It’s been a long and bumpy road, but the finish line may be in sight for Siga Technologies in its journey toward profitability.


Like many — if not most — small drug-discovery companies, Siga has burned through millions of dollars and posted year after year of losses as it tried to bring a developmental treatment to market. After a successful animal trial announced last week, however, the company could be on the verge of scoring a major coup with the first effective treatment for smallpox.

“In the biodefense area, smallpox is the number one concern, and we would expect this is going to be our big product,” said Dennis Hruby, Siga’s chief scientific officer and a microbiology professor at Oregon State University.

Smallpox was eradicated in nature 30 years ago but is considered a potential terrorist threat, and no proven treatment for the deadly virus exists. The Defense Department and other federal agencies funded the latest test, conducted on monkeys at a secure Centers for Disease Control facility in Atlanta.

Siga claims its drug, a once-daily pill called Siga-246, showed “100 percent protection” against the smallpox virus, both before and after exposure. The drug previously passed a human safety trial.

Additional tests are needed before the company can request approval from the Food & Drug Administration, but the Defense Department is footing the bill with a $16.5 million grant.

The news of a successful test triggered a financial windfall for Siga, which employs 50 people at its Corvallis research labs.

On Wednesday, the day the test results were announced, the company’s stock price more than doubled, shooting up to $4.54 a share after languishing at around $1 for most of the last year.

On Thursday, the company completed a $9 million private stock placement with some of its longtime institutional investors. Five hedge funds — Iroquois Master Fund, Cranshire Capital, Omicron Master Trust, Rockmore Investment Master Fund and Smithfield Fiduciary — bought the issue, consisting of 2 million shares of common stock at $4.54 a share. They also received warrants for an additional 1 million shares exercisable at $4.99 a share.

“It gave us the opportunity to bring in some cash quickly at a nice price,” said chief financial officer and acting CEO Tom Konatich, who’s been with the biotech firm for eight years. “Our balance sheet right now is about as strong as it’s been during my tenure.”

The stock placement caps a resurgence for Siga, which had entered a merger agreement last spring with an East Coast biotech company and faced delisting from the Nasdaq exchange this summer as its market capitalization slipped.

Now, with its cash reserves recharged and a smallpox drug marching toward approval, the merger is off and Siga is on the rebound.

“Siga’s a significantly different company today than it was in February and March,” Konatich said by phone from the company’s New York headquarters Friday. “We will be lobbying and negotiating with various agencies of the federal government for a sale of the drug.”

Konatich declined to speculate on when a deal to supply the drug might be reached or what it might be worth to Siga. But he did say that various industry estimates make it clear that the potential market for smallpox treatments is a lucrative one.

“It’s in the hundreds of millions of dollars, if not more,” he said.

Other potential markets await overseas, particularly in Europe. Hruby has been invited to Geneva to make a presentation to the World Health Organization’s advisory council, which he hopes will help spread the word about Siga’s research.

Hruby said Siga-246 can treat monkeypox and related viral diseases, and the firm is also pursuing drug candidates for a range of other exotic viruses.

“There’s two things: There’s biodefense, and there’s emerging diseases,” Hruby said. “Hopefully, we’ll never need it for biodefense. But it’s nice to have a drug like this on the shelf.”

Bennett Hall is the business editor for the Gazette-Times. He can be reached at 758-9529 or [e-mail].

[mrsun]

Official notification to shareholders of matters to be brought to a vote (Proxy) - Form DEF 14A

http://www.sec.gov/Archives/edgar/data/1010086/0001169232060…

[mrsun]

http://www.siga.com/pdf/BWT%20101906%20-%20SIGA%20Skyrockets…

[whyso]

Man beachte die beiden Piecharts-der von dieser Woche gefällt mir "irgendwie" besser

>>>>>>>

http://thomson.finance.lycos.com/lycos/iwatch/cgi-bin/iw_tic…

Die schweizer WHO Publikum ist sicherlich auch etwas hellhörig gewesen-(das zweite mal hintereinander mit SIGA) :

http://biz.yahoo.com/bw/061116/20061116005121.html?.v=1

"Smallpox virus is considered one of the most significant threats for use as a biowarfare agent due to the fact that since 1972 people in the United States have not been vaccinated against it. Smallpox is very easily transmitted from person to person, and has high mortality rates (30-60%) with 90% morbidity. Weaponized smallpox virus may have an incubation period as short as 3-7 days. It is classified as a Category A agent by the CDC. Mass immunizations of the general population using the current live vaccines are not recommended. Available vaccines are known to cause complications in certain individuals, including encephalitis, myocarditis, disseminated vaccinia virus infection, and death. At present there is no treatment for smallpox that can be safely administered to the general population without significant risk of adverse reactions."


Time will tell,
Whyso

[whyso]

Es lohnt sich das ganze Artikel mehrmals durchzulesen, SIGA's wahre Potential am Markt ist hier sehr gut zusammengefasst (und auch die politische Hintergründe sind hier sehr gut summiert)

Senate to Take Up Biological Threats-Firms Could Get Funding Sooner...
By Renae Merle
Washington Post Staff Writer
Wednesday, November 15, 2006; Page D01

The Senate is moving to take up legislation as soon as this week revamping a struggling multibillion-dollar effort to counter bioterrorism threats with a national stockpile of new vaccines and other drugs.

The legislation creates a central authority within the Health and Human Services Department to manage the effort, sets aside an additional $1 billion for research and gives the federal government the flexibility to provide cash infusions to the small firms doing most of the work.

Supporters of the bill, which is more than a year in the making, are cautiously optimistic that it will pass. Sen. Harry M. Reid (D-Nev.), who is slated to take over as majority leader, listed it among his priorities for Congress's lame-duck session.

"From a policy standpoint, there is nobody shooting at it," said Sen. Richard Burr (R-N.C.), one of the bill's sponsors.

If passed, the legislation would have to be reconciled with the House version, which was passed in September. The initiative is intended to salvage the Bush administration's Project BioShield, a $5.6 billion program to counter biological and radioactive weapons.

The two-year effort has been marked by delays and operational problems. Some companies, for example, have floundered as they conducted research and testing because the bulk of government payments typically do not arrive until firms are ready to produce approved drugs.

Meanwhile, Project BioShield's most significant investment, a nearly $1 billion effort by VaxGen Inc. to develop an anthrax vaccine, is in limbo after the Food and Drug Administration refused to let the company conduct human tests and Health and Human Services threatened to end the company's contract.

Project BioShield "didn't work because a majority of the companies choose not to participate and the ones that did, they were not financed through the valley of death," Burr said.

The new legislation aims to correct those problems, but it still may face some questions. Sen. Patty Murray (D-Wash.), who said she supports the intent of the bill, nonetheless raised safety concerns.

"We need to debate compensating those who may suffer adversely from new vaccines or treatments and expand protections for high risk populations like children, pregnant women, and the elderly," Murray said in a statement.

Under the current proposal, the bill would create the Biomedical Advanced Research and Development Authority to oversee the effort. The bill also attempts to pump more government money into the private market sooner. Under current law, participating companies are not paid until they deliver the drugs, even though Health and Human Services has the authority to give companies a 10 percent prepayment, which would have to be repaid if the company failed to deliver the product. But the agency has never exercised that option.

The legislation would speed up the development cycle by allowing Health and Human Services to pay companies up to 5 percent of the value of their contract when they reach certain milestones, providing them with a welcome cash infusion. The Senate version would also allocate $1 billion over three years for research not funded by a Project BioShield contract or the National Institutes of Health. The House version of the legislation sets aside $160 million per year for two years.

"The federal government is now their venture capital partner," Burr said.

Lance Ignon, VaxGen's vice president for corporate affairs, applauded the notion of the government playing a larger role in sharing the financial risk. Under the current program, "we have all of the financial risk," he said.

The change would not be a "panacea" in VaxGen's case, he said, but could be helpful to the company and the industry in general.

"The success of our nation's bio-defense effort will rest in large measure on the ability to form true partnerships between government and industry based on mutual respect," Ignon said. That includes an "understanding of the almost inevitable setbacks one encounters in drug development."

http://www.washingtonpost.com/wp-dyn/content/article/2006/11…

[amorphis]

SIGA - SIGA Technologies Inc. - Common Stock
Month
Short
Interest Percent
Change Average Daily
Share Volume Days to
Cover
November 2006 1,211,843 41.39 4,686,277 1.00
October 2006 857,074 1,131.96 635,572 1.35

[mrsun]

Der Grund warum´s nicht aufwärts geht,an der Story selber,hat sich nichts geändert

http://www.sec.gov/Archives/edgar/data/1010086/0001169232060…

wer ist noch mit dabei?!

[whyso]

Antwort auf Beitrag Nr.: 25.876.740 von mrsun am 02.12.06 00:30:26

Hi Mr.Sun, wer ist noch mit dabei?!

Ich jedenfalls nachwievor...

http://host.businessweek.com/businessweek/Historical_Quotes…

Da waren ein paar fette käufe im laufe der gestrigen Sitzung bei tja, anscheint geht es bald wieder los!

Good trades & steady hands,
Whyso

[overview]

Antwort auf Beitrag Nr.: 25.969.532 von whyso am 06.12.06 13:30:32

... ich auch.

[amorphis]

Senate bill 3678 (S. 3678 – the Pandemic and All-Hazards Preparedness Act) was voted on and passed in the Senate yesterday, December 5, 2006. Overall, the bill provides for enhancements to public health and medical preparedness and response functions of the Department of Health and Human Services (DHHS) and the establishment of a National Health Security Strategy. The bill, as amended, also contains provisions that would require the establishment within DHHS of a Biomedical Advanced Research and Development Authority (BARDA) as a single point of authority in the Federal Government for civilian medical countermeasure advanced R&D.

The BARDA would 1) coordinate and oversee activities that support and accelerate advanced R&D of qualified countermeasures or pandemic or epidemic products, 2) facilitate collaboration among DHHS components, other Federal agencies, relevant industries, academia, and other individuals, 3) promote countermeasure and product advanced R&D, 4) facilitate contacts between interested persons and individuals authorized by the Secretary of HHS to provide advice regarding Federal Food, Drug, and Cosmetic Act requirements, and 5) promote innovations to reduce the time and cost of countermeasure and product advanced R&D.

The bill authorizes (this does not mean that funds have been appropriated – that is a later function when federal budgets are passed) $1,070,000,000 for FY 2006–2008 for the Biodefense Medical Countermeasure Development Fund that would be established to carry out this activity, in addition to amounts otherwise available for this purpose.
Before everything passes and money flows to companies such as SIGA, the Senate bill has to be reconciled with a House version (H.R. 5533).

To read details of the Senate bill, go to Thomas (part of the Library of Congress) at http://thomas.loc.gov/ and type in the bill number. [The above information is paraphrased from a document of the Office of Legislative Policy and Analysis at NIH.]

[overview]

Antwort auf Beitrag Nr.: 25.978.005 von amorphis am 06.12.06 18:52:04

Wann bekommt ne BioTech-Firma schon mal eine Art "eigenes Finanzierungsgesetz" ?
Und dann das 3-Jahresbudget, aus dem SIGA mit bedient werden dürfte: 1.070.000.000 $.

Jetzt erklärt sich nachträglich vielleicht auch die kleine (Insti-?) Umsatzspitze gestern, die für mich Anlaß war, nochmal ein klein wenig nachzubunkern.

Jetzt noch wenige Wochen die Gesetzes-Bürokraten ihre Umsetzungsarbeiten machen lassen und dann dürfte es los gehen ...

[mrsun]

Hallo Leidensgenossen
jeden Tag das selbe spiel,neue shares,wie schon angekündigt
auch bei mir fangen ab 1,9$ die schmerzen an,aber vielleicht haben
wirs bald übestanden

Next week the Senate is expected to revamp Project Bioshield, a $5.6 billion spending plan meant to shore up the nation's defenses against a bioterror attack

viel grün undglück

[mrsun]

gestern starkes kaufvolumen und heute schwaches verkaufsvolumen,und das bei erstarktem kurs.
könnte es das ende der dilution bedeuten?!
was denkt ihr,eure meinung wird gern gelesen

[mrsun]

oh du fröhliche

FDA Approves Orphan Drug Designation for SIGA's Smallpox Drug, SIGA-246

[goyauno]

Antwort auf Beitrag Nr.: 26.353.399 von mrsun am 20.12.06 21:44:40

, hi mrsun

na, da hat sich doch unser stehvermögen und unser glaube doch noch ausgezahlt!!!!!

Und das war bei weiten noch nicht alles!

goyauno

[whyso]

Gratulation Mr.Sun...



Netter Chart...

An der Spitze heute: Last: 4.95 Change: +2.23 +82.15% Volume: 16,584,425 4:00pm 12/20/2006

allerdings After Hours: 4.76 -0.19 -3.92% 290,010

Aber das beste ist der Zug hat den Bahnhof noch gar nicht richtig verlassen bis dato-15$ here we come!!!

Viele Grüße & weiterhin UP,
Whyso

[whyso]

Antwort auf Beitrag Nr.: 26.356.732 von goyauno am 20.12.06 22:57:16

Hi goyauno-dat ist n'ding, genau gleichzeitig gepostet vorhin

Wie sagt man so schon:-
"great minds think alike, fool's seldom differ"

[mrsun]

hi whyso,hi goyauno
und auch viel grün an alle andern starken jungs
und vergeßt ja nicht eure SL´s raus zunehmen,denn jetzt geht das gefische warscheinlich erst richtig los.

viel glück und schönes fest ihr lieben

[whyso]

Zwei Gründe wieso SIGA shorts demnächst sehr schlecht schafen werden:

1. ."Smallpox has been designated by the Department of Homeland Security as a "material threat" to our national security, qualifying SIGA -246 for purchase for the Strategic National Stockpile under Project Bioshield. Currently, there is no effective and safe smallpox therapy available without the risk of significant complications, and the U.S. government has expressed strong interest in the development of novel smallpox therapies. Existing techniques to prevent or ameliorate smallpox have unacceptably high rates of complications, including encephalitis, myocarditis and death, and can take days or weeks to confer protection"


2.Infectious Diseases Specialist, Scott M. Hammer, M.D. Joins SIGA's Board of Directors


NEW YORK, Dec 19, 2006 (BUSINESS WIRE) -- SIGA Technologies, Inc. (SIGA : siga technologies inc com
News , chart, profile, more
Last: 4.95+2.23+82.15%

SIGA4.95, +2.23, +82.1%) announced today that Scott M. Hammer, M.D. was elected to serve on its Board of Directors at a meeting of the Company's shareholders held on December 19, 2006. Dr. Hammer is the Harold C. Neu Professor of Medicine, Professor of Epidemiology and Chief of the Division of Infectious Diseases at the Columbia University Medical Center (CUMC). Dr. Hammer is also the Chair of the AIDS Vaccine Research Working Group, an advisory committee to the Division of AIDS at the NIAID, and had also served as the Chair of the Antiviral Products Advisory Committee of the FDA. In his role as Chief of the Division of Infectious Diseases at CUMC, he has worked to enhance professional development and has focused on strengthening infection surveillance at the institutional and regional levels in order to improve and protect public health.

SIGA Chairman Donald G. Drapkin welcomed Dr. Hammer to the SIGA Board: "His years of experience as a leader in infectious disease detection and treatment will be a great asset to SIGA as we move forward in the approval process for our smallpox drug, SIGA 246, as well as SIGA's development of other anti-viral products."

http://www.marketwatch.com/news/story/infectious-diseases-sp…

(und das ganze ist vorgestern erst geschehen-dann am Tag danach FDA Approval und VOR ALLEM "Strategic National Stockpile under Project Bioshield" )

A very Happy Christmas @alle Siga Shareholders,
Whyso

[goyauno]

Antwort auf Beitrag Nr.: 26.358.712 von whyso am 21.12.06 00:40:03

hi whyso, das war geistige intuition.......

die big news, die richtigen big, big news kommen ja erst noch.

Ich wünsche euch und eueren Familien ein frohes Weihnachtsfest und ein hoffentlich ein guten rutsch ins neue Jahr.

Alles Gute und Liebe!!

goyauno

[rdeniro]

Antwort auf Beitrag Nr.: 26.359.113 von goyauno am 21.12.06 01:27:31

Wie definierst du "geistige intuition".......?

[whyso]

Jungs-wer SIGA hält sollten folgendes von SIGA unbedingt gelesen haben

http://www.siga.com/ppt/Non-Confidential%20Update_files/fram…

5 Billion USD Markt Potential....kein Wunder das man das Angebot von PharmaTheme damals dankend abgelehnt hat:
http://www.marketwatch.com/news/story/siga-terminates-merger…

Ich wünsche Euch und Euren Familien ein frohes und
geruhsames Weihnachtsfest, sowie für 2007 viel Erfolg!!!
Whyso

[mrsun]

Antwort auf Beitrag Nr.: 26.374.775 von whyso am 21.12.06 17:12:53

hi whyso
Denke,wir kriegen heut´ noch mal´n paar shares aufs Auge.
Aber selbst mit 35mio common stock kann ich ganz gut Leben,bei den Aussichten die uns da winken.

[Bienenvater]

bin seit heute hier auch dabei.
Habe mich einigermassen kundig gemacht und denke, 3.26 Euronen sind für das teil noch nicht zu viel.

good luck für uns alle!

[noogmann]

Antwort auf Beitrag Nr.: 26.381.300 von Bienenvater am 21.12.06 20:53:56

bin seit heute hier auch dabei.

Frohe Weihnachten und einen guten Rutsch in ein gesundes und erfolgreiches 2007

Noogmann

[mrsun]

sieht wohl danach aus,daß uns PharmAthene nicht so einfach ziehen lassen will

On December 20, 2006, PharmAthene, Inc. ("PharmAthene") filed a complaint (the “Complaint”) against SIGA Technologies, Inc. (“SIGA”) in the Delaware Chancery Court. PharmAthene's complaint alleges that it has the right to license exclusively development and marketing rights for SIGA’s drug candidate, SIGA-246, pursuant to, among other things, the recently terminated merger agreement between the parties. PharmAthene's complaint further alleges that SIGA failed to negotiate the terms of such license in good faith and otherwise failed to grant such license, and it seeks to compel SIGA to enter into such license and pay unspecified damages. SIGA believes that the complaint lacks merit and intends to contest vigorously the alleged claims

[mrsun]

wie schon vermutet,es kommen noch mal ein paar shares


PROSPECTUS Filed Pursuant to Rule 424 (b) (3)
Registration No. 333-139082

500,000 SHARES

SIGA TECHNOLOGIES, INC.

COMMON STOCK

----------

Shares of common stock of SIGA Technologies, Inc. are being offered by
this prospectus. The shares will be sold from time to time by the selling
stockholders named in this prospectus. The prices at which such selling
stockholders may sell the shares will be determined by the prevailing market
price for the shares or in negotiated transactions. We will not receive any
proceeds from the sale of shares of common stock by the selling stockholders.
Our shares are traded on the NASDAQ Capital Market under the symbol "SIGA." Our
principal executive offices are located at 420 Lexington Avenue, Suite 408, New
York, New York 10170. Our telephone number is [phone].

----------

Investing in the shares involves a high degree of risk. For more
information, please see "Risk Factors" beginning on page 6.

----------

Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a
criminal offense.

----------

The date of this prospectus is December 26, 2006

[noogmann]

allen Siga-Freunden noch einen guten Rutsch ins Jahr 2007

Noogmann

[mrsun]

Wünsche allen mitinvestierten,und auch allen anderen,ein schönes und glücklches neues Jahr 2007

[whyso]

Happy 2007 ihr lieben!

Watch the SIGA trades closely:
http://host.businessweek.com/businessweek/Historical_Quotes.…

immer wieder geschickt patzierte 10 & 20K Pakete (sogar im laufe ein negativen Freitags session )-

Hier ein paar triftige gründe to go (or stay) SIGA:

90 day silent period is officially over on Monday-
The Democrats intend to invest in viral protection policies
Siga is rated for a major squeeze any day soon
Merger rumors abound; could triple on news anytime; siga-246 needs a manufacturer
FACT:2nd stage human testing starts; results back in a month (1st phase complete success and 2nd will be a sho in!)
FACT:Washington wants & needs this drug and has awarded it special status via FDA, seldom seen.....on fastrack now( and financial backing has been unlimitedly granted for further research)
FACT:Siga's bottom line will be great with all the new grant money
Sigas potential application & research to other pathogens very promising; great long term future
Institutions were making year end window dressing sells -they are about to re-enter the marketplace for THE REAL INVESTMENT 2007-within the next few weeks!

Excellent management is pushing this company forward to the brink of "take off" (even turning down lucrative takeover bids on the way) I wonder why?

Five Hedge funds are invested higher than todays trading point:

Hedge funds paid more for long positions than the current price : On Thursday, the company completed a $9 million private stock placement with some of its longtime institutional investors. Five hedge funds — Iroquois Master Fund, Cranshire Capital, Omicron Master Trust, Rockmore Investment Master Fund and Smithfield Fiduciary — bought the issue, consisting of 2 million shares of common stock at $4.54 a share. They also received warrants for an additional 1 million shares exercisable at $4.99 a share.

Product Potential:
SIGA has a bigger blockbuster story of anti-biotics. Think about the drug resistant strains from over use of traditional anti-biotics. SIGA\'s anti-biotics will solve this problem. If SIGA pulls this off they will have the number 1 anti-biotic in the world & the "super germs" the name often given to drugs that resist current anti-biotics will perish. Think about sales from that no drug company can/could /would be able match....

Es bleibt richtig Spannend -ich denke wir werden "neues hören" bevor ende Januar!

Bis die Tage & weiter UP mit SIGA,
Whyso

[Kaufrausch1]

Antwort auf Beitrag Nr.: 26.728.611 von whyso am 06.01.07 23:11:31

Hallo Whyso.

Kann es sein das dieses Posting teils aus dem Yahoo-Board stammt?

Ich glaube Du hast bei Yahoo.Com auch einen Nick oder etwa nicht?

Siehe Link:

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…


Bin von SIGAs Erfolg überzeugt


Da Du ja in den US-Boards mitliest und schreibst kennst Du diesen Link sicher aber ich setzte Ihn einfach nochmal rein auch für andere USER.

http://pennystockpick.blogspot.com/2007/01/penny-stock-on-mo…

[whyso]

Watch this space::: Britain on smallpox alert-




Dramatic emergency plans to counter a biological warfare terrorist attack on Britain were announced by the Government today.

Within the next eight weeks, 12 disaster centres will be set up in London and across the United Kingdom ready to meet an attempt to spread smallpox among the population. In addition, some 700 key medical and Ministry of Defence staff are to be vaccinated against the disease to act as the front line against any attack.

The 12 "regional smallpox response groups" will hold supplies of vaccine under guard ready for rapid use.

The groups, including doctors, scientists, nurses and other health staff will be effectively combat-trained to counter an attack.

The Health Department and the Ministry of Defence, in a joint announcement, said there was "no evidence of a specific threat of a smallpox attack on the UK" but that it was "sensible and prudent" to ensure that any potential attack could be effectively dealt with.

Smallpox has always been seen as by far the most deadly of the biological weapons that could be available to al Qaeda or some other terrorist group. It is spread more easily and more rapidly than other germ warfare agents, with lethal effect.

The emergency plan lays down a series of "scenarios" for a terrorist strike and the proposals to deal with it.

The "primary" strategy would be to "contain and 'ring vaccinate' around any outbreak". The teams of key staff already vaccinated, says the government plan, are "central" to delivering the strategy.

The moves are the clearest sign yet of the seriousness with which the Government is treating the threat of a major attack.

Health Minister John Hutton said stocks of smallpox vaccine had already been substantially increased and announced that a "second procurement" had recently begun to add to supplies.

Today's proposals will be discussed over the coming weeks before they are finalised, to come into effect in January, Downing Street said.

Mr Hutton said there were three components to the response: "Improved vaccine stocks, a plan of action and a cohort of immunised staff to deal safely with any potential smallpox cases."

The 12 regional response groups, Mr Hutton went on, would include infectious disease physicians, public health physicians, microbiologists, acute care and communicable disease control nurses and occupational health staff.

"This core group of NHS staff will need to be immune to smallpox and therefore able to react quickly and work safely with patients with actual or suspected smallpox. Preparation for the vaccination of these key workers is now under way."

Downing Street said it had no knowledge of vaccination plans for ministers. Essential staff will be vaccinated on a voluntary basis.

http://www.thisislondon.co.uk/news/article-2289690-details/B…

[whyso]

Der Link is von 2002, aber es zeigt das man sich ernsthaft mit Smallpox als potentieller Agent befasst hat.... (und wird)

[whyso]

http://www.tradethenews.com/story/147961

[mrsun]

Heute völlig paradoxes Bild.
Hohes Verkaufsvolumen bei stabilen Kursen.
Für mich Hinweise,daß hier massiv eingesammelt wird.

[goyauno]

Antwort auf Beitrag Nr.: 26.864.946 von mrsun am 12.01.07 17:25:41

hi mrsun, sehe ich genau so.

Intis sind am kaufen!

[mrsun]

Antwort auf Beitrag Nr.: 26.872.489 von goyauno am 12.01.07 22:32:18

hi goyauno
schon gesehen?!kam heut nacht noch raus

Form Type Form Description Pages Date View
4 Statement of changes in beneficial ownership of securities 1 01/11/07
4 Statement of changes in beneficial ownership of securities 1 01/11/07
4 Statement of changes in beneficial ownership of securities 1 01/11/07
3 Initial statement of beneficial ownership of securities 1 01/11/07
4 Statement of changes in beneficial ownership of securities 1 01/11/07
4 Statement of changes in beneficial ownership of securities 1 01/11/07
4 Statement of changes in beneficial ownership of securities 1 01/11/07
4 Statement of changes in beneficial ownership of securities 1 01/11/07
4 Statement of changes in beneficial ownership of securities 1 01/11/07
4 Statement of changes in beneficial ownership of securities 1 01/11/07

jetzt wissen wir auch warum bis 19.12. auf 2,72$ gedrückt wurde

[goyauno]

Antwort auf Beitrag Nr.: 26.889.520 von mrsun am 13.01.07 17:54:38

hi mrsun,

danke dass Du uns darauf aufmerksam gemacht hast.

Unglaublich wieviele Optionen ausgeführt worden sind, und alle für
$2,72

SIGA : NASDAQ
Industry: Biotechnology

Recent Filings for SIGA All Recent Filings Past 12 Month Filings 10-Qs 10-Ks Company Events Proxy Statements Insider Filings Institutional Ownership Security Registrations
Filing Date Filing Type Description Format
01/10/2007 4 Insider Buy/Sell 2 Pages, 5154kb
01/10/2007 3 Initial Insider Filing 2 Pages, 4690kb
01/10/2007 4 Insider Buy/Sell 2 Pages, 5176kb
01/10/2007 4 Insider Buy/Sell 2 Pages, 5164kb
01/10/2007 4 Insider Buy/Sell 2 Pages, 5208kb
01/10/2007 4 Insider Buy/Sell 2 Pages, 5069kb
01/10/2007 4 Insider Buy/Sell 2 Pages, 5244kb
01/10/2007 4 Insider Buy/Sell 3 Pages, 6095kb
01/10/2007 4 Insider Buy/Sell 2 Pages, 5164kb
01/10/2007 4 Insider Buy/Sell 2 Pages, 5157kb
12/25/2006 424B3 Registrations 21 Pages, 56585kb
12/21/2006 EFFECT 1 Pages, 1982kb
12/19/2006 8-K Company Events 4 Pages, 8381kb
12/18/2006 8-K Company Events 1 Pages, 3664kb
12/04/2006 424B3 Registrations 22 Pages, 58749kb
12/03/2006 EFFECT 1 Pages, 1980kb
11/30/2006 S-3 Registrations 28 Pages, 75110kb
11/21/2006 SC 13G Institutional Ownership 5 Pages, 9399kb
11/21/2006 SC 13G Institutional Ownership 4 Pages, 8072kb
11/19/2006 DEF 14A Institutional Ownership 31 Pages, 71783kb

http://www.cnbc.com/id/15837259?q=siga

wenn ich das jetzt richtig interpretiere, heist das, dass sie mit festen Aufträgen seitens der Regierung rechnen.

Oder sehe ich da was falsch.

[mrsun]

Antwort auf Beitrag Nr.: 26.897.968 von goyauno am 13.01.07 22:11:14

Ich Denke,mit Geldern aus Projekt Bioshield rechnen wohl doch alle,oder?
Aber die Welt hört doch nicht gleich hinter Frisco oder NY auf.
Es ist doch deutlich zu erkennen,daß hier immer noch einige gerne bereit sind,nach einem Kurssprung von über 200% innerhalb von drei monaten,dazu zu kaufen.
Wahrscheinlich mit dem Wissen wohin die Richtung geht.

[mrsun]

Hallo @all
Das Volumenen von gestern war so klein,daß es geradezu nach einem up für heute schreit.Gepaart durch Käufe aus Ask und Bid,ein ganz gesunder Handel.
Nach dem Motto von KaLeu: wer viel schmeißt,hat bald nichts mehr!

viel Glück und Grün

[whyso]

Gruß dich Mr Sun!

Die alten Borsianer haben mal gesagt
"An der Börse wird das Geld nicht dem Kopf, sondern mit dem Siitzfleisch verdient ....

Good trades, but steady hands mit Siga,
Whyso

[mrsun]

Antwort auf Beitrag Nr.: 27.020.608 von whyso am 18.01.07 20:55:05

Hallo whyso
Heut wird´s wohl noch mal lustig,vorbörslich schon über 400K

[goyauno]

Jedesmal das selbe Spiel!!!

Die da drüben wissen schon wieder mehr als wir....

[overview]

Antwort auf Beitrag Nr.: 27.033.649 von mrsun am 19.01.07 15:43:53

upps ...

[mrsun]

Antwort auf Beitrag Nr.: 27.034.054 von goyauno am 19.01.07 15:59:44

Kann gut möglich sein,aber sind mir etwas zu viel Vekäufe dabei.
Gut möglich,daß heute nach Börse,noch was an news kommt.
Der Zeitpunkt zum Woende wäre optimal,um manchen,Zeit zum grübeln zu geben.

[mrsun]

Vielleicht könnte das der Grund sein

Breaking News Equity Alert for Friday, January 19, 2007: Key Product Order From Major Chinese Pharmaceutical Company!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.

Jan 19, 2007 11:09:00 AM

Share this story:
Save This Page

WESTON, FL -- (MARKET WIRE) -- 01/19/07 -- TheSUBWAY.com: Announces the following stocks to its Breaking News List: Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP), SIGA Technologies Inc (NASDAQ: SIGA), EasyLink Services Corporation (NASDAQ: EASY), JDSU (NASDAQ: JDSU).

Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP), just announced a major RMB 19 million (US$ 2.4 million) order from Anhui Huayuan Pharmaceutical Co. Ltd, which is one of the oldest and best-known pharmaceutical companies in China Renhuang Pharmaceuticals received the RMB 19 million order at the medical products purchasing conference in Taihe Town, Fuyang City in the Anhui Province. The conference is ranked as one of the biggest in the industry in China.

Related Quotes

Last Change % Change
RHGP N/A
N/A N/A
SIGA 3.8399
0.4299 12.61
EASY N/A
N/A N/A
JDSU 17.21
1.42 8.99



Renhuang Pharmaceuticals is a leading bio-pharmaceutical company located in Harbin in the Heilongjiang Province in Northeast China. It is estimated that 70% of China's natural supply of Siberian Ginseng is currently controlled by the Company. Over 2000 sales agents are employed in seventy sales centers across twenty-four districts and cover over 50% of the greater China area and 80% of its population, including the most populous and developed Eastern China. The company also anticipates approval within six to nine months by State Food and Drug Administration ("SFDA") for up to five of its new Monoclonal Antibody Reagent Box series products.

Other stocks highlighted include SIGA Technologies Inc (NASDAQ: SIGA): Hot Stocks List, up 15% on 2 million shares, EasyLink Services Corporation (NASDAQ: EASY): Hot Stocks List, up 20% on 1 million shares, JDSU (NASDAQ: JDSU): Hot Stocks List, up 7% on 7 million shares.

"After a strong showing of a 5.6 percent annual growth rate in the first quarter, the economy slowed to just a 2.9 percent pace in the second. Economists look for even slower growth over the second half of the year." More is available at: http://www.thesubway.com.

TheSUBWAY.com's Daily Stock Updates:

TheSUBWAY.com, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long-term" view of any of the companies listed. For more go to http://www.thesubway.com.

All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated forty thousand shares for RHGP. CRG has also purchased five thousand shares in the open market. CRG intends to sell its shares. CRG has sold approximately zero RHGP shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees intend to buy and sell additional shares in any company mentioned within and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

CONTACT:
Capital Research Group
Charles Tamburello
954-217-8555
www.TheSUBWAY.com

[goyauno]

Die Technik sieht zur Zeit sehr gut aus!



SIGA - SIGA TECH INC (NASDAQ)

Date Open High Low Last Change Volume % Change
01/19/07 4.16 4.22 3.66 3.76 +0.35 4181400 +10.26%

Composite Indicator
Trend Spotter TM Hold

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Hold

Short Term Indicators Average: 80% - Buy
20-Day Average Volume - 2561905

Medium Term Indicators
40 Day Commodity Channel Index Hold
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 75% - Buy
50-Day Average Volume - 2019656

Long Term Indicators
60 Day Commodity Channel Index Hold
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy

Long Term Indicators Average: 67% - Buy
100-Day Average Volume - 1951925

Overall Average: 72% - Buy

Price Support Pivot Point Resistance

3.76 3.32 3.88 4.44

[mrsun]

Hallo @all
Was war am Freitag nur wieder der Auslöser für diesen kurzen aber heftigen Sprung.
Zu beobachten war,daß schon die ganze Woche über eingesammelt wurde.Und zum Donnerstag nachbörslich nur noch Käufe stattfanden,
die den Kurs ins Plus schoben,und wahrscheinlich einige shorti´s dazu nötigten,am Freitag vorbörslich zu covern.
Viele werden jetzt sagen,daß es keinen vorbörslichen oder nachbörslichen Handel gibt,sondern nicht aufgezeigte Trades nachgereicht werden.
Diesen Skeptikern möchte ich widersprechen,und empfehlen,einfach mal etwas länger am Geschehen zu bleiben,und die MM´s und ihr Spiel
zu beobachten,wenn schon alle schlafen.
Natürlich waren bestimmt auch ein paar sammlerchen dabei,Die die Woche über genutzt haben,um kurzfristig einen schnellen Profit zu machen.
Das alles ist natürlich nur´meine´ Meinung und keine allgemeine Meinung.

Viel Grün und Glück,und Augen auf

[whyso]

Antwort auf Beitrag Nr.: 27.088.181 von mrsun am 21.01.07 16:36:59

Good posting von dir......Danke Dafür

Das Chart:



Events bei Siga seit knapp zwei Jahren:

http://news.moneycentral.msn.com/ticker/rcnews.asp?Symbol=SI…


N.B. Man merke folgendes bzgl. der Donnerstag/Freitag Handel mit SIGA Stateside:

1. Somebody knew something Thursday AH
SIGA-246 is a hot topic and the potential worth is either almost nothing or hundreds of millions if not billions. Since the U.S. alone considers smallpox a material threat and already spends vast amounts of money on it, any upcoming news be it legal or government will light up short positions like a Christmas tree at least short-term (longer if it's money in the bank of course). Paying 3.55 for 19K+ shares is a no brainer if that is the price one needed to pay. In order to get larger blocks of shares AH, and enough in a short period of time, it could necessary to offer a premium. However, this person would also have expected that news would be released today or they could have cheaply, and without suspicion, purchased them today during normal Black Friday prices.

2. Someone is playing games until news breaks.
A buy of 19,000 shares even AH probably won't get the attention of the SEC. Considering there was no gradual trading to get to 3.55/share AH yesterday it's reasonable to conclude the bulk of the trading came from a single buyer(which is I asked yesterday if anyone could tell who was buying). Strangely enough about the same amount of shares were traded again today AH, this time near the low of the day. If there was market manipulating the market would know that the best prices would come at the end of the day. This same manipulation based on shorted share volume appears to have happened not long ago when the stock price shot up to 4.29 at the close of the day from the 3.31 (Nov 7, 2006). This also went unexplained and the similarities in my mind are strong.

If we get news soon, all the better, but in the meantime, I'm sure glad to see the shorts get their come-uppance for manipulating the price down in the first place.

Pharmatene has a new CFO as of today...


Es bleibt jedenfalls Spannend,
Grüße-Whyso

[mrsun]

Item 5.02. Compensatory Arrangements of Certain Officers.

On January 22, 2007, SIGA Technologies, Inc., a Delaware corporation (“SIGA”), entered into an Amended and Restated Employment Agreement (the “CFO Employment Agreement”) with Thomas N. Konatich, its Chief Financial Officer. The CFO Employment Agreement expires on January 22, 2009, and, unless either party provides thirty (30) days notice prior to the end of the term, shall automatically renew for additional one (1) year periods thereafter. Pursuant to the CFO Employment Agreement, SIGA agrees to pay to Mr. Konatich an annual base salary of $250,000, subject to any cost of living adjustments as may be approved by the Board of Directors of SIGA (the “Board”), and an annual cash bonus of $60,000. Mr. Konatich is also eligible to receive such additional bonus payments (in either cash or stock options) as may be approved by the Board in its sole discretion. SIGA may terminate the CFO Employment Agreement with or without cause (as such term is defined in the CFO Employment agreement), provided that upon any termination by SIGA without cause (including, without limitation, termination without cause upon a change in control, as such term is defined in the CFO Employment Agreement), or termination by Mr. Konatich for good reason (as such term is defined in the CFO Employment Agreement), SIGA will be obligated to continue to pay Mr. Konatich’s base salary for two years, and all stock options and other stock-based grants to Mr. Konatich shall immediately and irrevocably vest and become exercisable upon the date of termination and shall remain exercisable for a period of not less than one (1) year from the date of termination.


Also on January 22, 2007, SIGA entered into an Amended and Restated Employment Agreement (the “CSO Employment Agreement”) with Dr. Dennis E. Hruby, its Chief Scientific Officer. The CSO Employment Agreement expires on January 22, 2010. Pursuant to the CSO Employment Agreement, SIGA agrees to pay to Dr. Hruby an annual base salary of $250,000, subject to any cost of living adjustments as may be approved by the Board, and an annual cash bonus of no less than twenty-five percent (25%) and no more than fifty percent (50%) of Dr. Hruby’s base salary. Dr. Hruby is also eligible to receive such additional bonus payments (in either cash or stock options) as may be approved by the Board in its sole discretion. SIGA may terminate the CSO Employment Agreement with or without cause (as such term is defined in the CSO Employment Agreement), provided that upon any termination by SIGA without cause (including, without limitation, termination without cause upon a change in control, as such term is defined in the CSO Employment Agreement), or termination by Dr. Hruby for good reason (as such term is defined in the CSO Employment Agreement), SIGA will be obligated to continue to pay Dr. Hruby’s base salary for two years, and all stock options and other stock-based grants to Dr. Hruby shall immediately and irrevocably vest and become exercisable upon the date of termination and shall remain exercisable for a period of not less than two (2) years from the date of termination.

[whyso]

Rating 5:00 >>>100% Bullish

http://stockfriend.com/Stock/frmStockView.aspx?StockNo=3db8a…

[whyso]

N' kleine "Errinerung" von November 06...

It gave us the opportunity to bring in some cash quickly at a nice price,” said chief financial officer and acting CEO Tom Konatich, who’s been with the biotech firm for eight years. “Our balance sheet right now is about as strong as it’s been during my tenure.”

The stock placement caps a resurgence for Siga, which had entered a merger agreement last spring with an East Coast biotech company and faced delisting from the Nasdaq exchange this summer as its market capitalization slipped.

Now, with its cash reserves recharged and a smallpox drug marching toward approval, the merger is off and Siga is on the rebound.

“Siga’s a significantly different company today than it was in February and March,” Konatich said by phone from the company’s New York headquarters Friday. “We will be lobbying and negotiating with various agencies of the federal government for a sale of the drug.”


Konatich declined to speculate on when a deal to supply the drug might be reached or what it might be worth to Siga. But he did say that various industry estimates make it clear that the potential market for smallpox treatments is a lucrative one.

****“It’s in the hundreds of millions of dollars, if not more,” he said.****


Deep Pockets RON PERLEMANN (Besitzer von Revlon Kosmetics) will "reich" werden mit siga (hat 5,6 Mrd $)

Ronald Perelman is getting into biowarfare defense. Through his investment vehicle MacAndrews & Forbes and TransTech Pharma (controlled by MacAndrews), Perelman will invest $10 million in Siga Technologies (SIGA ), a tiny biotech that is developing oral drugs to prevent and treat diseases, including smallpox and anthrax. The investment, which Siga shareholders have to approve, will give Perelman a 45% stake.

http://www.businessweek.com/@@Ha6abIUQjNGyZg8A/magazine/cont…

His good connections Stateside are about to pay off good!!!

Good trades & steady hands,
Whyso

P.S. zum mitschreiben:- SIGA gibt es für knappe 2,80€ in Frankfurt morgen zu haben..

[mrsun]

Wir kriegen einen neuen Vorstandsvorsitzenden,aber so neu is der gar nicht.
Aber dem Markt scheints zu gefallen.


SIGA Appoints Dr. Eric A. Rose Chairman of the Board, Will Become CEO on March 1, 2007
SIGA Technologies, Inc. (NASDAQ: SIGA) announced today that Eric A. Rose, M.D., was elected Chairman of the Company's Board of Directors at a meeting of the Board on January 25, 2007. On March 1, 2007, Dr. Rose will be taking leave from Columbia University and will become the Chief Executive Officer of SIGA. Dr. Rose has been a member of SIGA's Board since April 2001. He had also previously served as Interim CEO from April 19, 2001, through June 22, 2001. Dr. Rose succeeds Donald G. Drapkin as Chairman of the Board. Mr. Drapkin will continue to serve the Company as a Board member. Dr. Rose is currently Chairman of the Department of Surgery and Surgeon-in-Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital, a position he has held since August 1994. Dr. Rose is a past President of the International Society for Heart and Lung Transplantation. Dr. Rose is also Morris & Rose Millstein Professor of Surgery at Columbia University's College of Physicians and Surgeons' Department of Surgery. Dr. Rose also serves as a Director of Nephros, Inc., PharmaCore, Inc., TransTech Pharma, Inc. and Keryx Biopharmaceuticals, Inc. Dr. Rose is a graduate of both Columbia College and the Columbia University College of Physicians & Surgeons. In addition to his new roles at SIGA, Dr. Rose will become Executive Vice President - Life Sciences at MacAndrews & Forbes Holdings Inc., a SIGA shareholder.

Former Chairman, Donald G. Drapkin, said, "Dr. Rose has agreed to become CEO of SIGA at an important time for our Company. As a director Eric made major contributions to the success of the Company's smallpox anti-viral, SIGA-246, and now, as CEO, we believe that he will be instrumental in the regulatory approval and eventual commercialization of the drug."

Dr. Rose said, "I'm excited by the great potential of our smallpox anti-viral SIGA-246. We are confident that SIGA-246 will become a major contributor in the battle against potential biological terrorism. I look forward to working with our Chief Scientific Officer, Dr. Dennis Hruby, and his team in completing the development and approval of SIGA-246 and moving forward the development of our other product candidates."

In recent months, the Company has announced steady progress in both clinical development and receipt of government commitments to further fund the development of SIGA-246. In the clinic, the drug successfully completed its initial human safety trial. In a primate trial, the drug demonstrated complete prevention of smallpox disease. In two additional primate trials, SIGA-246 afforded complete protection against the monkeypox virus, a closely related disease that is even more virulent in that species. SIGA has also announced the receipt of over $20 million in additional grants from the National Institutes of Health to fund future SIGA-246 activities and advances in other drug programs.

[whyso]

Antwort auf Beitrag Nr.: 27.331.891 von mrsun am 31.01.07 21:07:03

Good news...travels fast

Die kern aussagen in der heutige Botschaft sind für mein dafürhalten wie folgt:

1. Dr. Rose is a past President of the International Society for Heart and Lung Transplantation.(Beste Beziehungen in der Branche)

2. We are confident that SIGA-246 will become a major contributor in the battle against potential biological terrorism. (Diese Aussage deutet an das die Regierung "Smallpox stockpiles" bereits zu recht gelegt bzw. bereits bestellt hat )

3.The development and approval of SIGA-246 and moving forward the development of our other product candidates-...(also SIGA 246 ist der Sprungbrett die nächste Produkte reifen zu lassen-die Produktionsstätten sind nach der SIGA 246 Launch bereits vorhanden )

4. Welche neuer Produkte??? (arenaviruses)

1. Lassa fever,
2. Junin,
3. Machupo,
4. Guanarito,
5. Sabia,
6. lymphocytic choriomeningitis),
7. Dengue virus,
8. and the filoviruses (Ebola and Marburg).


SIGA's product development programs also emphasize the increasingly serious problem of drug resistant bacteria. (Die nächste Zukunft für die US Regierung ...und später der kranke Durchschittsburger)


Die Story kann wirklich "big" werden- aber wie lange schaut big pharma noch tatenlos zu?

Steigende Grüße,
Whyso

[mrsun]

Antwort auf Beitrag Nr.: 27.332.598 von whyso am 31.01.07 21:38:24

hallo whyso
Deine Interpretation trifft es wie immer auf den Punkt.
SIGA-246 wird das Sprungbrett in die Oberliga sein,und weitere Investoren,über die Produktpipeline der nächsten Generation hellhörig werden lassen.
Desweiteren ein Danke schön für Deine vielen guten Recherchen,für die nicht nur ich oftmals zu faul bin.

grüssle

[mrsun]

ach ja,unser Kassenwart hat auch noch ein filing hinterher geschickt

[whyso]

Antwort auf Beitrag Nr.: 27.333.323 von mrsun am 31.01.07 22:06:23

De nada Mr.Sun

Es freut mich sehr das du noch mit von der Partie bist...schön iist es wenn eine 'kleinere Gemeinde' etwas größeres gemeinschaftlich am Markt entdecken kann-(sprich, die Entwicklung etwas voraus sein)-und ein Bestätigung der höhe Erwartungshaltung (im Kursentwicklung) tut uns allen 'ab und zu' einfach gut.

Viele Grüße & bis die Tage,
Whyso

[whyso]

Heres some brilliant "fact deduction" from Rocketdrug over at Yahoo:

Eric Rose is on the board of dirrectors for Transtech Pharma which with Ronald Perlman's MacAndrew & Forbes Holding already own a considerable amount of Siga. TransTech is in cohoots with Boehringer Ingelheim; a major German based pharma. So it looks like the BIG buyout may have already happened. Our new owner is the same owner we had. Now how is Perlman gonna get my shares......
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…

Das macht jedenfalls n'menge Sinn im meinem augen...

und daraus resultierend>>>> wilkommen beim neuen/alten SIGA Trend



Diese Woche kann noch Heiss werden-2,80 & counting!
Whyso

[whyso]

AIDS & SMALLPOX VACCINE: (wie weit liegen sie auseinander)


AIDS/Smallpox Vaccine OK in Early Test-AIDS Vaccine That Protects Monkeys Looks Good in First Human Test

AIDS Vaccine From Smallpox Vaccine

It's a two-part vaccine. First, a person gets two doses of a DNA vaccine carrying three important HIV genes called env, gag, and pol. Then a person gets two doses of a smallpox virus genetically engineered to carry the same three HIV genes.

The smallpox component of the vaccine makes it unique. The virus, called the modified Ankara virus or MVA, cannot replicate in humans and cannot cause disease. It was used in the waning days of the successful global smallpox eradication program to safely vaccinate some 120,000 people in Germany.

A side benefit of the GeoVax vaccine is that recipients will become immune to smallpox, should that virus return via bioterror attack or lab accident.

But the main reason for using the smallpox virus is that it is one of the most powerful stimulators of immunity known to man. And it seems that when the virus carries HIV genes, those powerful immune responses transfer to HIV as well.


http://www.webmd.com/content/article/131/118177.htm

[mrsun]

Antwort auf Beitrag Nr.: 27.656.749 von whyso am 12.02.07 11:43:32

hallo whyso
Was hast Du denn daaaa wieder angerichtet,mit Deinem Bericht von heute Morgen.
Wie mir scheint lesen alle Ami´s nur noch hier,im wo mit.

[goyauno]

Antwort auf Beitrag Nr.: 27.656.749 von whyso am 12.02.07 11:43:32

Hallo ihr lieben, sieht mal wieder sehr gut aus.

Das Volumen stimmt auch mal wieder.

Habe nur leider kein Cash mehr um nachzulegen, bin schon ziemlich voll investiert.

GL

goyauno

[goyauno]

und der Kurs zieht sofort an.

Press Release Source: SIGA Technologies, Inc.


SIGA Begins Second Human Safety Trial of Its Lead Smallpox Drug
Tuesday February 13, 2:45 pm ET


NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) announced today the launch of a 21-day, escalating, multiple-dose, Phase 1 safety, tolerability and pharmacokinetics human trial of SIGA-246, its lead smallpox drug. The study will examine the safety and pharmacokinetics of SIGA-246 at three different dosages in healthy volunteers when taken once a day for 21 days.
ADVERTISEMENT


"This is one more milestone in the path to FDA approval," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA. "This important study we believe will confirm the safety findings of an earlier human study and establish the likely human dose of SIGA-246."

The trial is being conducted at the Orlando Clinical Research Center in Orlando, FL, and is overseen by Dr. Thomas Marbury in collaboration with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The study is a double-blind, randomized, placebo-controlled, ascending multiple-dose study.

SIGA believes that SIGA-246 is the most advanced smallpox treatment currently in development. SIGA-246 represents a new approach to achieve a novel, orally active, antiviral therapeutic. It has already demonstrated significant antiviral activity in various animal trials, including the complete protection against human smallpox virus in primates as well as complete protection in two primate trials against high doses of monkeypox.

This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN266200600014C.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg).

For more information about SIGA, please visit SIGA's Web site at www.siga.com.

Forward-looking Statements

This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products and (f) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.



Contact:
SIGA Technologies, Inc.
Tom Konatich, 212-672-9100
Chief Financial Officer

Auf weiter steigende Kurse!!!!!

GL

goyauno

--------------------------------------------------------------------------------
Source: SIGA Technologies, Inc.

[mrsun]

Antwort auf Beitrag Nr.: 27.690.468 von goyauno am 13.02.07 20:51:49

hallo goyauno
Die Richtung dürfte doch wohl jetzt jedem klar sein.
Hier gibts kein "wenn und aber" mehr.
Bin nur gespannt wann die breite Masse aufspringt,dann sind die bisher gesehenen Sprünge,nur noch kleine Hüpfer sein.
Bis dahin weiter immer Grün

[overview]

Antwort auf Beitrag Nr.: 27.656.749 von whyso am 12.02.07 11:43:32

Gibt es einen Zusammenhang zwischen SIGA, HIV und dem hier?
http://onnachrichten.t-online.de/c/10/36/55/46/10365546.html

[mrsun]

wer zum teufel ist Gary S. Siperstein

Wed, Feb 14, 2007

FILING An amendment to the SC 13G filing - Form SC 13G/A

[mrsun]

Reader´s Digest März 2007

Upping the Odds of Survival
Smallpox Cure
But wasn't that disease killed off a long time ago? While the smallpox virus was officially stamped out in 1980, unknown samples of the virus may still be out there. And if they ended up in terrorists' hands, the results could be devastating, infecting thousands, possibly millions, of people. Up to a third would die.

Now scientists may have found a cure for smallpox. The new drug, SIGA-246, currently in the final stages of development and testing, not only safely protects against the disease but also can treat it and stop an outbreak in its tracks. The drug would also work for relatives of the virus, like monkeypox and cowpox, which could someday mutate and become just as dangerous as smallpox.
Available: 1-3 years
-- Cynthia Dermody

[whyso]

Antwort auf Beitrag Nr.: 27.721.772 von mrsun am 15.02.07 13:30:17

Smallpox verträge mit der US Regierung gegen ende 2001 hatten ein Gegenwert von 428$ für 155 millionen Behandlungen-in der folge Woche als SIGA bekannt gab das sie ein 100% Lösungsansatz für Smnallpox hatten kündigte die US Regierung alle weitere verträge & verhandlungen mit Acambis/Baxter

Think about it....
----
FOR IMMEDIATE RELEASE
Wednesday, Nov. 28, 2001 Contact: HHS Press Office
[phone]



HHS AWARDS $428 MILLION CONTRACT TO PRODUCE SMALLPOX VACCINE
Acambis/Baxter will produce 155 million doses by end of 2002

--------------------------------------------------------------------------------
HHS Secretary Tommy G. Thompson today announced that Acambis Inc., with support from its subcontractor Baxter International Inc., has been awarded a $428 million contract to produce 155 million doses of smallpox vaccine by the end of 2002.
Production of the vaccine under the new contract could begin as soon as December, and, once completed, will bring the total number of vaccine doses in the nation's stockpile to 286 million by the end of next year, enough to protect every United States citizen, if needed.

In light of increasing concerns regarding the possible use of biological agents such as smallpox in acts of terrorism or war, HHS is undertaking efforts to stockpile as much vaccine as needed to protect the nation in the event of an outbreak of smallpox.

"While the probability of an intentional release of the smallpox virus is low, the risk does exist and we must be prepared," Secretary Thompson said. "Expanding our stockpile so there is a smallpox vaccine for every American if needed prepares us to respond aggressively to minimize the spread of the disease should an outbreak occur. Additionally, we hope that increasing our smallpox vaccine stockpile would serve as a deterrent to those who might consider using smallpox as a weapon against us."

Acambis and Baxter will produce the smallpox vaccine using a purified strain of vaccinia virus grown in live tissue culture. Vaccinia virus is related to smallpox and stimulates immunity to the smallpox virus. The bulk vaccine will be produced in Baxter's production facility in Europe and will then be shipped to the U.S. for refinement and processing. The Food and Drug Administration will conduct a review of each vaccine production process along with testing of individual test lots of vaccine to assure the safety and effectiveness of the vaccine. The cost per dose of vaccine will be $2.76. The fixed-price contract protects taxpayers from any cost overruns, which would be borne by the manufacturer.

In addition to the 155 million-dose production announced today, other supplies of smallpox vaccine exist or are in development. The combination of the new contract with other supplies would bring the total number of doses in the smallpox vaccine stockpile to 286 million, and the new contract gives the federal government the option to purchase even more vaccine quickly.

An existing supply of 15.4 million doses of the "Dryvax" smallpox vaccine has been stored since production of the vaccine ended in 1983 and has retained its potency over this period of time. The National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health has been studying the possibility of diluting this supply of vaccine by a ratio of 1 to 5 as a potential means of extending the supply. Early results indicate that the diluted vaccine retains the same level of effectiveness as the fully concentrated vaccine, which essentially will expand the existing Dryvax vaccine supply to at least 77 million doses. Researchers are also studying whether a 1 to 10 dilution retains the same level of effectiveness, as well.

In September 2000 the Centers for Disease Control and Prevention (CDC) awarded a contract to Acambis to produce a new supply of 40 million doses of smallpox vaccine by 2004. In September 2001 CDC renegotiated an accelerated production schedule with Acambis, in which the company agreed to increase its production to 54 million doses and deliver them by late 2002.

"These combined efforts will give us enough smallpox vaccine doses in our nation's stockpile to ensure every American will have a vaccine with his or her name on it, if needed," Secretary Thompson said.

In preparing for the possibility of a smallpox outbreak, the CDC has developed an interim smallpox response plan that outlines the essential public health strategies and approaches for responding to a smallpox emergency, including the use of smallpox vaccine.

The CDC plan does not call for mass vaccination of the U.S. population in advance of a smallpox outbreak. Based on what we know today, the risk of an outbreak of smallpox is substantially lower than the risk of serious complications from the vaccine.

According to the plan, rings of personal contacts, such as family members and co-workers, would be identified and then be vaccinated and monitored. This strategy, known as ring vaccination, is credited with helping to wipe out smallpox in the late 1970s and is still the most efficient approach today.

The last case of smallpox occurred in the United States in 1949, and the disease was declared eradicated worldwide in 1980 by the World Health Organization (WHO). Vaccinations to prevent smallpox have not been routinely administered in the United States since 1972, and people vaccinated prior to 1972 very likely have diminished immunity to smallpox.

"Expanding our existing smallpox vaccine stockpile ensures that we are well prepared in the event of a bioterrorist attack using smallpox," said Dr. D.A. Henderson, director of the HHS Office of Public Health Preparedness and the person who led the WHO worldwide effort to eradicate smallpox. "This new contract gives us the insurance that we will have more than enough vaccine for any outbreak that might occur."

Smallpox symptoms include fever and a pock-like rash all over the body, appearing between seven and 17 days after exposure to the virus. People who are infected do not become contagious until the rash appears.

The foremost public health priority during a smallpox outbreak would be control of the epidemic. Doctors, health care workers and hospital personnel have been trained to identify infectious diseases, verify their diagnosis and then respond appropriately. The same system would identify any possible outbreak of smallpox.
http://www.hhs.gov/news/press/2001pres/20011128.html

Stockpiling continues -aber umso mehr heute auf basis der evtl. Viral-attake von unbekannt

Nun schaut Euch die US basiert SIGA näher an:
http://www.siga.com/press/071306.html
http://www.siga.com/press/100506a.html
http://www.siga.com/press/071306.html

und vor allem dieses

The worldwide annual market for antibiotics is estimated at nearly $22 billion. There are 25 million reported cases of "strep throat" annually in the U.S which results in a treatment cost of nearly $1 billion, while the cost alone of dealing with antibiotic resistance is estimated at $100 million annually. A novel therapeutic that will effectively clear a wide range of Gram-positive pathogens is expected to make a significant impact in this market. Our novel anti-infectives are anticipated to be effective against antibiotic resistance strains as they will block the adherence of organisms to tissue; working at a completely novel step in the pathogenesis pathway. Furthermore, our approach is not expected to apply strong selection pressure for the development of resistant organisms, as the drugs are not expected to be bactericidal.


Long & strong-schönes WE ihr Lieben,
Whyso

[goyauno]

Hallo Whyso,

danke für Deine Arbeit und Mühe hier im Thread!

Wie mrsun, weiter oben schon mal ausgeführt hat, warten wir einmal mehr auf die Masse, welche mit Sicherheit kommen wird.

Dir und Deiner Lieben, auch ein schönes WO.

goyauno

[whyso]

Tag zusammen!

was für ein Überschrift? (Washington Post 2006)
"The Secretive Fight Against Bioterror"

und die Ausgabenentwicklung unter Bush ist auch nicht von schlechten Eltern)



Habt ihr das mit die mögliche "Bioterrorismus Anschlag in Russland" mitbekommen von letzten Freitag????

"Bioterror Suspected in Hepatitis Outbreak"
http://english.mn.ru/english/issue.php?2005-22-8

Ich denke wir stehen hier eher am Anfang von SIGA's Gesamtentwicklung am Viralbekämpfungsmarkt...

Good trades,
Whyso

[whyso]

Etwas lesenswertes von Yahoooooooooo
-------------------
SIGA going up flippers want it lower because they know its good long term! (3 Ratings) 25-Feb-07 03:31 pm SIGA has been in a tight trading range & then dipped a bit Friday only to recover & the below link contains the resulting tech indication:
http://www.americanbulls.com/StockPage.a...

In addition to that SIGA's 50-100 day MACD Oscillator says buy & hold long term while the 7 day average directional indicator is also a buy.

SIGA may go hard this week in fact it should at some point by Wednesday or sooner. Technicals are speaking the way I read them.

Lets forget technicals though & look at the below reasons to buy SIGA:

1)SIGA is making rapid progress on several new boipharmaceuticals\biowarefare agents.
a.SIGA-246 (anti-smallpox) market potential - over $1 billion.
b.SIGA-294 (anti-arenavirus) market potential in hundreds of millions.

2)More than a nice earnings cc coming in March IMHO. Should include updates on potential markets for the above drugs.

3)Legal complaint being dropped should propel SIGA up to $6.60-$7.00 area.

4)Current trial to find dose is short in nature. SIGA may post interim dose news while continuing further portions of the trial on a bigger test group for safety.

5)Anti-infective program that deals with the growing problem of antibiotic resistance. World wide market said to be over $25 billion.

6)potential buy out based on both the anti-viral & anti-bacterial platforms.

7)SIGA developing new biopharmaceuticals intended for commercial sales including a vaccine that addresses the more than 120 varriants of strep throat bacteria in partnership with the NIH.

8)According to the Congressional Budget Office $5.6 billion was tagged for 5 pathogens. Smallpox being tops on the list.

9)The government is committed to have 2 approved drugs on hand for each pathogen. SIGA's oral 100% effective so its my top pick to be one of the 2.

10)Great Staff now headed by a large gun & deal maker Dr. Rose.


Other interesting things:
Shorts posting = bashing not shorting. People with big money want your shares.
Think about it why short a technical up trend with pending rocket news?
Answer to get your shares cheap. Selling below $4.84 if your a long term investor is nuts IMHO.
You might just get left behind in a flash run & for what nickles & dimes? The term over trading comes to my mind.

1st safety trial in humans proved to be safe. The monkeys had no problems either. We are related to monkeys just look at tollsname, Isa_cheese & cindy_jo_edwards as proof.
I guess in all fairness those 3 are much more closely related to monkeys than the rest of us. (no offense to the monkeys in the SIGA labs intended)

SIGA has had some nice moves up on down market days & has stopped following the market = very bullish.

The only question I have is will you have it or will you want it? Will you have enough of it when the time comes for a news release? http://www.youtube.com/watch?v=Af1OxkFOK...

Low $4's won't be seen much longer.

Do your own DD & I am sure you will agree!
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…

Die Uhr tickt Richtung Q ende -(und somit Testreihen ende)-sie tickt beständig & für shorties fast unaufhörlich...

[goyauno]

$$$$

Es wurde auch langsam Zeit!!

Auch das Volumen hat heute angezogen.

News habe ich bis jetzt noch keine gefunden!

@ Whyso
(Der Hilmar kopper sollte auch mal in Siga investieren)

wenn er klug ist, dann hat er vielleicht schon welche!!

Blood/Whyso, ich lese gerne auch drüben Deine Beiträge.

bis nachher

Steigende Kurse wünsche ich uns allen.

[whyso]

Antwort auf Beitrag Nr.: 28.193.999 von goyauno am 08.03.07 22:16:17

Hi Goyauno-wie heisst du eigentlich 'drüben'?

Haben wir hier ein 100% Buy im Depot liegen?-
http://quote.barchart.com/texpert.asp?sym=SIGA

Time will tell-Perlemann/Rose we are watching you



Ein schönes Restwochenende ihr lieben,
Whyso

[whyso]

Die Sonne scheint-(und nicht nur bei SIGA)-

Ready to rumble????
http://stockcharts.com/h-sc/ui?s=SIGA&p=D&b=5&g=0&id=p490860…

Langsam aber sicher kann 'die tüchtige Sammlertruppe' sich nicht mehr hinter den aktuellen Kursentwicklung verstecken!

Auf eine grüne Woche ihr lieben,
Whyso

[goyauno]

Antwort auf Beitrag Nr.: 28.252.103 von whyso am 12.03.07 12:25:15

Hi Whyso,

bin drüben nur ein stiller Leser.

Die $5,- sollten wir doch diese Woche knacken können.


con muchos Saludos y hasta luego mis amigos, vuestro
goyauno

[whyso]

Antwort auf Beitrag Nr.: 28.252.567 von goyauno am 12.03.07 12:58:40

Picture of Power Chart mit SIGA
http://stockcharts.com/def/servlet/Favorites.CServlet?obj=ID…

Ich habe mir die Mühe gemacht die 'Revenue Entwicklung' bei Siga seit knapp 4 Jahren nachzurechnen-die ergebnisse sind m.E. recht erfreulich-und seit 2006 mit die 100% Heilungsfindung für Smallpox (kommt erst jetzt zu Geltung, umso erfreulicher ) -N.B. In addition to smallpox, SIGA has antiviral programs targeting other Category A viral pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and LCM), flaviruses (Dengue), and the filoviruses (Ebola and Marburg), each of which presents a substantial, unmet medical need.- übrigens, 'Aids' lässt sich unter Viral auch sehr gut zuordnen!

2002: 344,450$ (growth rate -70,29%)
2003: 731,743$ (growth rate 112,44%)
2004: 1,839,392$ (growth rate 151%)
2005: 8.476.741$ (growth rate 360%)

Now what might 2006/2007 have in store for us & Dr. Rose??????

Keep the faith & the shares,
Whyso

P.S. Goyauno, Danke für die herzliche grüße-anscheint sind wir mittlerweile ganz unter uns-hasta luego mis amigos

[whyso]

Der 'Peer Performance' Vergleich ist auch recht interessant....
http://www.cnbc.com/id/15837290?q=siga

Bis denne!

[mrsun]

Hallo Jungs,10-K is da

[goyauno]

Hola amigos,

anbei ein paar neue News,

http://www.chicagotribune.com/news/local/chi-0703170122mar17…

Smallpox shot infects soldier's toddler son
Boy critically ill; mom also stricken

By Jeremy Manier
Tribune staff reporter
Published March 17, 2007
In the first case of its kind in years, a 2-year-old boy is being treated in Chicago for a rare and life-threatening infection that he contracted from his father, a U.S. Army soldier recently vaccinated against smallpox.

The Indiana boy is in critical condition with eczema vaccinatum, an unusual side effect of the smallpox vaccine that can affect people who receive the shot or their close contacts.



E-mail this story

Printable format

Search archives

RSS






Doctors also said the boy appears to have passed the infection to his mother, who has a much milder case of the virus in the smallpox vaccine, which is also called vaccinia. The virus is not smallpox, though it is similar enough to offer protection from that deadly disease, which was declared eradicated in 1980.

The mother and child are being treated at the University of Chicago's Comer Children's Hospital, which withheld their names at the family's request. There is no infection risk for the general population, government officials say, since the vaccine virus can spread only through close physical contact.

But the boy's diagnosis last week has prompted a frenzy of activity and daily conference calls involving the federal Centers for Disease Control and Prevention, the U.S. Department of Defense, and the state and city public health departments. The U.S. Food and Drug Administration gave emergency authorization for the hospital to treat the boy with ST-246, an experimental drug for smallpox that is untried as a therapy in humans.
The smallpox vaccine fell out of general use in the 1970s, but the case could be a lesson for the U.S. military, which has vaccinated 1.2 million personnel against smallpox since 2002 amid fears of bioterrorism.

It's unclear why the father was allowed to have contact with his son, who had a history of eczema, shortly after the vaccination. The skin condition is a well-known risk factor for eczema vaccinatum, and official guidelines warn that people with eczema should avoid contact with vaccinees.

"We are looking into how this could have happened," said U.S. Army spokesman Paul Boyce.

Officials say the general population could receive smallpox vaccinations in the event of a bioterrorist attack or other unforeseen exposure. For that reason, experts want to study the Indiana family to learn more about treatment and transmission of the vaccinia infection.

"There certainly are also conceivable insights into smallpox infection," said Dr. Inger Damon, chief of the CDC's poxvirus and rabies branch. Damon has been involved in the daily conference calls on the boy's treatment.

Experts said they knew of no cases of eczema vaccinatum since at least 1990, when the military last had a program of smallpox vaccination.

The vaccinia virus in modern smallpox vaccines is closely related to an older form of vaccinia called cowpox, the disease English doctor Edward Jenner used in the late 1700s to develop early methods of vaccination.

Jenner relied on the observation that milkmaids who had cowpox seemed to be protected from later smallpox infection. He found that patients inoculated with material from cowpox sores also got protection from smallpox. That history is why the word vaccine stems from the Latin word for cow.

Vaccinia was modified from its original form over the years but remains an infectious agent with the potential for side effects.

The father of the Indiana boy received the vaccine in late January before a planned military deployment. The Army delayed his departure and permitted him to visit his family in mid-February.

Two weeks later, a rash broke out on the boy's skin. He came to the U. of C. on March 3 after being transferred from St. Catherine's Hospital in East Chicago. Doctors first identified his widespread rash as a different form of eczema, but it worsened in his first few days at the U. of C.

His mother developed sores after she and her son arrived at the Chicago hospital. Doctors believe she contracted the disease from the boy because of their lengthy close contact.

A pediatric dermatologist, Dr. Sarah Stein, noticed the boy's lesions had changed to look like round blisters with a dimple in the middle--a potential sign of vaccinia infection. The medical team took scrapings from the lesions, which they analyzed and sent to the Illinois Department of Public Health's Chicago office for further testing.

Rapid tests by the state and further tests at the CDC confirmed the boy had the vaccinia virus, officials at those agencies said. The hospital also sent the CDC photos of the boy's lesions.

The hospital already was using infection precautions with the boy, but staffers then added such measures as gloves and face masks. They also placed the boy in a room with negative pressure so the air would always blow inward, keeping the virus inside.

The boy's rash had spread to cover 80 percent of his body, said Dr. Madelyn Kahana, chief of pediatric intensive care medicine at the U. of C. He was going into sepsis, a devastating, systemwide infection rarely seen with viral cases.

"In the later stages of [eczema vaccinatum], it can look like smallpox," said Damon of the CDC.

The boy needed a ventilator to help his breathing because of the powerful pain medication he needed for the lesions.

The boy received the primary treatment for eczema vaccinatum, a drug called vaccinia immune globulin, or VIG. The drug came from a stockpile the CDC keeps in case widespread vaccination ever becomes necessary.

He also got an antiviral drug called cidofovir and the experimental drug ST-246, which has been shown to protect laboratory animals from exposure to smallpox. The drug recently entered preliminary human trials but had never been used in a sick patient.
U. of C. officials said the boy has shown signs of improvement since hitting a low point last weekend. His mother's health was never in serious danger, but she has remained in his hospital room to keep others from being exposed. Health officials in Chicago and Indiana have tracked all of the family's contacts and found no additional cases so far.

Kahana said the boy probably will lose 20 percent of his outer skin layer, but she hopes he will recover without the need for skin grafts. She believes the case should be a lesson to the military, which must educate service members about the risks of the vaccines it requires them to take.

"I think the information simply wasn't disseminated properly or impressed in a manner that was understood," Kahana said, "because I don't think anyone would knowingly expose their child to this."

----------

[e-mail]
Copyright © 2007, Chicago Tribune
--------------------------------------------------------------
By Maggie Fox, Health and Science Editor

WASHINGTON, March 17 (Reuters) - The 2-year-old son of a soldier deployed to Iraq is in critical condition after developing a reaction to his father's smallpox vaccination, the U.S. Centers for Disease Control and Prevention said on Saturday.

The child, being treated in a Chicago hospital, has a rare but very serious reaction to the vaccination site called Eczema vaccinatum, the CDC said. It is the first such case since vaccination against smallpox resumed in 2002, said CDC pox virus expert Dr. Inger Damon.

The toddler's father is a soldier vaccinated while on deployment to Iraq. The father was unexpectedly furloughed and evidently his wife and son touched the vaccine site and became infected, the CDC said.

Reuters Pictures

Editors Choice: Best pictures
from the last 24 hours.
View Slideshow

"They can get a particularly noxious and sometimes fatal rash," Damon said in a telephone interview.

The smallpox vaccine is made using a closely related virus called vaccinia. It is scratched into the surface of the skin, where it causes a mild infection that makes people much less susceptible to smallpox.

But because it uses a live virus, the vaccine can cause severe and sometimes deadly side effects. Eczema vaccinatum is one of them, although this is the first case to be reported since smallpox vaccinations resumed in the United States in 2002.

"The child is a dependent of a U.S. Army Service member deploying to Iraq," the CDC said in a statement. Continued...

© Reuters 2007. All Rights Reserved.

ein schönes Wochenende, und auf eine hoffentlich tiefgrüne kommende Woche!


hasta luego amigos, vuestro

goyauno

[mrsun]

Antwort auf Beitrag Nr.: 28.341.417 von goyauno am 17.03.07 14:42:53

Traurige Situation für die Familie,aber für SIGA "die Chance",zu beweisen was in ST-246 steckt.
Wäre doch der Kracher,bei einem nachgewiesenen Behandlungserfolg durch ST-246.
Natürlich wünsche ich auch als Mensch,dem Kind und der Mutter einen raschen Erfolg.

[whyso]

Antwort auf Beitrag Nr.: 28.345.429 von mrsun am 17.03.07 18:17:45

Sehr sympatisch deine Einstellung mit ein absolut richtige Inhalt-es tut wirklich gut ein solche "WERT" zu besitzen, Siga is already changing lives

Dad's smallpox shot infects son, 2 -Experimental drugs bring Ind. boy back from brink of death

March 18, 2007
BY DAVE NEWBART Staff Reporter
A 2-year-old boy stricken with a rare infection from the smallpox vaccine is improving but remained in critical condition Saturday at the Comer Children's Hospital at the University of Chicago.
The boy was infected by his father, a U.S. soldier who was vaccinated in January in preparation for service in Iraq. But his deployment was delayed, and he returned home to Indiana late last month. His son, who suffers from skin lesions known as eczema, then became infected by vaccinia, a virus similar to smallpox and used in the vaccine against it.

The boy is the first person to suffer from the severe infection, known as eczema vaccinatum, since the U.S. military began inoculating troops in 2002. But his condition is so uncommon that U. of C. experts said they could not find reports of any cases in the United States since before 1972, when routine vaccinations for smallpox were halted.


Only seen in photos
"This is something that is new to us," said Kenneth Alexander, head of pediatric infectious disease at U. of C.
The boy, whose name was not released, was sent to U. of C. from a northwest Indiana hospital March 3 after he developed a severe rash. He didn't improve after treatment, and by March 7, a dermatologist noticed his lesions resembled those caused by smallpox -- something doctors had only seen in photos because the disease was eradicated.

Doctors contacted the federal Centers for Disease Control and Prevention, which agreed to fly in a treatment never used on a child, vaccinia immune globulin (VIG). The drug was hand-delivered by U.S. marshals.

The boy's condition continued to worsen, and last weekend, his lungs and kidneys began to fail. "He was near death," said Madelyn Kahana, chief of pediatric critical care medicine. Painful skin lesions covered most of his body.


'He is slowly improving'
The CDC then asked the Food and Drug Administration to grant emergency permission to try ST-246, an experimental drug being developed to fight smallpox. It had been effective in treating mice and monkeys infected with the virus, said U. of C. pediatrician John Marcinak, who is spearheading the boy's treatment.
But it had never been used on a sick person.
That, combined with VIG and another drug, seems to be working. Since he first got the drug March 11, "he is slowly improving," Marcinak said.

The boy's mother contracted a milder form of the vaccinia virus from the boy and has been quarantined in the boy's room but is recovering well, officials said.

She has cried some days but in general has been "very strong and optimistic," said Surabhi Vora, a U. of C. fellow who has been assisting in the boy's treatment.


'Military has to be careful'
Doctors said the father -- who has since returned from his deployment at the hospital's urging -- had no idea he should stay away from his son after receiving the vaccine.
Kahana said the "military has to be careful" in making sure soldiers understand the risks and that they stay away from high-risk populations, such as people with eczema.

"They are trying to figure out where the misstep was," she said of the military. A military spokesman could not be reached Saturday.

The boy has two siblings, but no one else appears to have been infected, doctors said. The hospital has taken extreme precautions in treating the boy -- including keeping him in a room where the air only flows inward. Officials say the general public is not at risk because the infection is only transmitted through close physical contact.

Now doctors are just hoping the boy will make a full recovery. Before the infection worsened, the boy was fairly cooperative and talkative, saying "cup, cup, cup" when he was thirsty, Vora recalled. But since then, the boy has been sedated and is on a ventilator.

"I'm looking forward to seeing him awake and talking," she said.
http://www.suntimes.com/news/metro/302333,CST-NWS-VACCINE18.…

Keep the faith & the shares-beste Sonntagsgrüße allerseits,
Whyso

[whyso]

Die jüngste drei 'realitäten' im Fall Siga

1. "The boy's condition continued to worsen, and last weekend, his lungs and kidneys began to fail. "He was near death," said Madelyn Kahana, chief of pediatric critical care medicine.

2.Die FDA granted emergency permission to try ST-246

3.Since he first got the drug March 11, "he is slowly improving,"

Siga finde ich...

[whyso]

Watch this space

SIGA’S SMALLPOX DRUG CANDIDATE-ADMINISTERED TO CRITICALLY ILL HUMAN PATIENT

New York, March 19, 2007-- SIGA Technologies, Inc. (NASDAQ: SIGA) announced today that a toddler who inadvertently contracted eczema vaccinatum has been treated with ST-246, SIGA’s lead smallpox drug candidate, pursuant to an Emergency Investigational New Drug Application (IND) granted by the U.S. Food and Drug Administration (FDA), and is now improving.

Due to the absence of smallpox disease in the general human population, the efficacy of ST-246 has been investigated in animals to date. However, the federal Centers for Disease Control and Prevention (CDC) was recently notified that a child had contracted eczema vaccinatum, a potentially deadly illness that can manifest with a generalized skin rash similar to smallpox, following accidental contact with an open skin lesion on a relative who had recently been vaccinated for smallpox using a live vaccinia virus vaccine. The patient developed late-stage manifestations of the disease, including hemorrhagic lesions, respiratory failure, shock and high viral loads in the blood. CDC facilitated communication between SIGA and FDA resulting in provision of ST-246 for the patient under an Emergency IND.

“There is a clear need for an effective therapeutic against smallpox and other orthopox virus diseases,” said Dr. Eric A. Rose, Chief Executive Officer of SIGA and Executive Vice President for Life Sciences at MacAndrews & Forbes Holdings Inc., SIGA’s largest shareholder. “We will continue to work closely with CDC and FDA to obtain the earliest possible approval (bereits von der FDA zugelassen als es "eng" wurde letzte woche) for ST-246, so that it can be purchased and widely available whenever needed.”

SIGA believes that ST-246 is the most advanced-stage treatment for smallpox currently in development. ST-246 represents a new approach to achieve a novel, orally active, antiviral therapeutic. It has already demonstrated significant antiviral activity in various animal trials, including the complete elimination of human smallpox virus or the related monkeypox virus in several primate studies. SIGA has not yet filed for final regulatory approval for ST-246, although FDA has granted “fast-track” status for the development and FDA review of this product.

Development of ST-246 has been supported by grants from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the CDC and the Department of Defense.

Ich denke wir haben es hier mit ein ACOR nummer zwei zu tun, hier sieht man die 12 Monats Abbildung bei Acor-SIGA's prospects, Marktsegment, Aussicht & Pipeline ist um einiges viel versprechender z.Zt- nur zur Errinerung mann könnte SIGA für 3,35 kaufen in Fraknkfurt heute morgen...



Long & strong,
Blood

[whyso]

Ooopssss...Sorry:, sollte selbstverständlich heissen
Whyso



Steigende Grüße ihr lieben!

[mrsun]

Antwort auf Beitrag Nr.: 28.372.724 von whyso am 19.03.07 15:51:26

hallo whyso
komme grad von der arbeit,und sehe,es funzt doch.
stimmt also doch,daß die ami´s das zeitung lesen nicht verlernt haben.

[whyso]

Das magisiche Elexir...



Lesen & Staunen:
-Toddler improving on experimental smallpox drug-

http://www.reuters.com/article/healthNews/idUSN1953739120070…

Bis denne,
Whyso

[mrsun]

Hallo Siga Gemeinde
Hier wird ja grad wieder gerüttelt ohne Ende,und das auf sehr hohem Niveau.
Würde mich nicht wundern,wenn schon positive Nachrichten in der Pipeline stecken,und die Grossen sich kräftig eindecken.
Nicht mehr zu übersehen ist,daß die Kursspitzen immer höher reichen.
Also,6$ wir kommen,und den letzten beissen die Hunde.

[whyso]

SIGA hat vieles zu verkunden demnächst...- (hier die 'kurze Liste' bis heute)

Recent Corporate Developments:
February 13, 2007 - SIGA announces launch of a 21-day, escalating, multiple-dose, Phase 1 safety, tolerability and pharmacokinetics human trial of ST-246, its lead smallpox drug
January 31, 2007 - Eric A. Rose, M.D. elected as Chairman of the Company's Board of Directors and CEO effective March 1, 2007
December 20, 2006 - FDA Orphan Drug designation granted for ST-246
November 10, 2006 - SIGA announces $2.3MM in new contracts with the U.S. Air Force
November 9, 2006 - SIGA announces successful results of two independent primate trials (National Institute of Allergy and Infectious Diseases (NIAID) and U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) conducted studies) of its smallpox drug ST-246
October 19, 2006 - SIGA announces $9 million private placement
October 18, 2006 - ST-246 is the first drug ever to demonstrate 100% protection against human smallpox disease in a primate trial conducted at the federal Centers for Disease Control and Prevention (CDC).
October 4, 2006 - SIGA receives 3-year, $16.5 million contract from the NIAID to advance the development of ST-246
September 12, 2006 - SIGA receives $6.0 million grant from the NIAID to support the development of antiviral drugs for Lassa fever virus, which is an arenavirus
August 2, 2006 - SIGA announces $4.8 million grant for the development of ST-246
July 13, 2006 - Successful completion of the initial human safety trial for ST-246
December 13, 2005 - FDA accepts Investigational New Drug (IND) application to begin clinical trials of ST-246 and grants the drug "Fast Track" status


http://biz.yahoo.com/bw/070322/20070322005837.html?.v=1
(die Begründung für diese Anheurung ist auch recht interessant anzuschauen):

"Company Seeks to Generate Greater Investor Awareness as its ST-246 Smallpox Treatment Continues Through the FDA Approval Process"
--------------------
I pray against a buyout bid...I hope and pray big pharma will 'recognise' the potential in this pearl at around 12$ -then let the bidding for the second round talks begin.

(lets not forget at 30$ a share we are still under the billion dollar pps)
----------------------------------
Naja, We will see in time!

Steigende Grüße,
Whyso

[whyso]

http://www3.niaid.nih.gov/biodefense/PDF/bolken.pdf

[mrsun]

Sat Apr 7, 3:29 PM ET



CHICAGO - A 2-year-old Indiana boy who contracted a rare and life-threatening infection from his soldier father's smallpox vaccination is recovering, a hospital spokesman said.

ADVERTISEMENT

Doctors have relied on some untested measures to save the boy's life, including skin grafts and an experimental drug that has never been used to treat a human patient, officials said. The boy's pox lesions left him with the equivalent of second-degree burns, requiring grafts to let the underlying skin heal.

"Everyone has been a little bit astonished that he has recovered as well as he has," hospital spokesman John Easton said Saturday. The boy should be should be upgraded to serious from critical condition soon, he added.

The boy has been in pediatric intensive care at the University of Chicago's Comer Children's Hospital for the past month with a virulent rash over 80 percent of his body. He developed the rash after coming in contact with his father, who had recently been vaccinated for smallpox before he was to be deployed overseas by the Army.

The boy is not suffering from smallpox, but from the related virus which is used to convey immunity to the much deadlier disease.

Health officials say there is no infection risk for the general population because the virus can be spread only through close physical contact.

The child suffered from eczema, which is a known risk factor for such an infection, doctors said.

The military resumed smallpox vaccinations in 2002 because of bioterrorism fears.

http://news.yahoo.com/s/ap/20070407/ap_on_re_us/vaccination_…

Hier kann sich´s doch nur um st-246 handeln,und der Markt sagt jaaa

[whyso]

Antwort auf Beitrag Nr.: 28.727.746 von mrsun am 09.04.07 16:28:20

Hi Mr Sun...es sieht verdammt gut aus z.Zt....



und wenn wir solche Analysten Kommentare lesen dürfen:

analyst estimate (2 Ratings) 6-Apr-07 10:24 pm
Andre garnet, the only analyst currently covering Siga estimates net income in fy 2010 of 2.25/share. At a 25 multiple that's a share price north of $50. Lots has to happen but I for one can wait. That's how you accumulate real wealth. Period.


Naja- weiterhin SIGA very long & strong,
Whyso

[jEo]

Antwort auf Beitrag Nr.: 27.716.396 von overview am 15.02.07 09:27:18

overview, wollte mich schon lange bei Dir bedanken. Neues Gefühl, eine Aktie mit Gewinn und weiteren Gewinnaussichten im Depot zu haben. jEo

[whyso]

The Company's anti-viral programs are designed to prevent or limit the replication of the viral pathogen. Its anti-infective programs are aimed at the increasingly serious problem of drug resistance. SIGA is also developing a technology for the mucosal delivery of its vaccines, which may allow the vaccines to activate the immune system at the mucus-lined surfaces of the body and urogenital tracts

[whyso]

HHS Finalizing 'Latest Project BioShield Plans', Official Says
Mrz 30, 2007

Rear Admiral Craig Vanderwagen, the new U.S. Department of Health and Human Services (HHS) assistant secretary for preparedness and response, said the agency will disclose its latest plan for vaccine development in the next few weeks, CQ Homeland Security reports. The Public Health Emergency Medical Countermeasures Enterprise Implementation Plan will be part of a broader effort by the office to improve communications with biotech drug firms and other vaccine development stakeholders, he said. In his new post, Vanderwagen is charged with revamping Project BioShield, a much-criticized federal program created to develop medical treatments for bioterror-related health threats. CQ reports that several pharmaceutical companies in the last few months have steered their research and development efforts away from biodefense. The journal suggests that the shift is in reaction to Project BioShield's cancellation of several major contracts and proposal requests. Other drug companies are awaiting HHS's new vaccine development plan, anticipating that officials will signal which vaccines will receive priority and when HHS will seek proposals. According to CQ, Vanderwagen also has suggested that his office will soon release plans for the procurement of a smallpox vaccine to benefit immunocompromised citizens That agreement would be the first Project BioShield contract since July 2006. In addition, Vanderwagen will oversee the Biomedical Advanced Research and Development Authority (BARDA). Congress created the authority last year—in part, to close the funding gap between the initial research and procurement contract phases of vaccine development (Berger, CQ Homeland Security, 3/28/07 [subscription required]).

http://www.rwjf.org/portfolios/features/digest.jsp?id=5326&i…

[whyso]

Insti's, (über die 5$ grenze) schwer im kommen



http://www.cnbc.com/id/15837275?q=siga

by the way, der 2 jährige junge ist nun auf der richtige Weg der Besserung:

Chicago Tonight
Monday, April 09, 2007

Smallpox Scare
A dramatic story continues to unfold at the University of Chicago Comer Children's Hospital where a 2-year-old child is recovering after he caught a deadly virus from his father who had recently been vaccinated for smallpox. Elizabeth Brackett has the story.

http://www.wttw.com/main.taf?p=28,1

Bis denne & up,up, up,
Whyso

[goyauno]

Antwort auf Beitrag Nr.: 28.736.420 von whyso am 10.04.07 10:58:00

Hola amigos, bin wieder zurück aus den Alpen.

Eine überzeugende Performens welche unsere Siga da geliefert hat!

Hi Whyso,

danke für die news.

Siga ist ein Rohdiamant, dass jetzt langsam zu einem Brillianten geschliffen wird. Am meisten freue ich mich, dass es den Jungen wirklich besser geht, und seine Familie wieder etwas zuversichtlicher sein darf.

Hasta luego....

goyauno

[mike32]

Antwort auf Beitrag Nr.: 28.736.726 von whyso am 10.04.07 11:21:10

Mahlzeit ,

muss mich erstmal richtig einlesen .

Daher vorweg , eine bescheidene Frage , hat SIGA ein ähnliches Potenzial wie DENDREON CORP. ?

mfG, mike32

[mrsun]

Das Ding ist Heute schon wieder short,da reicht nur ein kleiner Funke und .....
Aber sowas muß auch sein um nachlegen zu können,was ich Heute auch nochmal getan hab.

viel Glück und Ausdauer an alle mit investierten

[mrsun]

Antwort auf Beitrag Nr.: 28.739.965 von mike32 am 10.04.07 14:50:57

Hallo mike32
Ich versuche mal "Deiner Frage",an whyso,genüge zu tragen.
OB SIGA,ein ähnliches Potenzial wie DENDRON CORP. besitzt,kann Dir wohl niemand beantworten. Denn dazu besitzen wir nicht den nötigen Einblick in beide Firmen.
Wenn dem doch so wäre,wäen wir Hellseher,und wären jede Woche Lotto Millionär.
Was aber nicht zu übersehen ist,ist ein Produkt,das im Endstadium seiner Erprobung steht.(ST-246)
Darüber hinaus hat es eine Eilzulassung der FDA erhalten,und wurde durch unglückliche Umstände jetzt seiner Feuerprobe ausgesetzt.
Natürlich ist das weitere Produkt Portfolio von SIGA nicht zu unterschätzen,aber konservativ gesehen,warten alleine im Raum der Vereinigten Staaten,1Mrd Dollar darauf,ausgegeben zu werden,und dort setzt ST-246 an.

Weiterhin viel Glück und viel Grün

[mike32]

Antwort auf Beitrag Nr.: 28.803.290 von mrsun am 13.04.07 21:27:41

Dankeschön ,

und ein schönes WE :

[whyso]

Guten Tag zusammen

sorry Mike das es so lang gedauert mit ein Antwort auf deiner Frage-(und Danke Mr Sun für deinen Einsatz-unsere aktuelle Wetterlage tut dein 'Handel' alle Ehre)-dein Antwort ist m.E. genau richtig gewesen, keiner von uns besitzt ein "crystal ball" um in den Börsenzukunft schauen zu können-ABER- wir können einiges (durch entsprechend früh geleistete due diligence) im sachen Firmenentwicklung/Börsentendenz im voraus relativ klar deuten

SIGA's aussichten sind m.E. besser als je im Biotech Markt der Zukunft z.Zt. (hier ein paaar Gründe wie folgt):

1. (die best mögliche Werbung die man haben kann in die Branche kamm am Freitag Abend spät über die Ticker (war evtl. sogar nachbörslich gekommen?) http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn…

"His case has given new insight on the usefulness of drugs to treat smallpox and vaccine-related infections, knowledge that may be of use in the event of a smallpox or other biological attack.

"It's very useful information," said Dr. Inger Damon, a pox virus expert at the Atlanta-based U.S. Centers for Disease Control and Prevention.

She said the CDC will scrutinize lab tests and other materials gathered throughout the child's treatment to gain a better understanding of what works in such cases"....

The U.S. Food and Drug Administration granted special permission for its use.

"Both his immune response and his viral load improved dramatically," Hruby said."It wasn't magic, but he started getting better the next day," Dr. Marcinak added.

"He's hasn't really had any significant toxicity related to the medications. He did have a short period of renal failure right after having received the cidofovir, which may have contributed to that," Marcinak said.

Renal, or kidney, failure is a known complication of cidofovir, which is used to treat infections in HIV and AIDS patients



2. Pharmathene schmilzt mit ein andere Spieler am Biotech markt zusammen und wird 70 Mio $$$ auf die höhe kante liegen haben-die streit mit SIGA wird bald vom Markt ganz verschwinden-(die dortige Haupt Geldgeber ist wiederrum Ron Perlemann ) http://www.pharmathene.com/news_releases.html

3. BIG Pharmas MK's und Fond Interesse über 5$ & MK 400Mio$ -beide werden erst JETZT stattfinden

GILEAD Sciences cap: 36,48 Mrd.USD-total shares 465 Mio
PFIZER: 188,74 Mrd. USD, 7,1 Mrd shares
NOVARTIS:150,78 Mrd.USD-2,7 Mrd shares

SIGA (today):187,88 Mio.USD-total shares 33 Mio

4.Bei 30$ hat SIGA ein MK die immer noch unter die 1MRD MK notieren wird!!!
5.Bio Shield & Government Stockpiling wird defenitiv jetzt stattfinden-(wahrscheinlich auf globalen basis seit die "lebendingen Erfolg mit der Toddler"...“Siga’s a significantly different company today than it was in February and March,” Konatich said by phone from the company’s New York headquarters Friday. “We will be lobbying and negotiating with various agencies of the federal government for a sale of the drug.”


6. Die 'restlichen' drug resistant bacteria Arenaviruses Pipeline:
1.Lassa fever,
2. Junin,
3. Machupo,
4. Guanarito,
5. Sabia,
6. lymphocytic choriomeningitis),
7. Dengue virus,
8. and the filoviruses (Ebola and Marburg).
9. HIV & Aids kommt hinzu seit die erfolgreiche Behandlung der zwei jährigen.

Ich möchte behaupten-(natürlich auf meinen Investment alleine bezogen) das SIGA ganz am Anfang seine globalen Entwicklungsmöglichkeiten z.Zt steht-mein langfristige Kursziel bleibt weiterhin unbenannt!

Sonnige Stunden & good trades mit steady hands bei SIGA,
Whyso

[whyso]

Ach ja, ich vergass...das Chart wirkt wie eine Werbung an sich bei hungrige Biotech Fonds die nach neuen Möglichkeiten (die stars von übermorgen wie ARCA,DNDN, VPHM etc )am Biotechhimmel suchen sollten



Hedge funds paid more for long positions than the current price : On Thursday, the company completed a $9 million private stock placement with some of its longtime institutional investors. Five hedge funds — Iroquois Master Fund, Cranshire Capital, Omicron Master Trust, Rockmore Investment Master Fund and Smithfield Fiduciary — bought the issue, consisting of 2 million shares of common stock at $4.54 a share. They also received warrants for an additional 1 million shares exercisable at $4.99 a share.

More to come next week-sonnige Grüße,
Whyso

[goyauno]

Antwort auf Beitrag Nr.: 28.808.607 von whyso am 14.04.07 14:05:58

Hola amigos & liebe mitstreiter,

der informationsaustausch untereinander und die Kultur in diesem Thread spiegelt unsere Siga ganz hervorragend wieder.

Ich möchte behaupten-(natürlich auf meinen Investment alleine bezogen) das SIGA ganz am Anfang seine globalen Entwicklungsmöglichkeiten z.Zt steht-mein langfristige Kursziel bleibt weiterhin unbenannt!

----------------------------------------------------------------

Wenn dem doch so wäre,wäen wir Hellseher,und wären jede Woche Lotto Millionär.
Was aber nicht zu übersehen ist,ist ein Produkt,das im Endstadium seiner Erprobung steht.(ST-246)
Darüber hinaus hat es eine Eilzulassung der FDA erhalten,und wurde durch unglückliche Umstände jetzt seiner Feuerprobe ausgesetzt.

und da an der Wallstreet nur die Zukunft gahandelt wird, stehen wir hier ganz am Anfang einer großartigen Entwicklung.

Meiner Meinung natürlich!!

Was letztendlich zählt, sind Fakten und Resultate, um vorwärts zu kommen.

Meine blutige Nase und die Brandblasen in den letzten 8 Jahren Börse u.a. (GENTA), haben mich stark geprägt.


Wünsche euch auch ein schönes und vor allem erholsames Wochenende.

Hi Whyso, auch in der nähe DUS.................

[mrsun]

Hallo whyso,wie immer super recherchiert und deshalb ein grosses Danke schön.
Und auch Deine Meinung,goyauno,wird respektiert,weil selber schon auf anderen Schlachtfeldern eine blutige Nase geholt.
Lassen wir uns also nächste Woche überraschen,und sehen vielleicht bald die 6$,für länger vor dem Komma.

Auf ein sonniges Wochenende und den Spaß nicht vergessen

[goyauno]

Antwort auf Beitrag Nr.: 28.821.547 von mrsun am 14.04.07 23:29:58

wieder mal eine schöne Geschichte,

SCIENCE NEWS
April 13, 2007
New treatment aids U.S. toddler with rare ailment


E-mail Print RSS del.icio.us



By Julie Steenhuysen

CHICAGO (Reuters) - A U.S. toddler who nearly died from a rare skin reaction to his father's smallpox shot is out of intensive care and on the mend, thanks to a novel combination of drugs that had never been tried in children.

"He's making what we hope is a complete recovery," said Dr. John Marcinak, the University of Chicago pediatric infectious disease specialist who has helped treat the child since early March.

The 2-year-old Indiana boy, who has been upgraded to fair condition at the University of Chicago's Comer Children's Hospital, developed the rare rash known as eczema vaccinatum after being with his father, a soldier vaccinated for deployment in Iraq.

ADVERTISEMENT (article continues below)

His case has given new insight on the usefulness of drugs to treat smallpox and vaccine-related infections, knowledge that may be of use in the event of a smallpox or other biological attack.

"It's very useful information," said Dr. Inger Damon, a pox virus expert at the Atlanta-based U.S. Centers for Disease Control and Prevention.

She said the CDC will scrutinize lab tests and other materials gathered throughout the child's treatment to gain a better understanding of what works in such cases.

Smallpox was eradicated in 1979 but experts fear some groups might have samples to use as a bioweapon.

Smallpox vaccines do not use the smallpox virus, but a closely related and weaker virus called vaccinia.

Those who have eczema, like the toddler, are at particular risk for an eczema vaccinatum reaction. The child's case is the first to be reported since smallpox vaccinations resumed in the United States in 2002.

For Dennis Hruby, a leading pox virus specialist, the child's recovery is especially gratifying.

Hruby, now chief scientific officer of Siga Technologies Inc., did some of the basic research at Oregon State University decades ago that laid the groundwork for Siga's experimental smallpox drug SIGA-246.

The drug, which has been proven to work in primates infected with smallpox and monkeypox, was one of several treatments used on the child.

Other therapies included an intravenous form of vaccinia immune globulin -- developed in the 1960s to treat complications of smallpox vaccinations. He also received the antiviral drug cidofovir, made by Gilead Sciences Inc.

VERY SICK CHILD

"This was a very sick little boy. He was on multiple drug modalities but he was not doing well," Hruby said in a telephone interview.

At one point the rash consumed 80 percent of the child's body and he needed skin grafts to protect against infection.

Now, Marcinak said, the scabs are nearly all gone.

Marcinak and colleagues were having daily calls with a host of health officials, and in one, Dr. Damon suggested the experimental Siga drug.

The U.S. Food and Drug Administration granted special permission for its use.

"Both his immune response and his viral load improved dramatically," Hruby said.

"It wasn't magic, but he started getting better the next day," Dr. Marcinak added.
While doctors are still trying to parse out the relative contributions of the different drugs, they know they did little, if any, harm.

"He's hasn't really had any significant toxicity related to the medications. He did have a short period of renal failure right after having received the cidofovir, which may have contributed to that," Marcinak said.

Renal, or kidney, failure is a known complication of cidofovir, which is used to treat infections in HIV and AIDS patients.
"It's exciting to see your drug put to use this way," Hruby said

http://www.sciam.com/article.cfm?alias=new-treatment-aids-us…

Auf eine tiefgrüne neue Woche!!!

[whyso]

http://stockcharts.com/h-sc/ui?s=siga&p=D&b=5&g=0&id=p490532…

Ein Bildchen das Bände spricht-
Die Treppe gen Norden ist m.E. hier nachwievor voll Intakt(in my very humble opinio).

Two steps forward, one step back....damit lässt sich langfristig sehr gut mit leben!

Steigende Grüße ihr lieben,
Whyso

[whyso]

****HOT NEWS******

HHS Releases Plan for Development and Purchase of Medical Countermeasures
18-Apr-07 11:02 pm WASHINGTON, April 18 /PRNewswire-USNewswire/ -- HHS Secretary Mike
Leavitt today released for display in the Federal Register the Department's
new roadmap for developing and purchasing medical countermeasures against a
host of chemical, biological, radiological and nuclear (CBRN) threats.
The "Public Health Emergency Medical Countermeasures Enterprise
(PHEMCE) Implementation Plan for Chemical, Biological, Radiological and
Nuclear Threats" lays out the future course for prioritizing HHS'
acquisition of vaccines, drugs and medical diagnostic tests, including
purchases made under Project BioShield. The plan will be published in the
Federal Register Friday, April 20 and be posted online at
http://www.hhs.gov/aspr/ophemc.
"Since the terrorist attacks of September 11, our mission has been to
protect Americans by securing medical countermeasures for a range of
threats. We have made significant progress to increase our preparedness in
this area, but there is much more we must do," Secretary Leavitt said.
"This plan lays out our path forward in the coming years and will take
advantage of our new authorities under the Pandemic and All-Hazards
Preparedness Act to move forward with Project BioShield."
The PHEMCE plan assesses the current state of medical countermeasure
preparedness, and identifies the highest priority research, development and
acquisition programs to increase public health emergency preparedness. The
plan further identifies the proposed acquisitions HHS plans to make under
Project BioShield during the remaining five years of the program as well as
priority medical countermeasure programs that will be pursued up through
Fiscal Year (FY) 2023.
In addition, the plan emphasizes the importance of using the new
authorities provided for Project BioShield under the Pandemic and
All-Hazards Preparedness Act to support the research, development,
acquisition, and availability of safe and effective medical countermeasures
to protect the United States from CBRN threats. Appropriate advanced
development funding will also be critical to the future success of these
activities.
Funding support by the National Institutes of Health for basic
research, product development, and clinical research of CBRN medical
countermeasures has grown over thirty-fold from FY 2001 to FY 2006. Funding
for the Strategic National Stockpile has increased over ten-fold in that
same period. This dramatic growth in funding has led to the acquisition and
stockpiling of medical countermeasures and supplies to protect the American
public when public health emergency needs exceed or are otherwise
unavailable through local supplies.
The public will be able to submit comments on the PHEMCE Implementation
Plan through the Federal Register. Furthermore, HHS will hold a Public Health Emergency Medical Countermeasures Enterprise/BioShield Stakeholders Workshop o July 31-August 2, 2007 in Washington, D.C., to provide an opportunity for feedback and discussion of the plan. The workshop is an open meeting that will bring together representatives of the pharmaceuticaland biotechnology industries, professional societies, state and local public health organizations, the academic research and development community, public interest groups, stakeholder federal agencies and
Congress.Additional information on the PHEMCE Strategy and Implementation Plan,
Stakeholders Workshop and Project BioShield is available online at
http://www.hhs.gov/aspr/ophemc.

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=…

[whyso]

Die Uhr tickt

"The plan will be published in the Federal Register Friday, April 20"

[whyso]

Neue Kursziel...11,50$-Top Bericht:

http://adventfinancialinc.com/research_reports/SIGA%20Update…

Viel Spaß dabei,
Whyso

[whyso]

Thursday, April 26, 2007
CNN: Special Investigative Unit Finds America Still Vulnerable to Disaster
CNN Pressroom - Anderson Cooper, Top CNN Correspondents Investigate Solutions to Strengthen Nation’s Soft Targets

In the latest CNN: Special Investigations Unit documentary, anchor Anderson Cooper and homeland security expert Stephen Flynn not only show the nation’s vulnerabilities to a range of natural and man-made catastrophes but discuss real solutions. We Were Warned, Edge of Disaster, a one-hour documentary, will premiere on Saturday, April 28, and Sunday, April 29, at 8 p.m. and 11 p.m. All times Eastern.

Flynn, author of Edge of Disaster: Rebuilding a Resilient Nation, asserts that resiliency is America’s most valuable asset and offers his top security recommendations. CNN’s top investigative journalists uncover weaknesses in protecting the nation’s food supply, ports, and power grids. Security experts reveal the government’s preparedness to protect citizens against the threats of biological warfare and dirty bombs. CNN’s Justice Department correspondent Kelli Arena, national correspondent David Mattingly, homeland security correspondent Jeanne Meserve and special correspondent Frank Sesno also examine possible threats to the nation’s urban centers and suburban neighborhoods.

“A smallpox attack would kill one-third of all exposed. A major earthquake could leave thousands homeless and without access to even basic medicines or water. Unfortunately these issues are top of mind for Americans in this day and age,” said Mark Nelson, vice president and senior executive producer of CNN Productions. “Our goal is to offer thoughtful, realistic solutions to help viewers understand what they can do to protect themselves.”

Edge of Disaster was co-executive produced by Jeffery Reid and Claire Brinberg.

CNN Worldwide, a division of Turner Broadcasting System, Inc., a Time Warner Company, is one of the world’s most respected and trusted sources for news and information. Its reach extends to nine cable and satellite television networks; one private place-based network; two radio networks; wireless devices around the world; four Web sites, including CNN.com, the first major news and information Web site; CNN Pipeline, CNN.com’s premium live video news service; CNN Newsource, the world’s most extensively syndicated news service; and partnerships for four television networks and two Web
http://cnnobservations.blogspot.com/search/label/CNN:%20Spec…



Watch the stocks developement after Dr. Roses very first cc for SIGA on May 8th
http://biz.yahoo.com/bw/070423/20070423006003.html?.v=1

Bis die Tage (nur für den Fall das ich hier nicht ganz alleine Unterwegs bin und führe dementsprechend Selbstgespräche seit Tagen & Wochen )
Whyso

[amorphis]

NEIN...whyso...du weißt doch das die altbekannte gemeinde hier seit ein paar monaten zugange ist...na logo...ist eine der besten biotech-microcaps die der markt zu bieten hat. 12$ ist eher konservativ. sehr konservativ. wer mut hat...der denkt an kurse richtung 20$

ich habe mut und kein problem sie bis dahin laufen zu lassen

guck dir mal BDSI an...mich würde mal interessieren was du denkst. guck dir vor allem mal das letzte filing an...meine 8-K war es...ist am freitag abend gekommen.

greez

[mrsun]

Antwort auf Beitrag Nr.: 29.069.328 von whyso am 30.04.07 11:18:15

Hallo whyso
Du bist hier natürlich nicht alleine unterwegs,aber die meisten werden warscheinlich erst wieder aufspringen,wenn der Zug wieder schneller rollt.
Ich werde diese Woche den Kurs sehr genau beobachten,denn ich möchte nochmal nachlegen.
Habe bisher zweimal aufgestockt,und liege derzeit bei 2,91$ im Schnitt.
Bei den anstehenden Zahlen am 8.may,erwarte ich keine all zu grossen überaschungen,denn ich rechne erst 2008 mit Revenues.
Aber wie wir alle wissen,wird an der Börse ja die Zukunft gehandelt.

Also weiterhin Nerven behalten und Tiefen nutzen
viele Grüsse mrsun

[whyso]

Conference Call Highlights from yesterday:


- “SIGA owns ALL rights to 246” and owes nobody nothing for any part of its development.
- SIGA has 10+ Million$ in cash, does not need to raise anymore at this time (I heard they are good thru 2009), but they will compete to win additional Govt grants when appropriate, and MAY create more $ through the market (sell shares) IF the market conditions favorable. (I read that as if stock value is climbing because of revenue and more $ will get them where they to get to faster, than they would offer more stock. I read favorable as although more stock sold, it would not dilute share holder value… favorable) In fact they made a point their dilution to the share holders value has will continue to be insignificant in comparison to other companies in the same business. I like that very much and so should anybody who actually own SIGA shares.
- FDA has approved orphan drug status for 246 and SIGA on track to expedite bringing it to license.
- Double animal studies (246 worked* without any side effects), Single Dose study (being analyzed but no side effects observed), phase 1 of a dose a day for 21 days study (being analyzed but no side effects observed), phase 2 on the way, then the optimum dosage will be determined. The optimum dosage will be administered to 400-500 humans in a Safety Trial. I use the word “worked” to summarize their statement that “ALL manifestation of the disease were gone including death- no death occurred, no toxicity (harm from 246 to subject organs, etc)”
- They talked about the boy who had multiple failing organs due to disease and after 246, now lives without the disease and had no toxicity observed with him either.
- 246 can be orally self administered without need of medical professionals.
- 246 is proving to be effective on Small pox and 4 other diseases and its effectiveness of this class of disease can be compared to that of “penicillin”.
- “no other organization in the world comes even close to having anything as promising as 246 for small pox the 4 other fever producing diseases.” Or words to that effect. 246 has not failed. It has been 100%. It can be orally administered. It works both preventive and after the fact. No wonder they say no one else shows this promise, all others have some side effect, some % of side effect, some % of death. No wonder they use “penicillin” as the comparison. Not even statins to reduce cholesterol have this safe and effect a record.
- Govt bio shield documentation indicates the government intends to purchase 246 or its equal (there is no equal or better) for First Responders, hospitalized victims, and for the large populace that could not tolerate current vaccinations. World conference exposure of 246 findings and its self administering capability and speed to heal negate the need for “quarantine programs” brigning with 246 the likely potential of multi-national orders of 246 to stock pile for their first responders ... as well. To me this means that when (not if, when) the orders start, more orders are just going to keep on coming and this is much bigger than many who sold today ever thought. How big was/is penicillin anyway?
- Now they are starting the animal testing for other medicine to aid victims of the Ebola, Marburg, Dengue Fever virus, and Bunyavirus. Same patent techniques as 246 but for these diseases. Hymm, should be a fantastic stock price.
---------
FDA has strict rules regarding what can and cannot be said about FDA safety trials. SIGA is following those rules.

Identified ST-246 as a potent ortho pox remedy in small and large animals. There are remarkably low side effects to ST-246.

Successful 1st human safety and efficacy trial.

Dr. Rose has successfully partnered with Phizer on another drug that he has been involved with.

Funding from 29 million in government grants and contracts started in first qtr of 2007.

1.9 million in revenues in q1, 07, compared to 1.4 million in q1, 06.

Progress made to date re:ST-246
FDA has adapted to bioterrorist threats
FDA is using two animal rule to detrermine safety and efficacy for drugs being created for treating bioterrorist threats. Ebola, Lassa fever are both moving into two animal trials.
ST-246 is extremely effective in multi-animal trials with no toxicity. It can be used as a once a day pill. ST-246 is designated for FDA fast track status, and has been designated as an orphan drug.

21 day safety and efficacy trial is currently ongoing. 1st dose group has been completed successfully, and 2nd dose group is about to proceed.

Hemmoragic fever trials are entering multi-animal testing.

Back to Dr. Rose. Federal, state, and international market potential. ST-246 demonstrated potent and therapeutic action
against small pox and orthopox variations. ST-246 does not need to be administered by skin scratch. Dr Rose used penicillin as a comparson to illustrate ST-246 importance.
healthcare workers , police, medical personnel. Eliminate the need to institute quarantine procedures in order to deal with bioterrorist threats. Pleased to see that the HHS plan was to acquire antivirlas, and believes that ST-246 should be considered for widespread use and stockpiling and purchasing of ST-246. Compared to Cidofovir, ST-246 is 8000 times more effective, with no toxicity compared to cidofovirs liver toxicity. SIGA owns all patents regarding ST-246 through 2025. Dr. Rose likes where SIGA is now.

I believe that Dr. Rose is aggressively positioning SIGA to acquire ongoing contracts and purchases by the federal government.

Current trial is using 30 volunteers. The later pivotal trial should use 400 to 500 volunteers. No date for that larger pivotal trial has been set yet.
--------------------------------

Ich persönlich empfand der gestrigen Vortrag von Dr Rose als extrem Professional (etwas Kaltsnäutzig vielleicht) aber auch von ein sehr begrundete Optimismus begleitet
"I like where we are"

Ich habe das Gefühl das diese CC eine Art vorbote war, und bin von daher sehr enttäüscht übe rdie (hoffentlich) kurzfristige Einbruch des kurses aus gestrige Sicht:


Man soll beide Charts allerdings auch direkt nebeneinander vergeleichen dürfen.

Lange Rede, kurze sinn, bin & bleibe ein überzeute SIGA LONG!!!
Viele Grüße & bis die Tage,
Whyso

[hahel]

An alle,

was mein Ihr.
Noch warten oder jetzt einsteigen.
Danke für eure Meinung.

[overview]

Antwort auf Beitrag Nr.: 29.258.228 von hahel am 10.05.07 20:28:17

Meine Meinung:
da wird was in den Keller geprügelt, um Nachkaufmöglichkeiten zu schaffen. Der Boden kommt näher und ich spechte genauso wie Du darauf. Ob heute oder nächste Woche kann aber keiner sagen.
Kommt aber nicht auf das letzte % an, wenn man mittelfristig denkt.

[goyauno]

Super News!!!!!!!

Press Release Source: SIGA Technologies, Inc.


SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193
Tuesday May 15, 8:30 am ET


NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) announced today the successful results of a proof of concept guinea pig trial of its lead Lassa fever virus drug, ST-193.
ADVERTISEMENT


This study was conducted under Biosafety Level 4 conditions at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) by Dr. Kathleen Cashman under the supervision of Dr. Mary Guttieri, who has been working on various hemorrhagic fever viruses at USAMRIID for over 12 years. Strain 13 guinea pigs were challenged with a lethal dose of Lassa virus and treated with ST-193 once a day for 14 days. Administration with ST-193 resulted in significant reduction in mortality at the two doses tested, 80 mg/kg and 25 mg/kg (71% of the animals survived at the low dose), whereas all of the control animals and those treated with ribavirin succumbed to the disease within 20 days of the challenge. The disease course in these guinea pigs recapitulates what is seen in human Lassa fever infections, and SIGA expects that this model is one of the two animal models that will be required to fulfill the U.S. Food and Drug Administration's "Animal Efficacy Rule."

"This is a tremendous milestone for our research group," said Dr. Dennis E. Hruby, SIGA's Chief Scientific Officer. "This study should provide the basis for advancing this lead candidate into IND-enabling activities in the near future."

Lassa virus, considered a hemorrhagic fever virus due to some of its prominent symptoms, is one type of arenavirus. Arenaviruses are potential biological weapons agents due to their ease of dissemination, person-to-person transmissibility, and potential to cause widespread illness and death. Creating and deploying antiviral drugs targeting arenaviruses will enhance national and global security by acting as a significant deterrent and defense against the use of arenaviruses as bioterror weapons. Six separate arenaviruses are classified as Category A pathogens by the Centers for Disease Control and Prevention (CDC) due to the great risk that they pose to public health and national safety. Lassa fever is both a current world health threat, as it is prevalent in parts of West Africa (the CDC reports estimates of as many as 300,000 new cases each year), and a bioterror threat, due to its previous history as an object of weaponization research. Signs and symptoms of Lassa fever typically occur 1-3 weeks after the patient comes into contact with the virus. These include fever, retrosternal pain (pain behind the chest wall), sore throat, back pain, cough, abdominal pain, vomiting, diarrhea, conjunctivitis, facial swelling, proteinuria (protein in the urine), and mucosal bleeding. Neurological problems have also been described, including hearing loss, tremors, and encephalitis.

The Implementation Plan for Chemical, Biological, Radiological, and Nuclear Threats released in April by the Department of Health and Human Services lists arenaviruses as one of the biologic threats for which they plan to purchase medical countermeasures.

Dr. Eric A. Rose, Chairman and Chief Executive Officer of SIGA, adds, "Progress on our Lassa fever virus drug demonstrates the robustness of our product pipeline and furthers our goal to develop safe and effective countermeasures against all of the Category A viral pathogens."

Development of this Lassa antiviral is supported by the National Institutes of Health (NIH), which awarded SIGA a $6.0 million grant in September 2006.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA is a leading company in the discovery of pharmaceutical agents to fight emerging pathogens. SIGA leverages its proprietary technologies through multiple strategic partners, including the National Institutes of Health and TransTech Pharma, Inc. For more information about SIGA, please visit SIGA's Web site at www.siga.com.

About the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a critical role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

The information contained in this press release does not necessarily reflect the position or policy of the U.S. government, and no official endorsement should be inferred.

Forward-looking Statements

This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the safety or efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products, and (f) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release, are set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.



Contact:
SIGA Technologies, Inc.
Dr. Eric A. Rose, 212-672-9100
Chairman and Chief Executive Officer
[e-mail]
or
Cameron Associates
Al Palombo, 212-245-8800 Ext. 209
Investor Relations
[e-mail]

--------------------------------------------------------------------------------
Source: SIGA Technologies, Inc.

[hahel]

So, hab mir heute 5.275 Stück zu $ 3,81 zugelegt.
Dann wollen wir mal sehen was die nächsten 12 Monate bringen.

[goyauno]

Antwort auf Beitrag Nr.: 29.331.681 von hahel am 15.05.07 19:43:18

Hi hahel,

wünsche Dir nur das "Beste" mit Deinem neuen investment!!!!

Ich bin seit Nov. 06 schon dabei, und habe es bis heute nicht bereut. Bin halt überzeugt von der wirklich guten pipeline.

Alles gute

goyauno

[hahel]

Danke, Goyauno.
Hab mich heute nach langem Zögern und Recherche von einem Anteil Sigma getrennt und in Siga gepackt.
Wenns geht werde ich hoffentlich wie bei Sigma auch einen langen Atem haben.
Schönen abend noch.

[mrsun]

Soldier’s Smallpox Inoculation Sickens Son


By JOHN SCHWARTZ
Published: May 18, 2007
A 2-year-old boy spent seven weeks in the hospital and nearly died from a viral infection he got from the smallpox vaccination his father received before shipping out to Iraq, according to a government report and the doctors who treated him.

The boy, who lives in Indiana and has recovered, became ill in early March, two weeks after his father’s deployment was delayed and he was allowed to make a trip home. Over the next few weeks, the boy suffered kidney failure and lost most of his skin to the disease, eczema vaccinatum.

Experts said the father, who had eczema in childhood, should never have been given the vaccine because that fact made him more susceptible to side effects like vaccinia infection. And they said military doctors should have been doubly cautious because the son, too, suffered from eczema and would have been highly susceptible to infection. Military procedures call for asking about such conditions in soldiers and their families.

Vaccinia is the live virus used in smallpox vaccine. After vaccination, the body develops a resistance to vaccinia, a disease that is generally milder than smallpox, and the resistance also works against smallpox. The injection site can spread the vaccinia virus, however, and people without strong immune systems are particularly susceptible.

Smallpox was officially declared eradicated by the World Health Organization in 1979, and inoculation of military personnel was suspended in 1990. But after the terrorist attacks of Sept. 11, 2001, and the subsequent cases of anthrax sent through the mail, the government began vaccinating military personnel and many health care workers, with 1.2 million vaccinated as of March of this year.

Since then, a handful of vaccinia cases have been reported to the Centers for Disease Control and Prevention, including one, described in the May 4 Morbidity and Mortality Weekly Report, of vulvar infection in an Alaskan woman whose sex partner was a serviceman.

Dr. Inger Damon, the acting head of the disease center branch concerned with pox viruses, said, “I think this number of cases certainly raised our awareness and led to discussions between ourselves and the D.O.D.”

An account of the case was published this week in the morbidity report. According to the report, which did not give the family’s name, the boy was taken to the University of Chicago Comer Children’s Hospital on March 3.

Dr. Madelyn Kahana, the chief of pediatric intensive care medicine at the hospital, said in an interview that the child had been covered with “mounds of pox” that reminded her of photos of bees swarming over beekeepers. “I’m a veteran of 25 years of practice in the I.C.U.’s, and I thought I’d seen it all,” Dr. Kahana said. “But this was stunning to the eye.”

Dr. John F. Marcinak, an associate professor of pediatrics who worked 16 hours a day with the boy, said that in the first weeks of the case, “it was really touch and go.”

The doctors gave the boy narcotics to render him unconscious and free of pain. They also inserted a breathing tube and put him on mechanical ventilation to counter the breathing problems that can come with heavy doses of narcotics.

Doctors worked with the disease control centers to get shipments of Vaccinia Immune Globulin Intravenous. They also used an antiviral drug, Cidofovir. That drug, which has been associated with kidney problems in some cases, may have caused another crisis in which the boy’s kidneys began failing and his abdomen filled with fluid.

“He looked like he was going to die,” Dr. Kahana recalled.

The doctors worked with the Food and Drug Administration to allow the use of an experimental drug for smallpox, ST-246, from Siga Technologies, which appeared to begin turning the case around.

Meanwhile, doctors drained the boy’s distended abdomen and cut away the dead skin, a process called debridement that is commonly used in burn victims. They put skin from cadavers over his exposed flesh to promote healing underneath and dressed the wounds.

The child’s mother also developed lesions on her face and index finger. She has recovered, but because of her infection, she had to be confined to his room and witnessed every procedure performed on her child. The military brought the father back from Iraq after the boy became ill.

The procedures for smallpox vaccination were hammered out through long discussion to prevent those who were particularly susceptible to the side effects from receiving it, said Dr. William Schaffner, who served on the C.D.C. Advisory Committee on Immunization Practices.

The case, Dr. Schaffner said, raises the question of “whether the stringent procedures that were initially put in place have eroded somewhat.”

In an editorial accompanying the report, the authors said that the military was studying the incident, “which will determine whether screening and education practices need to be modified.”

The boy’s skin grew back at a phenomenal rate and shows remarkably few signs of the ravages of the disease, Dr. Kahana said. She attributed the recovery to “a lot of good, diligent care and a lot of luck — and maybe divine intervention.”

As for his emotional recovery from the ordeal, she said, “He doesn’t remember a thing.” She added, however, “His mom remembers all of it.”

http://www.nytimes.com/2007/05/18/health/18smallpox.html?_r=…

[mrsun]

Hier noch ein Gedanke zum Proxy Statement vom Freitag,aus dem Yahoo Board,das wie Balsam auf der Seele wirkt.

SIGA is undervalued (3 Ratings) 20-May-07 02:23 pm Just the same game as always called keep the rocket down while the "friends of Wall Street" better known as the "big boys" load up. Like RNAI back in the day. The bottom line is SIGA is a company that keeps proving itself over & over. SIGA ST-246 helped cure a 2 year old boy when other drugs failed. We have ST-193 clearing a 1st hurdle etc.

When the real move comes on SIGA the question just like RNAI before Merk bought them will be are you in or out? I hope some of the long term longs are able to capture what they deserve. RNAI had many private placements & still got bought for a pretty penny like SIGA should some day. Bottom line when a company grows from micro cap to small & mid cap it will have to go through the same growing pains that all companies go through. In the end the game is who bought the micro cap at micro cap prices & sold after a buy out or after its growth into a mid cap size company?

When the little guy figures SIGA out as I am sure most larger players have, then it will be to late to get in cheap. Why because SIGA has an anti-viral platform & does not have to target just military threats. Wait till it targets aids or some other virus then all will wake up to the true value of SIGA. It's in the platform.

Ob der Markt es genauso sehen will,werden wir wohl sehen müssen.
Im schlimmsten Fall sehen wir die 2$ von unten,was mich aber als "long and strong" noch mal zum Nachkauf nötigt.

Allen mit Investierten weiterhin viel Glück

[amorphis]

Antwort auf Beitrag Nr.: 29.258.228 von hahel am 10.05.07 20:28:17

eindeutig: einsteigen!

[amorphis]

wer hier kauft...mach gar nix falsch. hier hat sich ein starker boden gebildet, der schon x-mal angetestet wurde.

[hahel]

Hallo, weiß einer von euch wann die Zahlen von SIGA reinkommen?
Danke für Info.

[mrsun]

Was hat denn unser CEO nur vor?

Abiomed Appoints Eric A. Rose, M.D., a Leader in Circulatory Care, to Its Board of Directors
Abiomed, Inc. (NASDAQ: ABMD) announced today that Dr. Eric A. Rose has been appointed to its Board of Directors. Dr. Rose is an esteemed cardiothoracic surgeon, having authored or co-authored more than 300 peer-reviewed publications including articles on cardiovascular surgery, ventricular assist devices and cardiac transplantation. Dr. Rose has led the development of a premier Department of Surgery at Columbia University and has managed, investigated, and developed numerous complex medical technologies ranging from heart transplantation to novel approaches to treat Alzheimer’s disease and bioterrorism. He is currently on leave as Chairman of Columbia’s Department of Surgery, a position he held since 1994, and is serving as Chief Executive Officer and Chairman of the board of SIGA Technologies, Inc., a leading biotechnology firm addressing bioterrorist threats.

Dr. Rose co-founded TransTech Pharma (TTP), Inc., a pharmaceutical company focused on the discovery, development, and commercialization of therapeutics to treat a wide range of human diseases including cardiovascular disorders, central nervous system disorders, diabetes, obesity and cancer. Dr. Rose also serves as Executive Vice President for Life Sciences at MacAndrews and Forbes, Inc. He received his bachelor's degree from Columbia College and his medical degree from Columbia University College of Physicians and Surgeons. His postgraduate training was in general surgery and cardiothoracic surgery at the Columbia Presbyterian Medical Center. Dr. Rose also holds three honorary doctoral degrees.

“It is an honor to join Abiomed’s distinguished Board of Directors and I look forward to contributing to Abiomed’s strategy focused on heart recovery,” said Dr. Rose.

“Dr. Rose is an expert in FDA trial design, has led multiple clinical trials in circulatory care and is widely respected as a pioneer in the use of ventricular assist devices. We are excited and proud to welcome him to Abiomed’s Board of Directors,” said Michael R. Minogue, Chairman, CEO and President of Abiomed.

Dr. Rose is a member of more than a dozen academic and professional societies and committees, and is a former President of the International Society for Heart and Lung Transplantation

[mrsun]

Antwort auf Beitrag Nr.: 29.558.829 von hahel am 31.05.07 16:21:48

hallo hahel
find grad leider nur die termine vom letzten jahr,dürfte sich aber nichts geändert haben

o quarterly report on Form 10-Q for the quarter ended March 31, 2006;

o quarterly report on Form 10-Q for the quarter ended June 30, 2006;

o quarterly report on Form 10-Q for the quarter ended September 30,
2006; and

o amended quarterly report on Form 10-Q/A for the quarter ended
September 30, 2006;

[mrsun]

Hallo Sigianer

Schon gesehen,hier wurde nochmal kräftig eingekauft,beim Preis von 3,73$.
Mit von der Partie unser "Board of Directors".

Form Type Form Description Pages Date View
4 Statement of changes in beneficial ownership of securities 1 06/01/07
4 Statement of changes in beneficial ownership of securities 1 06/01/07
4 Statement of changes in beneficial ownership of securities 1 06/01/07
4 Statement of changes in beneficial ownership of securities 1 06/01/07
4 Statement of changes in beneficial ownership of securities 1 06/01/07
3 Initial statement of beneficial ownership of securities 1 06/01/07
4 Statement of changes in beneficial ownership of securities 1 06/01/07
4 Statement of changes in beneficial ownership of securities 1 06/01/07
4 Statement of changes in beneficial ownership of securities 1 06/01/07

[mrsun]

Abwarten und Tee trinken!!?

WHO says no outbreak of small pox in Myanmar
Kolkata, June 1 (PTI): The World Health Organisation has said reports of small pox outbreak in Bangladesh is yet to be checked but there is no eruption of the deadly disease in Myanmar, West Bengal Health Minister Suryakanata Mishra today said here.

"The WHO's South Asia office has informed the National Institute of Communicable Diseases that it is not small pox that has infected some people in Myanmar," Mishra told newspersons here.

"Regarding Bangladesh, they are yet to get information whether the disease is small pox or something else," he said.

Stating that steps like screening people coming in from Bangladesh through land borders or at the airports have begun, Mishra said there was no need to be alarmed.

"The CDC (Centers for Disease Control and Prevention) at Atlanta in the USA has been contacted on the issue," he said adding that at present there was no preventive medicine for small pox as WHO had several years back declared that small pox had been eradicated.

Alarmed by reported outbreak of small pox at Rajshahi district in Bangladesh, West Bengal government had yesterday sounded a general alert in the state's northern districts.

http://www.hindu.com/thehindu/holnus/485200706011722.htm

[mrsun]

Hallo liebe Trauergemeinde
Im Moment siehts ja wohl nicht so rosig aus,obwohl sich an der Geschichte ja nichts geändert hat.
Das einzige was den Anlegern angst auf die Stirn treibt,ist die geplante verdoppelung der outstanding Shares.
Dazu habe ich mir auch schon einige Gedanken gemacht,und bin auf mehrere Thesen gekommen die möglich währen.
-Siga braucht umgehend mehr Kapital um weitere Projekte voran zu treiben
-Siga braucht umgehend Kapital um sich von Pharmathene zu lösen
(weiß eigentlich jemand wie der Prozess ausgieng?)
-Siga braucht Kapital um durch Expansion zu wachsen und
erstarken,z.b.Vertrieb,Marketing,Logistik
-Siga kann sich vor Investoren kaum retten,die alle noch in den Zug einsteigen wollen,aber keine Shares mehr bekommen
-Siga kann sich vor Investoren kaum retten,die aber nicht bereit sind soviel zu bezahlen
-Siga gönnt seinen treuen Shareholdern mit Stichtag einen kleinen Bonus

Dies alles sind natürlich nur "meine" Gedanken,würde mich aber über andere Gedankenanstösse gerne freuen!

[mrsun]

Und hier noch ein interessanter Artikel,den ich auf dem Yahoo Board gefunden habe.Leider muß mann sich unter dem weiterführenden
Link anmelden,was mir zu teuer ist.

All SIGA Investors Should Read (5 Ratings) 8-Jun-07 07:11 pm From a well written article released today - this was the most thought provoking...

"A world-renowned bioweapons expert has confirmed that Syria has weapons grade smallpox resistant to all current vaccines developed under the cover of legitimate veterinary research on camelpox, a very closely related virus. The researcher further reports that Syria is suspected of testing the pathogen on prison populations and possibly in the Sudan.

Although there are close to 50 organisms that could be used offensively, rogue nations have concentrated their bioweapons development efforts on smallpox, anthrax, plague, botulinum, tularemia and viral hemorrhagic fevers. With the exception of smallpox, which is exclusively a human host disease, all of the other pathogens lend themselves to animal testing as they are zoonotic, or can be transmitted to humans by other species.
Biological weapons are among the most dangerous in the world today and can be engineered and disseminated to achieve a more deadly result than a nuclear attack. Whereas the explosion of a nuclear bomb would cause massive death in a specific location, a biological attack with smallpox could infect multitudes of people across the globe. With incubation periods of up to 17 days, human disseminators could unwittingly cause widespread exposure before diagnosable symptoms indicate an infection and appropriate quarantine procedures are in place.

Unlike any other type of weapon, bioweapons such as smallpox can replicate and infect a chain of people over an indeterminate amount of time from a single undetectable point of release. According to science writer and author of The Hot Zone, Richard Preston, "If you took a gram of smallpox, which is highly contagious and lethal, and for which there's no vaccine available globally now, and released it in the air and created about a hundred cases, the chances are excellent that the virus would go global in six weeks as people moved from city to city......the death toll could easily hit the hundreds of millions.....in scale, that's like a nuclear war."[1]

http://www.americanthinker.com/2007/06/t...

Now hitting at today's price levels, it may be time to start buying - this company has a bright future.

[mrsun]

Leider hab ich doch noch ein Haar in der Suppe gefunden,welches aber trotzdem jeder wissen sollte.Die meldung stammt vom 4.5.07

Mon Jun 4, 6:31 PM ET



WASHINGTON - The federal government will purchase 20 million doses of a smallpox vaccine that, in the event of an outbreak, would be used to treat people with compromised immune systems.

ADVERTISEMENT

The five-year contract with Bavarian Nordic, a Danish pharmaceutical company, is valued at more than $500 million. The contract contains options that could extend its value to $1.6 billion, the company and the Health and Human Services Department announced on Monday.

The smallpox vaccine is a completely new product that will be added to the Strategic National Stockpile. The current stockpile contains enough smallpox vaccine for every American. However, that vaccine was produced using a live, replicating virus, which can be potentially life-threating in rare instances. Patients, such as those getting chemotherapy, should not get such vaccines in non-emergency cases.

The smallpox vaccine to be purchased from Bavarian Nordic contains a highly weakened form of the virus that cannot replicate in humans. The 20 million doses purchased under the contract would be enough to treat the 10 million people in the U.S. with weakened immune systems.

WKN 917165 Bavarian Nordic,für alle die es genau wisse wollen.

Das einzig positive an der Meldung ist,wir wissen jetzt genau wie viel eine Dosis kosten kann.

[mrsun]

sorry,soll heissen vom 4.6.07

[hahel]

HalloLeute,
was meint Ihr??
Bin am 15.05.07 bei $3,81 rein. jetzt bei 15% Verlust raus oder abwarten?
Danke für eure Meinung.

[mrsun]

Antwort auf Beitrag Nr.: 29.892.758 von hahel am 14.06.07 16:10:57

Vielleicht hilft Dir ja das ein bisschen bei Deiner Entscheidung

SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193
SIGA Technologies, Inc. (NASDAQ: SIGA) announced today the successful results of a proof of concept guinea pig trial of its lead Lassa fever virus drug, ST-193.

This study was conducted under Biosafety Level 4 conditions at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) by Dr. Kathleen Cashman under the supervision of Dr. Mary Guttieri, who has been working on various hemorrhagic fever viruses at USAMRIID for over 12 years. Strain 13 guinea pigs were challenged with a lethal dose of Lassa virus and treated with ST-193 once a day for 14 days. Administration with ST-193 resulted in significant reduction in mortality at the two doses tested, 80 mg/kg and 25 mg/kg (71% of the animals survived at the low dose), whereas all of the control animals and those treated with ribavirin succumbed to the disease within 20 days of the challenge. The disease course in these guinea pigs recapitulates what is seen in human Lassa fever infections, and SIGA expects that this model is one of the two animal models that will be required to fulfill the U.S. Food and Drug Administration’s “Animal Efficacy Rule.”

“This is a tremendous milestone for our research group,” said Dr. Dennis E. Hruby, SIGA’s Chief Scientific Officer. “This study should provide the basis for advancing this lead candidate into IND-enabling activities in the near future.”

Lassa virus, considered a hemorrhagic fever virus due to some of its prominent symptoms, is one type of arenavirus. Arenaviruses are potential biological weapons agents due to their ease of dissemination, person-to-person transmissibility, and potential to cause widespread illness and death. Creating and deploying antiviral drugs targeting arenaviruses will enhance national and global security by acting as a significant deterrent and defense against the use of arenaviruses as bioterror weapons. Six separate arenaviruses are classified as Category A pathogens by the Centers for Disease Control and Prevention (CDC) due to the great risk that they pose to public health and national safety. Lassa fever is both a current world health threat, as it is prevalent in parts of West Africa (the CDC reports estimates of as many as 300,000 new cases each year), and a bioterror threat, due to its previous history as an object of weaponization research. Signs and symptoms of Lassa fever typically occur 1-3 weeks after the patient comes into contact with the virus. These include fever, retrosternal pain (pain behind the chest wall), sore throat, back pain, cough, abdominal pain, vomiting, diarrhea, conjunctivitis, facial swelling, proteinuria (protein in the urine), and mucosal bleeding. Neurological problems have also been described, including hearing loss, tremors, and encephalitis.

The Implementation Plan for Chemical, Biological, Radiological, and Nuclear Threats released in April by the Department of Health and Human Services lists arenaviruses as one of the biologic threats for which they plan to purchase medical countermeasures.

Dr. Eric A. Rose, Chairman and Chief Executive Officer of SIGA, adds, “Progress on our Lassa fever virus drug demonstrates the robustness of our product pipeline and furthers our goal to develop safe and effective countermeasures against all of the Category A viral pathogens.”

Development of this Lassa antiviral is supported by the National Institutes of Health (NIH), which awarded SIGA a $6.0 million grant in September 2006.

[hahel]

o.k., bleib erst mal drin. Wollen hoffen, dass in den nächsten Wochen dann mal was kommt.

[goyauno]

Press Release Source: SIGA Technologies, Inc.


SIGA Technologies Selected to Join the Russell Microcap Index
Tuesday June 19, 10:15 am ET


NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and other antiviral targets, today announced that the company has been selected to join the Russell Microcap(TM) Index. Russell recently posted a list on its website, www.russell.com, of companies being added to its Microcap index as of June 22, 2007.
ADVERTISEMENT


Dr. Eric Rose, Chairman and Chief Executive Officer of SIGA Technologies, Inc., commented, "Through the hard work of everyone on our team, we believe we have made substantial progress in our product development programs. We believe that Russell's decision to include SIGA in its index is a reflection of the seriousness with which the financial community views this progress."

The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to them.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA is a leading company in the discovery of pharmaceutical agents to fight emerging pathogens. SIGA leverages its proprietary technologies through multiple strategic partners, including the National Institutes of Health and TransTech Pharma, Inc. For more information about SIGA, please visit SIGA's website at www.siga.com

Forward-looking Statements

This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the safety or efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products, and (f) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release, are set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.



Contact:
SIGA Technologies, Inc.
Dr. Eric Rose, 212-672-9100
Chairman & Chief Executive Officer
[e-mail]
or
Cameron Associates
Al Palombo, 212-554-5488
Investor Relations
[e-mail]

--------------------------------------------------------------------------------
Source: SIGA Technologies, Inc.

http://biz.yahoo.com/bw/070619/20070619005930.html?.v=1

[mrsun]

Hallo Freunde und Leidensgenossen
Wie´s aussieht wird´s nochmal interessant,es bewegt sich was.
Vielleicht ist auch schon eine Entscheidung gefallen,und die Sitzung morgen,nur noch obligatorisch.
Der Freitag wird´s zeigen,ob es shares gibt oder keine.
Und denkt dran,nur die harten kommen in den Garten

[goyauno]

Antwort auf Beitrag Nr.: 30.850.330 von mrsun am 25.07.07 20:44:22

Guten Abend,

hallo mrsun, wir wollen doch alle nur das "BESTE" hoffen!

Der Baum wurde doch sehr häftig geschütelt, ich denke dass jetzt
die shares in starke Hände übergehen.

Auf eine hoffentlich noch tiefgrüne Woche!!

mfg

goyauno

[mrsun]

Antwort auf Beitrag Nr.: 30.850.608 von goyauno am 25.07.07 21:06:54

Hallo goyauno
Schön Dich zu lesen.
Im Moment erinnert mich die Wende an Dezember,als der Kurs bis unter 2,6$ gedrückt wurde,und dann bei 2,63$ kräftig eingekauft wurde.

[mrsun]

Ich hab´s doch gleich geahnt,hier wurde wieder eingekauft.
Es wurden zwar nur Kaufoptionen wahr genommen,aber die Menge ist nicht von schlechten Eltern.Und auch nicht von irgend jemand, sondern unserm Vorstand.
-------------------------------------------------------------------

1. Name and Address of Reporting Person*ROSE ERIC A MD

Number of Shares
Stock Option (Right to buy) $ 3.1 07/26/2007 A 200,000 (1) 07/26/2017 Common Stock, par value $.0001 per share 200,000 $ 0 918,610 (2) D
-------------------------------------------------------------------

1. Name and Address of Reporting Person*Hruby Dennis E


Stock Option (Right to buy) $ 3.1 07/26/2007 A 300,000 (1) 07/26/2017 Common Stock, par value $.0001 per share 300,000 $ 0 925,000 D
-------------------------------------------------------------------

1. Name and Address of Reporting Person*KONATICH THOMAS N


Stock Option (Right to buy) $ 3.1 07/26/2007 A 150,000 (1) 07/26/2017 Common Stock, par value $.0001 per share 150,000 $ 0 695,000 D


Und das obwohl 50mio neue Shares im Raum schweben wie ein Damokles
Schwert.
Wieder mal genug Anlass für ........?!
Mag sich jeder denken was er will,so wie ich auch

wünsch euch noch viel grün und spaß

[goyauno]

Antwort auf Beitrag Nr.: 30.953.996 von mrsun am 31.07.07 17:32:02

Hi mrsun,

na wer sagt´s denn, die Hoffnung stirbt zuletzt.

Ein versöhnliches Wochenende!!!


mfg
goyauno

[mrsun]

Antwort auf Beitrag Nr.: 31.011.125 von goyauno am 03.08.07 20:09:52

Hallo goyauno
tja,so schnell kann´s geh´n,und die welt sieht gleich wieder viel grüner aus.Was wir ja von Siga mitlerweile gewohnt sind.Heute Himmel,morgen Hölle und übermorgen wieder im Paradies.
Was mich trotzdem stört,ist der zähe Informationsfluß,aber davon lebt ja Spekulation,oder nicht?
Was ganz deutlich zu erkennen war,ist das stetige drücken mit 100er Stücken,und das nicht nur bei Siga.
Da kann mir einer erzählen was er will,aber für mich steckt dahinter Schiebung,gepaart mit Interesse.
Also heißt für mich die Devise,dran bleiben und Augen weiter offen halten.

Dir auch noch viel grün und ein schönes Wochenende

[goyauno]

Antwort auf Beitrag Nr.: 31.014.252 von mrsun am 03.08.07 22:03:27

Hi mrsun,

immer das gleiche!!!!

Da wissen einige intis schon wieder mehr!!!!

Dieser Anstieg in dem letzten Wochen, und dass ohne news.......,
das Volumen steigt auch mit!

Weist Du vieleicht mehr???


mfg

goyauno

[mrsun]

Antwort auf Beitrag Nr.: 31.145.836 von goyauno am 13.08.07 20:40:34

hallo goyauno

tappe leider auch im Dunkeln,und auf yahoo wird auch nur wild spekuliert.
ich tippe einfach mal,daß jetzt mal wieder Gewinne gemacht werden wollen.Aber die Tendenz zeigt doch wieder ganz klar,daß Interesse da ist,denn sonst hätten wir schon längst 1$ gesehen.
Selbst wenn 50mio neue share´s kommen sollten,kann keiner genau sagen wann sie kommen.
Was mich grad am meißten freut,ist das tägliche Volumen,das sehr vernünftig aussieht.
Aber wissen tu ich leider auch nichts genaues,nur spekulieren.
Bleibe deshalb weiter drin,und wünsche allen mit investierten weiterhin gute Nerven

[mrsun]

SIGA Technologies to Announce Second Quarter 2007 Results of Operations
Company to Host Investor Update Call on August 16, 2007 at 10:00 a.m. Eastern

SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that the company’s senior management will discuss SIGA’s results of operations for the second quarter during a conference call scheduled for Thursday, August 16, 2007, at 10:00 a.m. Eastern. The company’s financial results for the first quarter are scheduled to be released earlier that day.

What: SIGA Technologies, Inc. Investor Update Call

When: Thursday, August 16, 2007, 10:00 a.m. Eastern

Web cast address: http://www.streetevents.com,
http://www.fulldisclosure.com

Dial-in Numbers: [phone] (domestic) or
617-597-5395 (international), pass code # 33753202

Contact: Al Palombo, Cameron Associates,
[phone] Ext. 209, [e-mail]

If you are unable to participate, an audio replay of the call will be available beginning two hours after the call and will be available until 11:59 p.m. on August 23, 2007, by dialing [phone] (domestic) or [phone] (international) using confirmation pass code 89430727.

[mrsun]

http://www.sec.gov/Archives/edgar/data/1010086/0001169232070…

[mrsun]

SIGA Technologies, Inc. (SIGA)
Q2 2007 Earnings Call
August 16, 2007, 10:00 AM ET

Executives

Eric A. Rose - Chief Executive Officer and Chairman of the Board
Thomas N. Konatich - Chief Financial Officer and Treasurer
Al Palombo - Investor Relations, Cameron Associates

Analysts

Joaquin - Nolan Berger Capital
Ronald Brown - Analyst
Andre Garnet - Advent Financial

Presentation

Operator

Good day ladies and gentlemen and welcome to the Second Quarter 2007 SIGA Technologies’ investor update conference call. My name is Feb [ph] and I will be your coordinator for today. At this time, all participants are in a listen-only mode. We will conduct a question-and-answer session towards the end of this conference. [Operator Instructions]. I would now like to turn the presentation over to Dr. Eric Rose, Chairman and Chief Executive Officer, please proceed sir.

Eric A. Rose - Chief Executive Officer and Chairman of the Board

Thank you operator. Good morning everyone and welcome to this investor update conference call. Today’s call is being broadcast over this conference line and is also available via the Web as noted in our press release. It will be available after the call in a recorded format through the conference service and on our website. A transcript of this call will be furnished to the SEC on Form 8-K. With me on the line today is Tom Konatich, our Chief Financial Officer as well as Al Palombo from our Investor Relations firm Cameron Associates.

While it has been a relatively quiet quarter from a news perspective, we continue to make deliberative substantive progress with our antiviral drug portfolio. We are going to keep our comments in today’s call relatively brief so that we can get to the question-and-answer portion of the call sooner. The question-and-answer session will be open to analysts and institutional investors and we will also be taking your questions by email at [e-mail]. Before we begin our review of operations, I will ask Al to read our disclaimer regarding forward looking statements.

Al Palombo - Investor Relations, Cameron Associates

Thanks Eric. This morning’s conference call will include certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates and assumptions and are subject to uncertainties, many of which are beyond SIGA’s control. Actual results may differ materially from those anticipated in any forward-looking statement.

Factors that may cause such differences include the risk that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products and (f) regulatory approval for SIGA’s products may require further or additional testing that will delay or prevent approval.

More detailed information about SIGA and risk factors that may affect the realization of the forward looking statements, including the forward-looking statements made this morning are set forth in SIGA's filings with the SEC, including its Annual Report on form 10-K for the fiscal year ended December 31, 2006. SIGA urges investors and security holders to read those documents free of charge at the Commission's website at www.sec.gov or obtain them from SIGA. Forward looking statements speak only as of the date they are made, and SIGA undertakes no obligation to publicly update any of the forward looking statement as a result of new information, future events or otherwise, except as required by law.

Finally, I need to say a quick word about the FDA approval process. As you know, SIGA’s principal product is an unapproved drug. As such, the FDA has strict rules regarding what can be said about the drug’s safety and effectiveness. SIGA respects those rules and nothing said today should be taken as a definitive claim regarding the safety and/or effectiveness of ST-246.

With that said I’ll now turn the call back to Eric.

Eric A. Rose - Chief Executive Officer and Chairman of the Board

Thank you Al. We continue to make progress on our primary objective of bringing ST 246, our lead drug candidate, for the treatment of smallpox through the regulatory pathway. Before we get started Tom will provide you with the financial highlights of the quarters.

Thomas N. Konatich - Chief Financial Officer and Treasurer

Thanks Eric. Again as Al said, our financial statements are available at the www.sec.gov and you can look at our recently filed 10-Q for the quarter ended June 30th in more detail at your leisure, but the highlights of the month again. We had revenues of approximately $1.5 million from grants and contracts. This number is virtually identical to the revenue figure for the prior year. We reduced our operating loss to $2 million compared to $2.6 million last year; the reduction was primarily attributable to lower SG&A expense of approximately $350,000 which was due to lower-legal and professional fees incurred this year as compared to last year when we are involved in a proposed business transaction. R&D expenses were lower by approximately $230,000, most of that was a result of non cash amortization charges declining which was partially offset by some increases in manpower as we fully gear-up our laboratory R&D workforce.

There was recognition of a non-cash gain of $2.4 million in the quarter which is a function of certain rights and warrants that were attributable to a financing we did in 2005. This is an accounting charge and as a result of this our fully-diluted earnings per share was actually earning of $0.01 per share. Last year our loss was $0.08 for the second quarter. The accounting charge that we incurred was a result of changes in market value of the securities that underlie these warrants, it’s not germane of the operation of the business.

For the six months ended June 30, 2007 the company reported revenue of $3.3 million, an increase of approximately 17% to the $2.9 million reported for our last year. The increase is primarily attributable to increased revenues from our grants and contracts with the NIH.

Operating loss for the period was approximately $3.8 million slightly less than the $3.9 million operating loss that we reported for the second quarter for the six months last year. Net loss per share for the periods ended June 30, 2007 and 2006 were $0.08 and $0.19 respectively. Reflected in net income was a non-cash gain of approximately $1 million in 2007 compared to a non-cash loss of $1.1 million in 2006, reflecting changes in the fair value of rights and warrants, approaches common shares.

From a balance sheet perspective cash in equivalence and short-term investments as of June 30, 2007 were approximately $9.3 million as compared to approximately $10.7 million at December 31, 2006.

As many of you will recall, the nature of funding is unusual in relation to a typical business. Since mid-2004 SIGA has been successful in financing a significant portion of its product development through grants and contracts with a number of federal government agencies including National Institute for Health and the Defense Department. We cooperate very closely with our governmental partners. During the two years ending 12/31/2006 we generated $15.8 million in revenue from research grants and contracts with these agencies. That funding represented approximately 75% of the cash used in our operations over this two year period.

In addition, the cash received under the grants and contracts, federal agencies have performed critical studies on our products at no cost to SIGA. When considering SIGA’s financial resources the value of these services should not be overlooked or underestimated.

As a normal course of business, we routinely apply for additional grants and contracts as we become aware of them and have several applications and proposals in the pipeline that we help to secure. We do not speculate on the probability or receipt of any additional grants funding, but we’re hopeful based on past experiences that we will continue to receive additional commitments as we go forward.

Our near-term operations are largely funded by the grants and contracts we entered into in the second half of 2006, which totaled $29.6 million. The funding from these grants and contracts began in the first quarter of the federal fiscal year, which started October 1, 2006 and will continue through September 30, 2009.

Before I hand the call back to Eric, I’d like to address a couple of housekeeping items. Our shareholders recently approved an increase in the number of authorized shares of our company’s common stock from 50 million to 100 million shares. As mentioned in the proxy, preceding the vote, the increase was needed to provide the company with flexibility as we go forward and to provide some options to key SIGA personnel.

Finally, I would like everyone to know that I will be making a presentation at the upcoming Noble Financial Conference in South Carolina on August 21, at 12:30 p.m. Eastern. More information on the conference can be found at www.nobleresearch.com.

With that I will now turn the call back to Eric for his comments.

Eric A. Rose - Chairman of the Board, Chief Executive Officer

Thanks Tom. Today’s call is primarily designed to provide a reconfirmation to our investors that our smallpox antiviral lead product ST-246 is fairly progressing on track through studies to support an NDA for regulatory approval and we have the resources to see this project through. As with most drug candidates progressing through the FDA process, this process is deliberate and thorough. We are relatively limited in the amount we cay say however, and we will do our best to answer any questions that you may have at the end of the call.

In addition to continue our progress with ST-246, the quarter was highlighted by the progress we made with ST-193, our Lassa Fever drug. In mid-quarter we were pleased to announce that our Lassa Fever program generated a proof-of-concept data in a rigorous guinea pig model. The disease course in these guinea pigs mirrors what is seen in human Lassa Fever infections, and we expect that this model is one of the two animal models that will be required to fulfill the U.S. Food and Drug Administration’s Animal Efficacy Rule.

This study should provide the basis for advancing this lead candidate into IND-enabling activities in the near future and it’s a significant milestone for our research group.

Our other hemorrhagic fever programs are entering proof-of-concept animal studies, which is successful with support initiation of IND-enabling activities to begin in the near future for these programs as well.

So, to summarize, our smallpox antiviral lead product ST-246 is fairly progressing on track through studies to support an NDA regulatory approval. ST-193 is now been validated in rigorous proof-of-concept animal model. The hemorrhagic fever programs other than Lassa are entering proof-of-concept animal studies, which is successful and will support initiation of IND-enabling activities.

Our early stage of programs to identify inhibiters of other important viral biothreat agents are progressing and promise to expand our portfolio products even further. We have in place $29.6 million in grants and contracts to support our activities and we will continue to seek and compete for additional federal funds where and when appropriate.

SIGA’s overall corporate mission remains unchanged, to discover and develop effective, selective and safe oral antiviral drugs directed at treating, preventing and complimenting vaccines for high threat biowarfare agents. Our goal is to lead the development and provision of these drugs domestically and throughout the world to ensure leading-edge biodefense capability, and to prevent and treat naturally occurring illness caused by agents that we target. Our progress with ST-246 and other drugs candidates in our pipeline is continued evidence of our work in this area.

That’s the end of our prepared statements. We appreciate you taking the time to hear our update and before we open the call up for questions, I’d like to take the opportunity to see if we received any email questions. Al, can you help out here?

Al Palombo - Investor Relations, Cameron Associates

Yeah. Eric, currently nothing has come in, but why don’t we go ahead and open up the call for questions at this point and if anything pops up I’ll let you know.

Eric A. Rose - Chairman of the Board, Chief Executive Officer

Operator, can we have your help with this? Do we have an operator on the line?

Question-and-Answer Session

Operator

[Operator Instructions] Your first question comes from the line of Joaquin (inaudible) from Nolan Berger Capital. Please proceed.

Joaquin - Nolan Berger Capital

Good morning guys.

Eric A. Rose - Chief Executive Officer and Chairman of the Board

Hi Joaquin, how are you?

Joaquin - Nolan Berger Capital

Great. Just a couple of questions; one, can you comment on the child that you treated with the ST-246 and how the results are there?

Eric A. Rose - Chief Executive Officer and Chairman of the Board

The child was discharged from the hospital and has done remarkably well. He is now free of orthopox virus infection, and a report of the child’s illness appeared in Morbidity & Mortality Weekly Report, which is the publication wing of the CDC. So, we are very pleased with his course.

Joaquin - Nolan Berger Capital

In the last call you mentioned that your current trials of ST-246 with the NIH would be finalized in September or over within September, is that still on track?

Eric A. Rose - Chief Executive Officer and Chairman of the Board

I think they will be finished some time in the fall. I can’t say specifically they will be fully complete in September.

Joaquin - Nolan Berger Capital

Let me ask you, if you can comment on this. Is there any reason why you would have to wait or someone would have to wait for FDA approval before they order your product?

Eric A. Rose - Chief Executive Officer and Chairman of the Board

Based on the ordering pattern for the other smallpox products that are now in the stockpile both the Acambis vaccine and the recently purchased MVA vaccine from Bavarian Nordic, neither of those is an FDA approved product. So, we do think that there is an opportunity for us to have a request for proposals for smallpox antiviral sale prior to FDA approval.

Joaquin - Nolan Berger Capital

Will the product be sold other than, say, to the US government; are there opportunities to sell it to other foreign countries or, say, the World Health Organization or the UN or whatever.

Eric A. Rose - Chief Executive Officer and Chairman of the Board

There certainly are opportunities to sell this to foreign governments and in addition to the opportunity to sell into the BioShield program in the United States, there are also the opportunity to sell to the Department of Defense, and to analogous to Tamiflu and other bird flu antivirals, there is a market for this type of drug for private industry to protect their workforce.

Joaquin - Nolan Berger Capital

I am sure you’ll noodle this around, but what the size of the potential market is?

Eric A. Rose - Chief Executive Officer and Chairman of the Board

We have expressed our view to the prudent sized purchase for a combination of the stockpile for treatment of smallpox and prevention of smallpox in a post exposure outbreak scenario would be about 30 million courses in the United States. We are particularly excited about the prospect of using the drug as an adjunct to standard vaccination, which we believe could have a substantial positive effect on decreasing the well known and severe side effects of the vaccine. Most of which are probably due to viremia [ph] with which our drug is particularity prone (ph). If that is the case, if the standard of care were to become vaccination plus ST-246 and arguably and that should be stockpiled or ideally should be stockpiled equivalent to the amount of vaccine that is stockpiled. Right now there is vaccine stockpiled in the United States for every citizen.

Joaquin - Nolan Berger Capital

That is huge market then.

Eric A. Rose - Chief Executive Officer and Chairman of the Board

That is a substantial market.

Thomas N. Konatich - Chief Financial Officer and Treasurer

Right.

Joaquin - Nolan Berger Capital

Any comments back from the Judge on the PharmAthene lawsuit?

Eric A. Rose - Chief Executive Officer and Chairman of the Board

We can’t comment on that other than to say that to my knowledge there has been no response yet.

Joaquin - Nolan Berger Capital

Okay, thank you. I will let somebody ask some questions.

Eric A. Rose - Chief Executive Officer and Chairman of the Board

Thanks.

Operator

Your next question comes from the line of Ronald Brown, please proceed.

Ronald Brown - Analyst

Yes, Tom a question for you. I am still showing institutional ownership at about 5% and if you guys could just talk about what you are doing to increase awareness to institutions? And the other question that I have is you talked a little bit about the rest your portfolio and if you could talk about, you specifically mentioned ST-193. If you could talk about the stages of development in those other arena viruses and (inaudible) if you just elaborate on that a little more if you would please.

Thomas N. Konatich - Chief Financial Officer and Treasurer

Let me answer the institutional investor part and Eric can do the other part. We have with the help of Al Palombo and our own resources set up meetings with a goodly number of institutional investors. We are going to be going on some road trips; Eric is scheduled to make one soon, I believe out of the West Coast. We will be presenting at certain conferences. As mentioned earlier, I am going to be at the Noble Financial Conference in Charleston next week. We had an institutional investor who just filed a filing stating that they now own 1.1 millions shares of SIGA Technologies that is Baker [ph] Brothers and that should be on the SEC website and we are starting to see our efforts bare fruit, which began several months ago and we will continue to do that. We were making some trips to Europe to see if we can bring in some Europeans institutional investors and Eric you can comment on the developmental aspects of the question.

Eric A. Rose - Chief Executive Officer and Chairman of the Board

Sure, essentially a wide array of targets that are in the implementation plan for the Public Health Emergency Countermeasures Enterprise called PHEMCE, all of these or many of them are in our sites. And the developmental process is very much the same and much of it being performed by the same scientists that created ST-246. We essentially study the viruses in cell culture models where the viruses are available for agents like Ebola. We make pseudo viruses, essentially an HIV construct that has biochemical elements of the specific virus on the surface.

Obviously, we can’t work in the laboratory with agents like that safely or legally. But in both the pseudo constructs and the actual virus constructs we screen a very large library that we have, more than 300,000 compounds that did yield the ST-246 and look for agents that inhabit file replication in the cell culture, and have many, many hits across many of our programs at this point and with the most prominent [ph] of those hits we see to dissect out essentially through growth of resistance frames what’s specifically in the viral molecular biology is required for that resistance.

We then impute that resistant component of the virus is what the drug is targeting and then goes specifically and much more specifically at designing small molecules that go after the specific target. That’s exactly how we developed ST-246 and that is certainly the path that we are following for these other agents as well.

Al Palombo - Investor Relations, Cameron Associates

Now, Eric and Tom, we have just received an email inquiry here and Eric it has to with the current trial. I think it might make sense just to review what’s happening or the nature of that trial. I’ll read the question, the question states; it’s been almost six months since the first ST-246 trials ended, what’s taking so long to get the results published? Can you just review the nature of the trial, and how that actually, its not actually a 21-day trial but it actually takes an extended period of time.

Eric A. Rose - Chief Executive Officer and Chairman of the Board

Sure, first going back to our first trial, our first trial was just single dose of – and a dose ranging study to look at safety in the pharmacokinetics of single doses of ST-246, and what we gleaned [ph] from that was that the drug was probably a once-a-day drug and that we are capable of achieving blood levels that are in the same range as we see efficacy in our most stringent animal particularly the primate models. The more recent studies have been 21-day courses of ST-246 in a dose-escalation mode. That’s where we are, we are in the midst of that dose escalation at this point and while each individual subject in these trials receives drugs for 21 days, they are not all started at the same time, so that enrolling a group takes longer than 21 days.

In addition, after each step-up in dosed our protocol which is on clinical trials that requires a routine safety monitoring Board review of outcomes after each dose escalation. So, that’s the process that’s been going on; we had projected that we would be done with the final dose escalation, probably some time in September, I think it might be a little bit later than that; we feel that we are reasonably on track with that.

Al Palombo - Investor Relations, Cameron Associates

Great, we have one more inbound question here, this is addressed to Tom; it has to do with the authorized shares Tom. Hello! I think the recent decline in SIGA shares has at least partially been due to the increased number of authorized shares. Do you expect to use these shares to fund operations or do you have enough cash/grant money to fund operations for the foreseeable future, i.e. the next year?

Thomas N. Konatich - Chief Financial Officer and Treasurer

You will note in our 10-Q filing, we state that we have sufficient cash to carry us through the warp [ph] beyond the next 12 months, and that really is all we are allowed to say under the ordering rules and SEC rules. Again, as I have mentioned earlier when I was making my prepared remarks, we had a number of employees or key employees; Dennis, Ruby, Eric and a lot of individuals out on the west coast, who had not received any stock options in a long time because the number of authorized shares we had did not allow that room. That was the primary reason for asking for that increase. You are not going to go ask for an increase of 5 million shares or 10 million shares, which you don’t want to have to keep coming back for the shareholders.

So, we just went to a larger number, and I said in the proxy beyond the immediate need which we have issued these options to people and we mentioned that in our 10-Q to those individuals - those officers who got it and a lot of the options that were granted are contingent on certain performances issues have and things happening for the company. We at this point in time, have no plans beyond that.

So, it is there to permit flexibility we do not know what’s going to occur three months from now, six months from now, or next year. An opportunity to acquire some technology, opportunity to do other things that might requires some additional shares. They are there when we need it, we don’t want to have to go get them and not have enough time to do transactions that would be very beneficial to the company, but again all that has been done now, and all that’s in our plans is issuing some of those options that I discussed.

Al Palombo - Investor Relations, Cameron Associates

That’s it for the inbound email questions.

Operator

Your next question comes from the line of Andre Garnet from Advent Financial, please proceed.

Andre Garnet - Advent Financial

Hello, good afternoon. My first question is this; it is about ST-246 and the upcoming large scale pivotal trial. Will that trial be the last one before the submission of the NDA?

Eric A. Rose - Chief Executive Officer and Chairman of the Board

Well, we are in the midst of the dose escalation that I described, and following the acquisition of that data we will decide what we think is the appropriate dose of the drug. We still believe it will be a once-a-day drug. The pivotal safety trial will follow upon that which we anticipate will be about a 400-500 Patient Safety Trial, at the dose that we believe is the therapeutic and preventive dose. We think those are likely to be the same although we are still investigating that as well with our animal models. That would be, we believe, the last and pivotal trial that we will need to do in humans.

Andre Garnet - Advent Financial

So, are you still expecting to file an NDA in early 2009?

Eric A. Rose - Chief Executive Officer and Chairman of the Board

We think that, that is still feasible that’s correct.

Andre Garnet - Advent Financial

Okay, I have another question about ST-246. There have been rumors that camelpox could be used as a bioweapons. Now, figures have shown that ST-246 is effective against camelpox. My question is this, in order for camelpox to become an approved application for ST-246, would it be necessary to perform some additional efficacy trials.

Eric A. Rose - Chief Executive Officer and Chairman of the Board

That’s an excellent question to which I do not have an immediate answer. We do know without question that the S13LG [ph] and the ST-246 attacks is ubiquitous across the pathogenic orthopox viruses. So, we would have every expectation that the drug would be effective against camelpox. Actually, one of the things that has been pointed out to us by people in this field is that camelpox is probably the closest of the still widely occurring orthopox virus infections that’s the closest in terms of its gene structure to the smallpox virus. It’s only about a 145, 146 base pairs that are different between the camelpox virus and smallpox.

So, it’s conceivable that a rouge molecular biology pursuit could convert camelpox to the orthopox virus. So, I think your question is very, very pertinent. I do believe that if there were a camelpox outbreak and our drug have been stockpiled and was available that it would be used to deal with it, but still our primary focus and I think the BioShield purchasing pattern right now is to focus on smallpox antivirals and to make sure that we get to that stage of an order we are going to focus on smallpox first.

Andre Garnet - Advent Financial

I understand, thank you that was my last question.

Thomas N. Konatich - Chief Financial Officer and Treasurer

I guess that was his last question.

Operator

There are no further questions at this time. I would now like to turn the call back over to Dr. Eric Rose for closing remarks.

Eric A. Rose - Chief Executive Officer and Chairman of the Board

Yes, thank you very much operator. We appreciate this opportunity to bring you all to up to date on our progress. We continue to make progress with ST-246. We continue to make progress on our other antiviral programs. We have a first rate scientific and clinical team and I believe our story is being better understood by the investment community as well and we look forward to future communications with you as well. Thanks so much.

Operator

Thank you for your participation in today's conference; this concludes the presentation. You may now disconnect. Have a wonderful day.

[goyauno]

August 20, 2007

HomeArchivesRSS SyndicationMerchandiseDonationsContactAboutSearch


Home --> Articles
Email Friend | Print Article
June 08, 2007
The Threat of Bioweapons
By Janet Ellen Levy
Immediately following 9-11, an anthrax attack originating from letters containing anthrax spores infected 22 people, killing five. After almost six years, the case has not been solved.


Intelligence analysts and academics report that North Korea has developed anthrax, plague, and botulism toxin and conducted extensive research on smallpox, typhoid and cholera.


A world-renowned bioweapons expert has confirmed that Syria has weapons grade smallpox resistant to all current vaccines developed under the cover of legitimate veterinary research on camelpox, a very closely related virus. The researcher further reports that Syria is suspected of testing the pathogen on prison populations and possibly in the Sudan.


Although there are close to 50 organisms that could be used offensively, rogue nations have concentrated their bioweapons development efforts on smallpox, anthrax, plague, botulinum, tularemia and viral hemorrhagic fevers. With the exception of smallpox, which is exclusively a human host disease, all of the other pathogens lend themselves to animal testing as they are zoonotic, or can be transmitted to humans by other species.


Biological weapons are among the most dangerous in the world today and can be engineered and disseminated to achieve a more deadly result than a nuclear attack. Whereas the explosion of a nuclear bomb would cause massive death in a specific location, a biological attack with smallpox could infect multitudes of people across the globe. With incubation periods of up to 17 days, human disseminators could unwittingly cause widespread exposure before diagnosable symptoms indicate an infection and appropriate quarantine procedures are in place.


Unlike any other type of weapon, bioweapons such as smallpox can replicate and infect a chain of people over an indeterminate amount of time from a single undetectable point of release. According to science writer and author of The Hot Zone, Richard Preston, "If you took a gram of smallpox, which is highly contagious and lethal, and for which there's no vaccine available globally now, and released it in the air and created about a hundred cases, the chances are excellent that the virus would go global in six weeks as people moved from city to city......the death toll could easily hit the hundreds of millions.....in scale, that's like a nuclear war."[1]


More so than chemical and nuclear research, bioweapons development programs lend themselves to stealth development. They are difficult to detect, can be conducted alongside legimate research on countermeasures, sheltered in animal research facilities within sophisticated pharmaceutical corporations, disguised as part of routine medical university studies, or be a component of dual use technology development. Detection is primarily through available intelligence information and location-specific biosensors that test for the presence of pathogens.


Biological weapons have many appealing qualities for warfare and their effects can be engineered and customized from a boutique of possibilities. Offensive pathogens are inexpensive compared to conventional weapons and small quantities can produce disproportionate damage. They have unlimited lethal potential as carriers and can continue to infect more people over time. Bioweapons are easy to dispense through a variety of delivery systems from a missile, an aerosol or a food product. They can be placed into a state of dormancy to be activated at a later stage allowing for ease of storage. Pathogens are not immediately detectable or identifiable due to varying incubation periods and can be rapidly deployed, activated and impossible to trace. The technology to develop biological agents is widely available for legitimate purposes and large quantities can be developed within days.


Bioweapons can be tailored for specific situations from a variety of desired characteristics, including pathogenicity or disease-producing capacity, incubation period, virulence and transmissibility. Pathogenicity is relative to the quantity of a particular agent that is necessary to cause disease. The incubation period is critical for determining the timing of the desired period between exposure and the onset of illness. Virulence determines how debilitating and lethal the disease will manifest in the target population. Transmissibility defines the ease in which the disease is able to spread.


The ultimate goal of bioterrorism is to induce fear, panic and chaos by high morbidity and mortality rates to breakdown the existing political, economic and social structure. For bioweapons to be successful, "The biological agent should consistently produce the desire effect of death or disease. It should be highly contagious with short and predictable incubation period and infective in low doses. The disease should be difficult to identify and be suspected as an act of bioterrorism. The agents should be suitable for mass production, storage, weaponization, and stable during dissemination. The target population should have little or no herd immunity and little or no access to treatment. The terrorist should have means to protect or treat their own forces and population against the infectious agents or the toxins."[2]


Due to their virulence, ease of dissemination and detection difficulties, bioweapons experts and the Department of Homeland Security assert that smallpox and anthrax are the most worrisome biothreats to national security. Both have been weaponized which means they can be produced in a particle size that is releasable in the air and can be easily inhaled into the respiratory system. Both smallpox and anthrax are extremely deadly and present unique forensic, environmental, logistical and public health care delivery challenges.


Smallpox

Although smallpox was officially eradicated in 1980, there is evidence of the virus beyond the two World Health Organization-designated repositories. There is little immunity in the U.S. population as the smallpox vaccination program ended in 1963 and the vaccinations are believed to be effective for a ten year period.


Following 9-11 and heightened fears of a bioattack, the U.S. government, under the direction of Health and Human Services, revitalized the smallpox program and by 2003 acquired sufficient live-virus vaccines in the Strategic National Stockpile for the entire population. Approximately 50-60 million Americans are identified either as high risk for developing post-vaccination complications or unable to be vaccinated. These include individuals who are allergic to vaccine components, are HIV-positive, have immune system disorders, are undergoing chemotherapy, have certain dermatologic conditions and pregnant and breast-feeding women.


The FDA just recommended for approval a new smallpox vaccine that is grown in a cell culture in a laboratory and has less of a risk of complications. It can be used for populations who can't receive the conventional smallpox vaccination and will most likely be added to the stockpile within the next year. An anti-viral drug that effectively treats adverse vaccine reactions will be purchased for the stockpile as well.

The challenges presented by a smallpox outbreak are numerous for diagnosis, surveillance and containment. Although easily diagnosed, the majority of practicing physicians has never seen a case of smallpox and may not accurately identify symptoms at first. Due to the long incubation period, infected individuals may remain undetected for extended periods leading to misjudgments in the trajectory of the epidemic and delayed implementation of quarantine procedures. Potential contacts of cases may be too great to effectively trace and monitor. Also, the vaccine is ineffective beyond the first few days of exposure when people are asymptomatic and few health care workers have been immunized. During the 20th century, with greater immunity, smallpox killed 300 million people.


Anthrax


Anthrax is a serious disease that is caused by spore-producing bacteria that releases toxins in the body. It cannot be spread through direct human contact but can be transported on inanimate objects and disseminated through the air. Anthrax infections can occur through the skin, by inhalation and by ingesting contaminated food.


Anthrax presents difficult challenges for clean-up and decontamination. The spores tend to be widely dispersed in the environment and can survive for long periods of time after release. Decontamination procedures are costly and extremely time-consuming as the bacteria is highly stable and maintains its potency.


A number of treatments exist for anthrax infections and several are in the national stockpile or in the process of being acquired. Vaccinations provide pre-exposure protection for individuals at high risk for anthrax contact. For post-exposure, a combination of vaccination and oral antibiotics is used. For those who are symptomatic, intravenous antibiotics are the treatment of choice. HHS is in the process of acquiring the next generation of anthrax vaccine that can be produced more rapidly than what is currently available. Also, drugs that clean up the toxins excreted by anthrax bacteria are being developed and will be added to the stockpile.


September 11th and the anthrax attack that followed were watershed events that spawned programs to fight bioterrorism. The newly established DHS was charged with the responsibility of performing threat assessments and communicating the need for countermeasures to Health and Human Services to procure countermeasures for the national stockpile. In 2002, several programs were enacted by the Bush administration to create the necessary infrastructure for the detection and necessary interventions for a bioterrorist attack against the United States. The programs include Project BioWatch, Project BioSense and Project BioShield.


Project BioWatch


Project BioWatch is an early biothreat detection system coordinated through the Department of Homeland Security (DHS), the Environmental Protection Agency (EPA) and the Center for Disease Control (CDC) with the goal of minimizing casualties, assisting law enforcement efforts and identifying exposed populations and contamination patterns. BioWatch monitors a network of biosensors or filters in 30 U.S. cities that detect the presence of biological materials, capture samples and analyze them in a field laboratory. The current system tests for the existence of up to eight toxins, bacteria and viruses. If bioagents are detected, BioWatch has a series of protocols to follow to initiate an appropriate course of action and affect public health policy. The acquisition and implementation of next generation technology biosensors that will perform insitu sample collection, analysis and wirelessly report biothreats is being explored by DHS and should be ready for pilot testing shortly. The new technology, which can test for around 20 pathogens, will provide cost savings that could possibly result in greater coverage or increased density within currently monitored locations.


Project Biosense


Project BioSense was established to reduce the time between the detection of a potential biothreat and the initiation of an appropriate response. It's primary function is to analyze multiple data streams from hospitals, pharmacies, Project BioWatch and other relevant sources, for the purpose of expediting a coordinated comprehensive response. The goal is to have a single center collect and evaluate available data and transmit critical threat information to health care providers. It aims to strengthens the working relationship between the CDC and the caregivers on the frontlines in a biothreat emergency.


Project Bioshield


Project Bioshield's charter is to procure vaccinations and drugs for potential biothreats for the national stockpile. In 2004, $5.6 billion was allocated over ten years to fund research and purchase countermeasures against threats from private companies. Bioshield was established to simplify the procurement process and enable the FDA and the NIH to partner with research communities and the biopharma industry in the fight against bioterrorism. In its initial stages, it was difficult for Project Bioshield to incentivize biotechnology companies to develop countermeasures for bioweapons. More lucrative drug development projects for cancer and HIV had greater market potential and promised better returns on investment. Also, Project Bioshield contracts included extensive regulations, offered no liability protection, and lacked purchase guarantees. Private companies were incurring all of the risk of doing business with the government and received no payments until the actual delivery of products to the stockpile. Once a product was developed, companies were saddled with costs for extensive testing that could span a five year period and be difficult to recover.


In 2005, BARDA, the Biomedical Advanced Research and Development Authority, was established to facilitate the development of medical countermeasures against national security threats. BARDA simplified the procurement process, provided liability protection for private companies and advanced development money for testing promising products.


Two new bills have been proposed to improve the national response to biological threats. The Material Threats Act, H.R. 1089, aims to improve the ability of DHS to assess chemical, biological, radiological and nuclear threats and the availability and effectiveness of countermeasures that may be grouped together to address multiple threats. The second bill, H.R. 1290, establishes a National Biosurveillance Integration Center to monitor, review and consolidate data from multiple sources in the event of a biological incident.


Conclusion


The testimony before Congress in April of 2006 of Tara O'Toole, M.D., M.P.H., Director and CEO of the Center for Biosecurity at the University of Pittsburgh Medical Center sums up the current situation vis a vis biothreats. "The U.S. does not yet have a coherent biodefense strategy, nor do we have a strategy for countermeasure research, development, and production that takes account of the full spectrum of possible bioweapons agents, including engineered threats."[3] Dr. O'Toole went on to explain the urgency for national security of developing and stockpiling countermeasures against high-priority threats such as anthrax, smallpox, plague and others. In the long term, she criticized the futility of chasing countermeasures for specific pathogens due to the multitude of pathogens that are potentially weaponizable. What is needed according to Dr. O'Toole is the "ability to rapidly design, develop and produce new countermeasures from a standing start - in weeks, if not days."[4] This will occur with technological improvements, wider sharing and accessibility of data, streamlined clinical testing and regulatory review and through public-private partnerships.


Even with the BioWatch, BioSense and BioShield projects, still in their infancy, current measures fall far short of this broad, well thought out approach. The two proposed Congressional bills are a step forward. But the United States remains almost as ill prepared today to cope with a bioweapons attack as it proved itself to be shortly after 9/11. We must begin to remedy this now.

--------------------------------------------------------------------------------

[1] "A conversation with Richard Preston" in Laboratory Medicine, vol. 30, pg 517 Aug. 1999.


[2] Beeching NJ, Dance DA, Miller AR, et. al. Biological warfare and bioterrorism. BMJ 2002; 324:336-339.


[3] Tara O'Toole, MD, MPH, Hearing on "Project BioShield Reauthorization Issues," testimony before the Congress of the United States, April 6, 2006.


http://upmc-biosecurity.org/website/resources/hearings/conte…


[4] ibid. Recent Articles
It's Not Just Scott Beauchamp (II)
Global Warming Bureaucrat Hansen Lashes Out at Critics
America's Nuclear Military Dilemma with China
Lost Posterity
Don't Tug on Superman's Cape
Appeasement Finds a Home in the Academy
What to do to with Hostages to Islamists
Why not Newt?
Why Would Anyone Trust NASA's Climate Data Now?
NASA Flacks for Global Warming and Skirts Scientific Ethics
Blog Posts
Speaking of phobias (updated)
Obama campaign retreats in the face of gaffes
Zimbabwe Collapse "In Four Months"
Ethanol Follies: Go Green by Burning Gas and Planting a Tree
Sad Truth
Iraq Stock Exchange up 64% This Year
Hurricane Dean May Threaten US Gulf Coast (Updated 8/19)
Hijackers Surrender in Turkey
Report: Don't Neglect Homegrown Jihadists
Iraq Troop Drawdown Likely Next Year
Monthly Archives
August 2007
July 2007
June 2007
May 2007
More...

About Us | Contact © American Thinker 2007

[mrsun]

Hab mir grad die Noble Financial Small Cap Conference im Internet angeschaut.
Präsentation war ganz gut gemacht,aber nichts neues.
Die meist gestellte Frage im Anschluss war,mit wieviel kann man bei einer Order rechnen.
Ganz interessant war die Aussage,das ST-246 als reines bio-warfare produkt bei siga angesehen wird.
Deshalb wird auch eine Vermarktung auserhalbs der USA noch gar nicht ins Auge gegriffen.

Aber was nicht ist,kann ja noch werden
also good luck

[mrsun]

Hier ist schon wieder irgendwas im Busch

After Hours Trade Reporting


After Hours
Last: $ 4.1598 After Hours
High: $ 4.1598
After Hours
Volume: 167,116 After Hours
Low: $ 3.75

After Hours
Time (ET) After Hours
Price After Hours
Share Volume
16:22 $ 4.1598 160,000
16:14 $ 3.85 500
16:14 $ 3.84 500
16:14 $ 3.82 200
16:14 $ 3.80 526
16:14 $ 3.85 500
16:14 $ 3.84 300
16:14 $ 3.84 200
16:14 $ 3.75 500
16:14 $ 3.75 200
16:14 $ 3.75 526
16:14 $ 3.75 700
16:14 $ 3.75 1,574
16:14 $ 3.75 700
16:04 $ 3.89 190

http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx…

[mrsun]

Antwort auf Beitrag Nr.: 31.276.015 von mrsun am 24.08.07 00:13:39

oooh sorry,falscher Alarm leute
hab mich im ticker symbol vergriffen
mea culpa

[Uptick08]

4,00 USD wieder, nett, ganz nett...

[mrsun]

http://adventfinancialinc.com/research_reports/SIGA%20Update…

[whyso]

Antwort auf Beitrag Nr.: 31.364.888 von mrsun am 01.09.07 17:33:45

Hi Mr Sun,

ich habe gut zutun gehabt im laufe der letzte paar Monate, aber schon zu sehen das du immer noch mit von der (Siga) Partie bist

Ich denke nach Roses zukäufe, und der schnell näher rückende Herbst und Epediesaison das wir bald ein neuen "Initialzündung" erleben werden...ich bin jedenfalls noch voll & ganz dabei!

Hast du die jüngste Ebola Nachrichten aus dem Kongo vernommen, ich denke Rose & Co sind hier extrem gut zugange das hört sich wirklich verheerend an:
http://news.bbc.co.uk/2/hi/africa/6990759.stm



Nun ja, ich wünsche die dort lebende Menschen nur das beste (und natürlich das ein schnell wirkende "Kit" baldigst gefunden wird der die 100% schutz bietet, ähnlich wie im Fall Smallpox)

Sonnige Grüße & ein schönes wochenende an die "alte Brigade",
Whyso

[whyso]

Antwort auf Beitrag Nr.: 31.570.955 von whyso am 14.09.07 11:36:45

Sorry, sollte heissen "epidemic season "

http://www.who.int/csr/don/2006_03_21/en/index.html

Also, bis demnächst...

[mrsun]

Antwort auf Beitrag Nr.: 31.571.015 von whyso am 14.09.07 11:40:50

Hey whyso
Schön Dich mal wieder zu lesen,und natürlich bin ich hier auf der long Seite.
Die Nachricht war mir schon bekannt,hab sie aber nicht für lohnenswert gehalten,da ich mir eine neue Theorie zurecht gelegt habe.
Trotzdem gut daß Du sie für Die anderen einstellst.
Achso .... neue Theorie
Aufgrund der Small Cap Conference vom 21.08.07 hab ich den Verdacht,daß Siga durch die vielen Grants,durch Klauseln,stärker an US Gouverment gebunden sind als wir uns wünschen.
Wie schon am selbigen Tag schon von mir erwähnt,war deutlich heraus zu hören,daß st-246 nur für den amerikanischen Markt bereit steht.
So bekommt auch die ganze Conference einen Sinn,auf der Suche nach neuen Investoren für neue Produkte.
Was mich doch noch zuversichtlich stimmt,sind die 50mio neuen shares von denen nichts mehr zu hören ist,und der feste Kurs mit geringem Volumen.
Vielleicht ..........?!
Wie gesagt alles Theorie,und hinterher sind wir alle schlauer.

Bis dahin allen Siga Freunden happy Days,und guten Mut tut allen gut

[mrsun]

http://www.news-medical.net/?id=30011

Australian doctor awarded for uncovering smallpox bioterrorism risk
Medical Research News
Published: Tuesday, 18-Sep-2007
Printer Friendly Email to a Friend




A University of Sydney professor who developed a system to combat bioterrorism has received a major award from the US military.
Professor Raina Maclntyre has won the 2007 Sir Henry Wellcome Medal and Prize from the Association of Military Surgeons of the US (AMSUS) for developing the world's first system to comprehensively rank the different types of bioterrorism risks - an honour for a non-US and non-military person.

Professor Maclntyre's risk-priority scoring system for the most severe (category A) bioterrorism agents, published in the journal Military Medicine, will help governments prepare for potential attacks.

"Traditionally government decisions about the risk of attack by a particular agent have been made simply on the basis of the probability of attack," said Professor MacIntyre, from the University's National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases and the Faculty of Medicine.

"We hypothesised that multiple factors should be considered other than probability of attack - including the severity of an attack's consequences, the potential for person-to-person transmission, the potential for an agent to genetically modify, the relative ease of decontamination, and the availability of vaccinations."

Professor MacIntyre and her team exhaustively reviewed the history of bioterrorist incidents, the known science about each agent, and the transmission potential of each category A agent. Synthesising this information into a matrix of 10 different categories of threat allowed them to create a "priority score" for each agent.

"We found that anthrax and smallpox are the highest priority, followed by viral haemorrhagic fevers, botulism, plague and tularaemia," she said. "Anthrax topping the list is not a surprise, because it is widely available globally and easy to weaponise, but smallpox scoring highly is a surprise."

The high priority for smallpox flies in the face of the low priority governments have given to it on the basis of probability of attack alone, according to Professor MacIntyre. Although the global supply of the smallpox virus is limited, it has high person-to-person transmission rates, high fatality rates, and it has the potential for high numbers of infections and to be genetically modified into more virulent strains.

"Governments will benefit from this research in that it provides a framework and a tool for rationally and efficiently assigning priority for bioterrorism agents - and therefore planning stockpiles of drugs, vaccines and other supplies," Professor MacIntyre said.

Professor MacIntyre will receive the award in November at the AMSUS conference in Salt Lake City.

Background notes on bioterrorism:

The use of biological agents ("Biowarfare", "bioterrorism") dates back at least to 300 B.C, when the Greeks, Romans and Persians used cadavers to contaminate the water supplies of their enemies.

The Japanese used biowarfare with plague and anthrax agains the Chinese in Manchuria in the 1930s and 1940s. The former Soviet Union had an unparalleled bioweapons program which developed sophisticated weaponised anthrax, plague, smallpox and viral heamorrhagic fevers, and continued large scale work well into the 1990s despite signing the Biological Weapons Convention.

Bioterrorism is still a concern - in 2001 in the USA, anthrax spores were mailed to several cities and resulted in 11 cases of inhalational anthrax and five deaths. The economic consequences of this attack were disproportionate to the number of cases, with the shut-down of essential services such as the US Postal Service.

Potential bioterrorist agents are classified by there severity into category A (the most severe) and category B (less severe). Category A agents include anthrax, smallpox, tularaemia, plague, botulism and viral hameorrhagic fevers (eg. Ebola and Marburg viruses).

http://www.usyd.edu.au

[goyauno]

Halo Gemeinde,

nachbörslig sehr gute News.

Der Kurs hat auch schon angezogen.

Press Release Source: SIGA Technologies, Inc.


ST-246 Completely Prevents Mortality in Symptomatic Orthopox Virus Infected Primates
Wednesday September 26, 4:05 pm ET
100-Fold Dosage Reduction Still Fully Effective in Preventing Mortality


NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) today announced that its lead smallpox drug, ST-246, has passed another milestone by demonstrating 100% protection against death in cynomolgus monkeys showing signs of infection with monkeypox virus as part of a primate trial conducted at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The study included a wide range of doses, all of which successfully prevented death, including a dose that was one one-hundredth of the dose given in prior primate trials. The amount of virus introduced into each animal is usually fatal absent ST-246 (all of the control subjects died), and all of the animals had developed fever and skin lesions prior to the administration of SIGA's drug.
ADVERTISEMENT


"We are particularly pleased with the results of this study," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA. "The timing of drug administration in this study correlates to a late stage in the disease progression in humans. With this new information, we believe that ST-246 can be used to prevent mortality in humans even several days after elaboration of symptoms. Furthermore, the protection afforded by modest drug doses further enhances our confidence that a protective level in humans can be achieved with a low risk of toxicity," Hruby concluded.

In the study, once-daily, oral administration of ST-246 beginning 72 hours after infection protected cynomolgus monkeys from death following intravenous dosing with a lethal dose of monkeypox virus. ST-246 reduced lesion formation, reduced viral load and prevented death in all animals with no obvious toxicity. Furthermore, the test included a range of dosages (100 mg/kg to 3 mg/kg) of ST-246, and all were effective. The U.S. Department of Defense's Defense Threat Reduction Agency under the supervision of Dr. John Huggins, Chief of the Viral Therapeutics Branch, USAMRIID, funded and ran the study.

Commenting on the study, Dr. Huggins stated, "This is the first drug candidate that successfully treated monkeypox in our primate models after the onset of pox lesions, the most likely time that patients would be diagnosed with disease. We are encouraged and believe that this drug candidate may represent a practical solution to treating disease in a wider population where rapid laboratory-based diagnosis is not practical."

Smallpox is considered one of the most significant biowarfare threats. The federal Centers for Disease Control and Prevention (CDC) classifies variola, the virus that causes smallpox, as a "Category A" (highest level threat) bioterrorism agent. Smallpox is readily transmitted between humans, it has significant mortality rates, and the population is no longer vaccinated against it. Mass immunizations of the general population using the current live vaccine can be problematic, as there are known complications affecting some individuals, which may include encephalitis, myocarditis, and death. Immunocompromised individuals receiving this vaccine are at particular risk from a systemic infection. At this time, there is also no approved treatment for smallpox.

The Department of Homeland Security has designated smallpox a "material threat" to our national security, which renders ST-246 eligible for purchase for the Strategic National Stockpile under Project Bioshield.

SIGA previously announced that ST-246 has been shown to be safe to administer to humans as a once-a-day pill. ST-246 has also demonstrated 100% disease protection in several mouse models of infection, which results SIGA will use, along with additional tests yet to be completed, to fulfill the U.S. Food and Drug Administration's "Animal Efficacy Rule." In December 2005, the FDA granted "fast-track" status to ST-246.

About SIGA Technologies, Inc.:

SIGA is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). SIGA's product development programs also emphasize the increasingly serious problem of drug-resistant bacteria. For more information about SIGA, please visit SIGA's Web site at www.siga.com.

About the Defense Threat Reduction Agency (DTRA):

DTRA is an agency of the U.S. Department of Defense that safeguards America and its allies from weapons of mass destruction by providing capabilities to reduce, eliminate and counter the threat and mitigate its effects. DTRA headquarters is located at Fort Belvoir, Virginia, and it also operates field offices worldwide. The DTRA has identified an orthopox therapeutic as a critical need in its ongoing threat reduction efforts.

About the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID):

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program and plays a critical role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

Forward-looking Statements:

This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the safety or efficacy of ST-246 and other potential products, the use of ST-246 as a pox treatment for a wide population, and the human protection from a pox virus potentially provided by the use of ST-246. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products, and (f) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release, are set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.

The information contained in this press release does not necessarily reflect the position or policy of the U.S. government, and no official endorsement should be inferred.



Contact:
SIGA Technologies, Inc.
Dr. Eric A. Rose, 212-672-9100
Chairman and Chief Executive Officer
[e-mail]
or
Cameron Associates
Al Palombo, 212-245-8800 Ext. 209
Investor Relations
[e-mail]

--------------------------------------------------------------------------------
Source: SIGA Technologies, Inc.


mfg

goyauno
http://biz.yahoo.com/bw/070926/20070926006190.html?.v=1

[goyauno]

Hallo Gemeinde, ist denn keiner mehr da????

Langsam nimmt der der Kurs wieder fahrt auf.

Ich bleibe investiert!!!

goyauno

[mrsun]

Antwort auf Beitrag Nr.: 31.942.719 von goyauno am 11.10.07 17:46:14

Hallo goyauno
ich bin noch mit dabei,und mit meiner ersten Position seit 29.09. und zweite Position seit 9.10. steuerfrei.
Kaufkurs 1,58€ und 1,35€.
Bleibe trotzdem weiterhin drin,denn ich habe Zeit.
Lese zur Zeit viel im Yahoo Board mit und versuch mir einen Reim zu machen,ist aber nicht leicht,da ja Siga sehr mit Infos geizt.
Wenn ich was interessantes hätte würde ich es gern mitteilen,ist aber leider nichts fundamentales da.
Also weiter viel Glück und gute Nerven

[goyauno]

Antwort auf Beitrag Nr.: 31.945.971 von mrsun am 11.10.07 20:34:21

Hi mrsun,

schön wieder einmal was von Dir zu hören,
bin auch schon über ein Jahr dabei!!!

Auf einen tiefgrünen Jahresabschluss!!


Viel Glück

goyauno

[mrsun]

SIGA Technologies to Announce Third Quarter 2007 Results of Operations
Company to Host Investor Update Call on November 15, 2007 at 10:00 a.m. Eastern

SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that the company’s senior management will discuss SIGA’s results of operations for the third quarter during a conference call scheduled for Thursday, November 15, 2007, at 10:00 a.m. Eastern. The company’s financial results for the third quarter are scheduled to be released earlier that day.

What: SIGA Technologies, Inc. Investor Update Call

When: Thursday, November 15, 2007, 10:00 a.m. Eastern

Web cast address: http://www.siga.com


Dial-in Numbers: 888-215-7027 (domestic) or 913-312-1486 (international)

Contact: Al Palombo, Cameron Associates, [phone] Ext. 209,
[e-mail]


If you are unable to participate, an audio replay of the call will be available beginning two hours after the call and will be available until 11:59 p.m. on November 22, 2007, by dialing 888-203-1112 (domestic) or 719-457-0820 (international) using replay pass code 4023702.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's Web site at www.siga.com.


SIGA Technologies, Inc.
Dr. Eric A. Rose, 212-672-9100
Chairman and Chief Executive Officer
[e-mail]
or
Cameron Associates
Al Palombo, 212-245-8800 Ext. 209
Investor Relations
[e-mail]




Source: Business Wire (November 8, 2007 - 2:08 PM EST)

[23_2011]

http://biz.yahoo.com/bw/071114/20071114006288.html?.v=1

mfg

[mrsun]

SIGA Chief Scientific Officer, Dr. Dennis Hruby, to Present ST-246 Progress and Human Clinical Safety Study Data to The World Health Organization (WHO)
Representatives from USAMRIID and CDC Also Expected to Present Animal Study Data and Chicago Eczema Vaccinatum Case Study Information

SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced that its Chief Scientific Officer, Dr. Dennis Hruby, will be presenting information regarding the company’s progress in developing its lead drug candidate, ST-246, to the WHO Advisory Committee on Variola Virus Research on November 28, 2007 in Geneva, Switzerland.

Commenting on the WHO presentation, Hruby stated, “This year’s presentation to the WHO is of particular significance to SIGA. In conjunction with our research partners in the United States, we have made substantial strides during the course of the year in the preparation of ST-246 for the approval of a New Drug Application (NDA) from the Food and Drug Administration (FDA). We have also begun the process of regulatory submissions for the European Union as we believe a number of countries in the EU can and will procure ST-246 as part of their own strategic stockpile programs. We plan to parallel track European approval activities with those ongoing with the FDA and expect that our presentation of ST-246 data to the WHO, along with our colleagues from USAMRIID and the CDC, will help update the European regulatory body as to our progress.”

“In the United States smallpox has been declared a material threat of the highest level to our nation’s security. It is an ideal bio-weapon that is easy to grow, easy to spread and does not become symptomatic until more than two weeks after contact, making the potential for global delivery a very real scenario with devastating human health and economic consequences. The importance of this work cannot be underestimated as mass immunizations of the general population using the current live vaccines are not recommended. Available vaccines are known to cause complications in certain individuals, including encephalitis, myocarditis, disseminated vaccinia virus infection, and death. At present there is no approved treatment for smallpox that can be safely administered to the general population without significant risk of adverse reactions,” Hruby concluded.

About SIGA Technologies, Inc.:

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential biowarfare pathogens. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's Web site at www.siga.com.

Forward Looking Statements:

This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary domestic or international governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products and (f) regulatory approval for SIGA’s products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.


SIGA Technologies, Inc.
Dr. Eric A. Rose, Chairman and Chief Executive Officer
212-672-9100
[e-mail]
or
Cameron Associates
Al Palombo, Investor Relations
212-554-5488
[e-mail]




Source: Business Wire (November 26, 2007 - 11:09 AM EST)

News by QuoteMedia

[23_2011]

Antwort auf Beitrag Nr.: 32.439.238 von 23_2011 am 15.11.07 15:51:04

aus dem yahoo board !!!!The big boys don't buy high...they drive the price down!!!
Be patient...good things will happen!!!!


" target="_blank" rel="nofollow ugc noopener">http://www.secform4.com/insider-trading/1010086.htm

mfg

[whyso]

Watch this space



SIGA Completes 21 Day Multi-Dose Human Clinical Safety and Dose-Ranging Trial of Its Lead Smallpox Drug ST-246
Thursday December 6, 8:35 am ET

NEW YORK, Dec. 6, 2007 (PRIME NEWSWIRE) -- SIGA Technologies, Inc. (NasdaqCM:SIGA - News), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced that its lead drug candidate, ST-246, has successfully completed another human clinical trial.

Although the final study report is not yet available, preliminary results indicate that the drug is safe and well-tolerated at all tested doses when administered orally for 21 days to healthy human volunteers. In addition, blood level exposures were dose-dependent, and the levels obtained in the volunteers were the same as those previously shown to protect monkeys from disease and subsequent death in challenge models. Furthermore, the drug's half-life was sufficient to support once-a-day dosing. This data reinforces SIGA's ability to establish that ST-246 will be not only a potent therapeutic drug against smallpox, but a safe and reliable one as well.

``We are very pleased with the results of this second safety study with ST-246. The data obtained here will be an important and helpful part of our full submission for FDA approval,'' said Dr. Eric A. Rose, Chief Executive Officer of SIGA.

The clinical trial, considered a ``Phase I'' trial by the FDA, was performed at the Orlando Clinical Research Center in Orlando, Florida. The study was a double-blind, randomized, placebo-controlled, ascending multiple-dose study in healthy volunteers.

SIGA believes that ST-246 is the most advanced smallpox treatment currently in development. ST-246 represents a new approach to achieve a novel, orally active, antiviral therapeutic. It has demonstrated significant antiviral activity in various animal models of poxvirus disease, including the complete protection of primates from lethal doses of monkeypox and smallpox virus. SIGA will use animal efficacy data as part of its full FDA approval submission under the FDA's ``Animal Efficacy Rule.'' In December 2005, the FDA granted ``fast-track'' status to ST-246. In December 2006, the FDA granted to ST-246 an orphan drug designation.

This project has been funded in whole or in part with Federal funds from the Biomedical Advanced Research and Development Authority, Department of Health and Human Services, in conjunction with the National Institute of Allergy and Infectious Disease, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN266200600014C.

In addition to smallpox, SIGA has antiviral programs targeting other Category A viral pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg).

Ein lieben Gruss an die faithfull,
Whyso

[mrsun]

SIGA CEO, Dr. Eric Rose, Selected to Serve as Member of National Biodefense Science Board
SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced the appointment of the company’s Chief Executive Officer, Dr. Eric Rose, to serve as an inaugural member of the newly formed National Biodefense Science Board (NBSB).

The NBSB was created under the authority of the Pandemic and All-Hazards Preparedness Act, signed into law in December 2006, and chartered in May 2007. The NBSB will provide expert advice and guidance to the Secretary on scientific, technical and other matters of special interest to the Department of Health and Human Services (HHS) regarding activities to prevent, prepare for and respond to adverse health effects of public health emergencies resulting from current and future chemical, biological, nuclear and radiological agents, whether naturally occurring, accidental or deliberate.

The NBSB held its inaugural meetings on December 17 & 18, 2007, in Washington, DC.

Commenting on the nomination, Dr. Rose stated, “It is an honor for me to be asked to serve on a board that seeks to inform and assist HHS in its decision making processes surrounding preparedness and emergency response planning. I look forward to being an active contributor and will bring to bear any experience I can in assisting the board to make positive ongoing advisory contributions to the health and safety of the nation.”

[goyauno]

Hoffentlich wird das neue Jahr besser...........???

Press Release Source: SIGA Technologies, Inc.


SIGA To Present at the 26th Annual JPMorgan Healthcare Conference
Monday January 7, 2:50 pm ET
Dr. Eric Rose to be a Featured Panel Member of JPMorgan's Biodefense & Pandemic Flu Presentation


NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced that its Chief Executive Officer, Dr. Eric Rose, will present an overview of the company’s business activities at the upcoming 26th Annual JPMorgan Healthcare Conference to be held in San Francisco on January 10, 2007 at 12:30 p.m. Pacific time.
ADVERTISEMENT


Dr. Rose has also been invited to participate as a panel member of the JPMorgan Biodefense & Pandemic Flu Presentation, moderated by Ipsita Smolinski, JPMorgan’s healthcare policy research analyst. Keynote speakers at this special session include Dr Rajeev Venkayya, former Special Assistant to the President and Senior Director for Biodefense at the White House National Security Council and Brian Kamoie, Deputy Assistant Secretary at the US Department of Health and Human Services. Both keynotes will speak to the US government’s understanding of the various biological, chemical, radiological and nuclear threats and how they have evolved over time, including the latest on special government programs and awards to counter biothreats and pandemic flu.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential biowarfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA’s Web site at www.siga.com.



Contact:
Investor Relations:
Cameron Associates
Al Palombo, 212-554-5488
[e-mail]

--------------------------------------------------------------------------------
Source: SIGA Technologies, Inc.

http://biz.yahoo.com/bw/080107/20080107006422.html?.v=1

[23_2011]

Antwort auf Beitrag Nr.: 32.973.603 von goyauno am 07.01.08 22:23:40

http://biz.yahoo.com/prnews/080116/new096.html?.v=25

[Uptick08]

I'm in

[23_2011]

Antwort auf Beitrag Nr.: 33.224.061 von Uptick08 am 31.01.08 11:20:35

I´tooo whyso!

[Uptick08]

????

AH stark gestern, frühen handel heute wieder Schwach

Abwarten

[23_2011]

Antwort auf Beitrag Nr.: 33.240.703 von Uptick08 am 01.02.08 16:12:57

ja abwarten und tee trinken

habe gedacht du bist der user whyso, ähnlichen schreibstil und gleiche
aktien


hab bei 2 dollar noch ein paar shares gekauf mal sehen


mfg

[Uptick08]

http://www.uchospitals.edu/pdf/uch_014594.pdf

[goyauno]

Endlich kommt bewegung in die Aktie!!!!!

[mrsun]

Antwort auf Beitrag Nr.: 33.359.264 von goyauno am 13.02.08 19:59:25

hallo goyauno
bin auch noch da,les grad auf yahoo zurück
wird lange über diese nachricht disputiert

SIGA Technologies, Inc.
4575 SW Research Way
Suite 230
Corvallis, OR 97333

Contact: Melissa Lehew
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Web Site: http://www.siga.com

Project Title: Small Molecule Inhibitors of Smallpox Virus Replication
Related Award(s): 1 R43 AI056409-01, 2 R44 AI056409-02 - 06
Technology Developed:
The Phase I SBIR supported development of a validated virus-specific high throughput screening assay to identify specific inhibitors of variola virus. This assay was used to screen a proprietary chemically diverse library of over 400,000 small molecule compounds for inhibitors of orthopoxvirus-induced cytopathic effects. Inhibitor compounds were evaluated for chemical tractability, antiviral potency and spectrum and selectivity as well as activity against authentic variola virus in cell culture (performed through collaborating laboratories). Lead compounds were optimized and mechanism of antiviral action was determined.
The Phase II SBIR supported lead optimization, animal efficacy evaluations, and preclinical development of ST-246 the lead compound identified from the initial screen. This work resulted in a submission of an investigational new drug application (IND) with the FDA to support human clinical development of ST-246 for the treatment of pathogenic orthopoxvirus infections.


Key Words: antiviral, smallpox, ST-246, egress inhibitor, biodefense, high throughput screen.
Uses of Technology/Products/Service:
The primary use of ST-246 is to treat and prevent diseases caused by pathogenic orthopoxvirus infections including smallpox and to prevent side-effects associated with the current smallpox vaccine.
While smallpox is no longer endemic it is considered a formidable biowarfare threat. ST-246 works by preventing egress of extracellular forms of virus thereby, blocking the ability of the virus to spread to other cells. This compound is well-tolerated and has been demonstrated to protect mice, rabbits, ground squirrels, and non-humam primates from lethal orthopoxvirus challenge. The compound is safe and well tolerated in humans with plasma drug exposure levels comparable to those that provide efficacy in animal models of orthopoxvirus disease. The FDA has designated ST-246 for “fast-track” status, creating a path for expedited FDA review and eventual regulatory approval. ST-246 can be used for the following indications:

• prophylaxis: preventing the orthopoxvirus disease in non-vaccinated individuals

• post-exposure therapeutic: treating disease in non-symptomatic people exposed to smallpox virus

• therapeutic: treating those with smallpox symptoms

• adjunct to vaccination: combining with smallpox vaccines to prevent disease and reduce vaccine-related complications.


Benefit to Company:
Prior to initiation of the biodefense-specific RFA, there was little financial incentive to develop therapeutics for biodefense applications. The SBIR program provided the impetus for establishing screening programs to identify inhibitors of category A biodefense pathogens. The success of these screening programs have lead to potential products that have created value through grants, contracts, and partnering opportunities with the ultimate goal of procurement to the Strategic National Stockpile for biodefense products. SBIR funding provided SIGA with the opportunity to utilize in-house expertise to develop a smallpox antiviral to fulfill this critical unmet need.

How Product Was Commercialized:
The primary customer for biodefense antiviral products will be U.S. government, and specifically the Strategic National Stockpile (SNS). In addition, many category A biowarfare agents are endemic and governments investing in public health will also serve as potential markets. Continued collaboration with the NIH and other government agencies involved in the development and procurement of biodefense products is the primary means to commercialize SIGA products.

Other Comments Related to Company's Success Story:
ST-246 is the first drug to demonstrate complete protection against death from variola and monkey pox. In 2007, SIGA was granted an emergency IND to treat a patient suffering from severe eczema vaccinatum with ST-246.

Estimated Future Annual R&D and/or Sales from this Project: $100M

http://grants.nih.gov/grants/funding/sbir_successes/3106.htm

[goyauno]

Antwort auf Beitrag Nr.: 33.359.402 von mrsun am 13.02.08 20:08:08

Hi mrsun,

ich bin ziemlich fest davon überzeugt, dass die FDA ST-246 dieses Jahr noch zulässt und erst dann das US- government das Mittel beschaffen wird.


mfg

goyauno

[mrsun]

Antwort auf Beitrag Nr.: 33.359.660 von goyauno am 13.02.08 20:26:35

hallo goyauno
Die Zulassung wird kommen,es nur eine Frage der Zeit.
ich glaube im Moment wird pauschaliert abgestraft,und da trifft es eine kleine Firma wie SIGA um so härter,die auf Investoren angewiesen ist um zu wachsen.Leider ziehen Diese grade Ihre Gelder überall heraus.
Als Indikator betrachte ich mir da gerne GE oder GD,oder auch Bavarian Nordic unsern Konkurenten.Trotz Auftrag für 20 mil Dosen rutschte der Kurs satte 50%.
Also einfach nur warten an alle Sigianer.

[mrsun]

SIGA to Present at Susquehanna's SIGnificant Options in Healthcare Conference
SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced that its Chief Executive Officer, Dr. Eric Rose, will present an overview of the company’s business activities at the upcoming SIGnificant Options in Healthcare Conference in New York. The presentation will take place at 9:00 a.m., March 4th, 2008 in the Arbor Room of the W Hotel at 49th and Lexington.

For one-on-one investor meetings, please contact your SIG representative directly or Lori Aversano at [e-mail].

Interested parties are invited to listen to a live audio webcast of SIGA’s investor presentation on Tuesday, March 4, 2008 at 9:00 a.m. Eastern Time at the following link: http://www.wsw.com/webcast/sig7/siga/. An archive of the presentation will be available for replay following the conference.

Na da bin ich ja mal gespannt!!!

[mrsun]

Grade frisch reingekommen

SIGA Technologies, Inc. Retains KCSA Strategic Communications as Investor Relations Counsel

Wer das 10-k vom 13.3. genau gelesen hat dürfte mitlerweile drauf gekommen sein,die grants laufen aus.
Hier jetzt die reaktion:

March 17, 2008 - 1:01 PM EDT

SIGA Technologies, Inc. Retains KCSA Strategic Communications as Investor Relations Counsel
SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced it has retained KCSA Strategic Communications to implement a comprehensive investor relations program.

Commenting on the appointment, Eric A. Rose, MD, Chief Executive Officer, said, “This is an exciting time for our Company. We have built an impressive biological warfare defense product portfolio and we look forward to working with KCSA to raise awareness of these agents while communicating our strategy for success to the investment community. We believe KCSA has the resources in place to help convey our unique position in the Biotech and Pharmaceuticals sectors and to support our communications efforts with Wall Street.”

Todd Fromer, managing partner of KCSA Strategic Communications, added, “We are excited to have been selected as SIGA Technologies’ communications partner. The Company presents a compelling story and management has expressed a strong commitment to increase awareness among core constituents. We look forward to providing our integrated services and the full range of our expertise in support of SIGA’s communications initiatives.”

[goyauno]

Antwort auf Beitrag Nr.: 33.664.204 von mrsun am 17.03.08 18:46:34

News..........
hi mrsun,

folgende news, könnten ein meilenstein füe siga bedeuten!

ST-Press Release Source: SIGA Technologies, Inc.


SIGA Files Application Supporting Emergency Use Approval for ST-246
Monday March 24, 8:00 am ET


NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it has submitted to the FDA an application to support an Emergency Use Authorization (EUA) of its drug ST-246, an orally active, smallpox antiviral, to treat individuals exposed to the smallpox virus in the event of an outbreak.
ADVERTISEMENT


The EUA mechanism was created by Congress to enable the FDA Commissioner to authorize the use of a drug that has not been approved, or has not been approved for a particular use, when the nation is in a state of declared emergency. EUA approval is given only to those drugs or products that may be effective in the prevention, diagnosis or treatment of serious or life-threatening diseases or conditions that can be caused by specified biological, chemical, radiological or nuclear agents.

Dr. Eric A. Rose, SIGA’s Chief Executive Officer and Chairman, commented, “Opening a dialogue with the FDA regarding EUA status brings us closer to the opportunity for large-scale production and stockpiling of ST-246 to treat individuals with symptomatic smallpox infection. Based on the success to date of our product candidate in trials, we believe that we have the most advanced smallpox treatment in development, and that ST-246 represents the most effective treatment option should a smallpox threat ever arise.”

Dr. Rose continued, “One year ago we were asked by the CDC to provide a formulation of ST-246 for treatment of a moribund child with eczema vaccinatum, an illness that mimics clinical smallpox. The FDA approved the compassionate emergency use of ST-246 within hours, and the child recovered after receiving ST-246 along with other medications. We believe that in the event of a smallpox outbreak responsible government agencies will also want to provide ST-246 to patients with clinical signs and symptoms, who otherwise would have an estimated mortality rate of 20 to 30%. Over the past year, we have completed additional animal effectiveness and human safety trials which, in the Company’s view, have reasonably defined the adult dose of the drug for this purpose and a safety profile which, we believe, compares very favorably to the natural history of symptomatic smallpox. In addition, we have developed a manufacturing process to create substantial quantities of the drug for stockpiling.”

“If the FDA determines that ST-246 is eligible for an Emergency Use Authorization, it will be a major milestone for our Company, facilitating government acquisition of the drug through Project BioShield. As we understand the BioShield requirements, ST-246 must demonstrate a path to FDA approval. Our EUA submission demonstrates, we believe, that ST-246 is progressing well on this path.” Whether this or any drug receives Emergency Use Authorization is dependent on many factors, and the submission of an application to FDA provides no assurance that the application will be favorably acted upon by the agency.

The ST-246 project has, in part, been funded with Federal funds from the National Institute of Allergy and Infectious Disease and the Department of Defense’s Threat Reduction Agency. The drug has previously shown significant antiviral activity in numerous animal models of orthopoxvirus disease, including the complete protection of primates from lethal doses of monkeypox and smallpox virus.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential biowarfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA’s Web site at http://www.siga.com/.

Forward-looking Statements

This Press Release contains or implies certain ``forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary domestic or international governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce adequate legal protection, including patent protection for its products and (f) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this Press Release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.



Contact:
KCSA Strategic Communications
Todd Fromer, 212-896-1215
[e-mail]
or
Marybeth Csaby, 212-896-1236
[e-mail]
or
David Burke, 212-896-1258
[e-mail]

--------------------------------------------------------------------------------
Source: SIGA Technologies, Inc.

http://biz.yahoo.com/bw/080324/20080324005326.html?.v=1

[mrsun]

Antwort auf Beitrag Nr.: 33.712.079 von goyauno am 24.03.08 13:41:54

hallo goyauno
Grad auf quotemedia gelesen,und siehe da,bin doch nicht ganz alleine.
Schön von Dir zu hören.
Hoffe wir bekommen noch nachträglich ein Osterei ins Nest gelegt.
Bewiesen hat Siga ja bereits letzten Jahres mit der Sondergenehmigung was es kann.
Jetzt wär es an der Zeit alle Zulassungen abzugreifen.
Besonders gefällt mir dieser Satz:

"In addition, we have developed a manufacturing process to create substantial quantities of the drug for stockpiling.”

Das beweist daß die Jungs nicht ganz untätig waren,und den Markt wollen.
Jetzt muß nur noch der Markt Siga wollen.
Bis dahin noch schöne Tage,auch an alle mit investierten.

[goyauno]

Antwort auf Beitrag Nr.: 33.712.308 von mrsun am 24.03.08 14:34:15

Hallo mrsun,

schön das Du noch dabei bist.

Wäre natürlich nicht abgeneigt, noch ein kleines Osterei nachträglich zu bekommen, meine Kinder auch nicht

Nur der Kurs will noch nicht so richtig anspringen.

Wünsche auch Dir und Deiner Familie noch einen schönen Ostermontag, und natürlich eine tief- grüne Woche.

mfg

goyauno

[Uptick08]

das sieht gut aus

http://biz.yahoo.com/bw/080327/20080327005112.html?.v=1

SIGA Successfully Completes ST-246 Multiple Ascending Dose Human Clinical Trial
Thursday March 27, 8:00 am ET
Un-blinded Results Supportive of Previous ST-246 Safety and Efficacy Data

Lets go...

[Uptick08]

Antwort auf Beitrag Nr.: 33.742.799 von Uptick08 am 27.03.08 18:11:49

http://www.thebuylist.com/default.aspx?Stock=siga

3 Buys, no sells

[Uptick08]

Bin seit gestern komplett raus...Rose ist m.E. eine echte Schlaftablettenersatz

Werde im Herbst mal vorbeischauen, viel glück bis dahin

[goyauno]

Also wenn das keine guten news sind!!!

Pressemitteilung Source: SIGA Technologies, Inc. Quelle: SIGA Technologies, Inc.


SIGA Initiates Manufacture of ST-246 NDA Registration Batches SIGA initiiert Herstellung von ST-246 NDA Registrierung Chargen
Friday April 4, 8:00 am ET Freitag 4. April, 8.00 Uhr ET
Final Chemical Formulation Selected for Large-Scale Production Final chemische Formulierung für Large-Scale Production


NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News ), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced the company has initiated the activities necessary to produce the NDA registration batches of its lead smallpox antiviral, ST-246. NEW YORK - (BUSINESS WIRE) - SIGA Technologies, Inc. (NASDAQ: SIGA - News), ein Unternehmen, spezialisiert auf die Entwicklung von pharmazeutischen Wirkstoffen zur Bekämpfung von Krankheitserregern biowarfare und zum Schutz der Bevölkerung, gab heute bekannt, das Unternehmen hat die Aktivitäten erforderlich, um die NDA Registrierung Chargen von seinen Vorsprung Pocken antivirale, ST-246. In recent months, SIGA selected, following consultation with the FDA, the final chemical formulation for large-scale production. In den letzten Monaten, SIGA ausgewählt, nach Rücksprache mit der FDA, die endgültige Formulierung für die chemische großtechnische Produktion. SIGA has also finalized the market image and packaging of the commercial material. SIGA hat auch finalisiert den Markt Bild-und Verpackung der kommerziellen Material.
Dr. Eric Rose, Chief Executive Officer of SIGA Technologies, stated, “ Now that we have submitted to FDA our package supporting emergency use authorization for ST-246 and have successfully completed a multiple ascending dose human clinical safety trial, we are moving to complete the other elements necessary to get full marketing approval. Dr. Eric Rose, Chief Executive Officer von SIGA Technologies, sagte: "Nun, wir haben unser Paket FDA Unterstützung Einsatz für die Autorisierung und die ST-246 erfolgreich abgeschlossen haben, sind ein Vielfaches aufsteigend Dosis menschliche Sicherheit der klinischen Testphase, wir bewegen uns zu kompletten Die anderen Elemente notwendig, um vollständige Vermarktung zugelassen wurde. Scale up of the final formulation is complete, and manufacturing of the registration batches is underway. Scale up der endgültigen Formulierung ist abgeschlossen, und die Herstellung von Chargen ist die Registrierung im Gange. We expect to complete all registration batches of ST-246 in the second half of 2008. ” Wir erwarten den Abschluss der Registrierung der Reihen der ST-246 in der zweiten Hälfte von 2008. "

Dr. Rose continued, “ After several years of research and development, we are extremely satisfied to see the hard work of our team rewarded with yet another step forward in the FDA approval process. Dr. Rose weiter: "Nach mehreren Jahren der Forschung und Entwicklung sind wir sehr zufrieden, um zu sehen, die harte Arbeit unseres Teams belohnt mit noch einen weiteren Schritt nach vorn bei der FDA-Zulassung. Every step we take toward the commercialization of ST-246 is an important, value-driving milestone for SIGA and its shareholders. Jeder Schritt in Richtung nehmen wir die Kommerzialisierung der ST-246 ist ein wichtiger, Wert-Driving Meilenstein für SIGA und seine Aktionäre. Given the success that this drug has demonstrated thus far in our efficacy studies, we believe that ST-246 can be the preferred antiviral option for defending against possible bio-terror and bio-warfare attacks using the smallpox virus. ” Angesichts der Erfolg, dass dieses Medikament hat gezeigt, die bisher in unseren Wirksamkeit Studien sind wir der Meinung, dass die ST-246 kann der antiviralen bevorzugte Option für die Verteidigung gegen mögliche Bio-und Bio-Terror-Krieg Angriffe mit dem Pocken-Virus. "

SIGA has contracted with Albemarle Corporation (NYSE: ALB - News ) to provide its scale-up and manufacturing services to produce three registration batches in anticipation of the upcoming pivotal safety clinical trial. SIGA hat mit Albemarle Corporation (NYSE: ALB - News), um seinen Scale-up und die Herstellung von Dienstleistungen zu produzieren drei Registrierung Chargen im Vorgriff auf die kommende zentrale Sicherheit klinischen Prüfung. In order to obtain FDA marketing approval, SIGA must manufacture “ registration batches, ” which are commercial amounts of ST-246 produced in accordance with the FDA ’ s current standards for good manufacturing practices, sometimes called “ cGMP. ” Im Hinblick auf eine FDA-Zulassung, Herstellung SIGA müssen "Registrierung Chargen," die kommerziellen Mengen von ST-246 produziert im Einklang mit der FDA die aktuellen Standards für Good Manufacturing Practices, manchmal auch als "cGMP."

The project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority, Department of Health and Human Services, in conjunction with the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN266200600014C. Das Projekt wurde finanziert im Ganzen oder in Teilen mit Mitteln aus dem Bundeshaushalt Advanced Biomedical Research and Development Authority, Department of Health and Human Services, in Zusammenarbeit mit dem Nationalen Institut für Allergien und Infektionskrankheiten, National Institutes of Health, Department of Health and Human Services, unter Vertrag Nr. HHSN266200600014C.

In addition to smallpox, SIGA has antiviral programs targeting other Category A viral pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus and the filoviruses (Ebola and Marburg). Zusätzlich zu den Pocken, SIGA hat antivirale Programme für Angriffe auf andere virale Erreger der Kategorie A, einschließlich arenaviruses (Lassa-Fieber, Junin, Machupo, Guanarito, Sabia, und lymphozytäre Choriomeningitis), Dengue-Fieber-Virus und das filoviruses (Ebola-und Marburg).

About SIGA Technologies, Inc. Über SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA Technologies ist die Anwendung der viralen und bakteriellen Genomik und ausgefeilte Computational Modeling in der Konzeption und Entwicklung neuer Produkte für die Vorbeugung und Behandlung von schweren Infektionskrankheiten, mit einem Schwerpunkt auf Produkten für die biologische Kriegführung Verteidigung. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA der Auffassung, dass es sich um ein führendes Unternehmen in der Entwicklung von pharmazeutischen Wirkstoffen zur Bekämpfung von potenziellen Krankheitserregern Bio-Kriegsführung. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). SIGA hat antivirale Programme gezielt Pocken-und andere Erreger der Kategorie A, einschließlich arenaviruses (Lassa-Fieber, Junin, Machupo, Guanarito, Sabia, und lymphozytäre Choriomeningitis), Dengue-Fieber-Virus, und die filoviruses (Ebola-und Marburg). For more information about SIGA, please visit SIGA ’ s Web site at http://www.siga.com/ . Für weitere Informationen über SIGA, besuchen Sie bitte die SIGA 's-Website unter http://www.siga.com/.

Forward-looking Statements Zukunftsgerichtete Aussagen

This press release contains or implies certain “ forward-looking statements ” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the continued development and possible eventual approval of such products. Diese Pressemitteilung enthält oder impliziert gewisse "forward-1995 in der geänderten Fassung, einschließlich der Aussagen in Bezug auf die Wirksamkeit der potentiellen Produkte, die Fristen für die solche Produkte auf den Markt und die weitere Entwicklung Und mögliche spätere Zulassung von solchen Produkten. Forward-looking statements are based on management ’ s estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond SIGA ’ s control. Vorausschauende Aussagen sind Aussagen, die auf der Grundlage der Schätzungen, Annahmen und Prognosen und Unsicherheiten unterliegen, von denen viele außerhalb SIGA 's Kontrolle. Actual results may differ materially from those anticipated in any forward-looking statement. Können die tatsächlichen Ergebnisse wesentlich von denen abweichen, erwartet in den zukunftsgerichteten Aussagen angenommen werden. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce sufficient legal rights in its products, including sufficient patent protection for its products and (f) regulatory approval for SIGA ’ s products may require further or additional testing that will delay or prevent approval. Faktoren, die zu derartigen Abweichungen führen auch die Risiken, dass (a) potenzielle Produkte, die zu viel versprechenden SIGA oder seine Mitarbeiter können nicht angezeigt werden, um wirksam oder sicher in den folgenden präklinischen oder klinischen Studien, (b) SIGA oder seine Mitarbeiter nicht erhalten Angemessen oder notwendig, staatliche Genehmigungen zu vermarkten diese oder andere potenzielle Produkte, (c) SIGA möglicherweise nicht in der Lage zu erwartenden Mittel für die Entwicklung ihrer Projekte oder andere Mittel benötigt, (d) SIGA Mai nicht in der Lage, die Finanzierung zu sichern erwartet von Regierung und Zuschüsse, (e) SIGA möglicherweise nicht in der Lage zu sichern oder durchzusetzen ausreichende Rechte in seinen Produkten, einschließlich ausreichender Patentschutz für ihre Produkte und (f) die Zulassung für SIGA 's Produkte können verlangen, weitere oder zusätzliche Tests, verzögern oder verhindern Genehmigung. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA ’ s filings with the Securities and Exchange Commission, including SIGA ’ s Annual Report on Form 10-K for the fiscal year ended December 31, 2007, and in other documents that SIGA has filed with the Commission. Detailliertere Informationen über SIGA-und Risikofaktoren, die möglicherweise Auswirkungen auf die Realisierung von zukunftsgerichteten Aussagen, darunter die zukunftsgerichteten Aussagen in dieser Pressemitteilung, die in SIGA 's Anmeldungen bei der Securities and Exchange Commission, einschließlich der SIGA' s Annual Report on Form 10-K für das Geschäftsjahr zum 31. Dezember 2007 und in anderen Dokumenten, dass SIGA hat bei der Kommission. SIGA urges investors and security holders to read those documents free of charge at the Commission ’ s Web site at http://www.sec.gov. SIGA fordert Investoren und Wertpapierinhaber zu lesen, diese Dokumente kostenlos bei der Kommission 's-Website unter http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Interessierte Parteien können auch erhalten diese Dokumente kostenfrei von SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the US federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise. Forward-looking statements sprechen, nur an der Tag, an dem sie gemacht werden, und, abgesehen von einer Verpflichtung im Rahmen der US-Wertpapiergesetze, SIGA übernimmt keine Verpflichtung, vorausschauende Aussagen öffentlich zu aktualisieren Aussagen als Folge neuer Informationen, zukünftiger Ereignisse oder aus sonstigen Gründen .



Contact: Kontakt:
KCSA Strategic Communications Todd Fromer, 212-896-1215 [e-mail] or Marybeth Csaby, 212-896-1236 [e-mail] or David Burke, 212-896-1258 [e-mail] KCSA Strategische Kommunikation Todd Fromer, 212-896-1215 oder [e-mail] Marybeth Csaby, 212-896-1236 [e-mail] oder David Burke, 212-896-1258 [e-mail]

--------------------------------------------------------------------------------
Source: SIGA Technologies, Inc. Quelle: SIGA Technologies, Inc.

[mrsun]

Antwort auf Beitrag Nr.: 33.809.746 von goyauno am 04.04.08 14:15:16

hallo goyauno
in der ruhe liegt die kraft,das gilt besonders bei werten mit potenzial.nicht umsonst sagte schon kostolany,kaufen sie sich bluchips wenn sie keiner haben will,nehmen sie dann schlaftabletten,gehn dann für fünf jahre schlafen und schaun dann was passiert ist.
anders mit otc werten oder pinksheets,hier muß getradet werden,mit ein paar ausnahmen.
aber zurück zu siga,hier fügt sich ein puzzleteil zum andern,was uns am montag und die nächsten tage nicht davor schützen wird,
wieder mal ein opfer der shoties zu werden.
ich für meinen teil werde vorsichtshalber nochmal eine kauforder bei 1,9$ reinsetzen.wäre doch gelacht wenn..........
viel glück und erfolg für die nächsten wochen!!!

[goyauno]

Antwort auf Beitrag Nr.: 33.820.119 von mrsun am 06.04.08 14:20:52

Hallo mrsun,

weiter geht´s mit neuen news.........

Press Release Source: SIGA Technologies, Inc.


SIGA Advances ST-246 Smallpox Antiviral Development in Europe
Tuesday April 15, 8:00 am ET
Granted 'Small and Medium Enterprise,' or SME, Status to Support Regulatory Submission Objectives


NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that its subsidiary, SIGA Pharmaceuticals (Europe) Limited, has qualified as a ‘small and medium-sized enterprise’ (SME) with respect to its application for approval of ST-246 in Europe. ST-246 is a smallpox antiviral and SIGA’s lead product candidate. SIGA has also initiated the process for obtaining Marketing Authorization with ST-246 with the EMEA, which is the European equivalent of the United States Food and Drug Administration.
ADVERTISEMENT


The European Agency for the Evaluation of Medicinal Products (EMEA) established SME as a dedicated office in 2005 to provide special assistance to small and medium-sized enterprises. SME provides qualified companies with scientific advice and protocol assistance in the development of new medical products. SME status also entitles SIGA to certain fee reductions or deferrals, including reduced fees for scientific advice and certain administrative services of the EMEA, and a deferral of the fee payable for an application for marketing authorization.

“Obtaining SME status is a significant achievement in our pursuit of European regulatory approval for ST-246. The SME Office works with small companies like SIGA to assist and provide support throughout the application process. We now have access to advice from the EMEA on the approval process for ST-246 that will allow us to expedite many of the procedures during the approval path. SIGA will continue to work closely with the EMEA in the coming months as it moves forward in its efforts to obtain marketing authorization in Europe for ST-246,” Dr. Eric A. Rose, Chief Executive Officer of SIGA Technologies, stated.

In addition, SIGA engaged the SME Office in a pre-submission meeting to discuss development of ST-246 in Europe. The pre-submission meeting with the SME office provided regulatory guidance with respect to the approval process for ST-246 in Europe. SIGA is in the process of scheduling a Scientific Advice Working Party (SAWP) meeting with the EMEA to discuss the development path for ST-246.

Dr. Rose added, “The SAWP meeting will help SIGA construct an appropriate development pathway for ST-246 in Europe since there is currently no European guidance available on development of a drug that cannot be tested for efficacy in human beings due to the lack of a naturally infected population.”

About ST-246

SIGA believes that ST-246 is the most advanced smallpox treatment currently in development. ST-246 represents a new approach to achieve an orally active, antiviral therapeutic. It has demonstrated significant antiviral activity in various animal models of poxvirus disease, including the complete protection of primates from lethal doses of monkeypox and smallpox virus. In December 2005, the FDA granted "fast-track" status to ST-246. In December 2006, the FDA granted to ST-246 an orphan drug designation.

SIGA’s development of ST-246 has been funded in whole or in part with Federal funds from the Biomedical Advanced Research and Development Authority, Department of Health and Human Services, in conjunction with the National Institute of Allergy and Infectious Disease, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN266200600014C.

In addition to smallpox, SIGA has antiviral programs targeting other Category A viral pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg).

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA’s Web site at http://www.siga.com/.

Forward-looking Statements

This press release contains or implies certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the continued development and possible eventual approval of such products. Forward-looking statements are based on management’s estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond SIGA’s control. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce sufficient legal rights in its products, including sufficient patent protection for its products and (f) regulatory approval for SIGA’s products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA’s filings with the Securities and Exchange Commission, including SIGA’s Annual Report on Form 10-K for the fiscal year ended December 31, 2007, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission’s Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.



Contact:
KCSA Strategic Communications
Todd Fromer, 212-896-1215
[e-mail]
or
Marybeth Csaby, 212-896-1236
[e-mail]
or
David Burke, 212-896-1258
[e-mail]

--------------------------------------------------------------------------------
Source: SIGA Technologies, Inc.

http://biz.yahoo.com/bw/080415/20080415005341.html?.v=1

[mrsun]

Antwort auf Beitrag Nr.: 33.888.160 von goyauno am 15.04.08 14:20:40

Hallo goyauno
Mit dieser Meldung hab ich eigentlich nie gerechnet.
Bisher ging ich immer davon aus,daß st-246,finanziert von der Gesundheitsbehörde und dem Millitär,ausschließlich für Bioshild
bereit stehen sollte,aber jetzt haut mich diese Meldung um!!
Ich glaube den meisten ist gar nicht klar was das alles bedeutet.
Eine Zulassung in Europa wäre mit einem Gütesiegel zu vergleichen,
denn was für Übersee gut genug ist,ist es noch lange nicht für Europa.
Und wenn Europa SIGA will,dann steht auch die WHO nicht lange abseits.
Ich denke mal wir sizten hier auf einem Katapult,der nur darauf wartet starten zu dürfen.
Kursziele von 12$ sind dann mal gewesen.
Trotzdem immer locker bleiben und nicht ins Bockshorn jagen lassen.
Auf viel Grün und eine schöne Woche

[goyauno]

Antwort auf Beitrag Nr.: 33.890.696 von mrsun am 15.04.08 18:09:12

hi mrsun,

Bin genauso überrascht wie Du. Auch wenn man nur ein klein wenig Realist sein will, sind die Perspektiven bei Siga, die Zulassung von ST-246 vorausgesetzt ein Hammer!!
Die Pipeline von Siga ist mehr als bemerkenswert.

Liebe Grüsse

goyauno

ps: die jetztigen kurse sind mehr als ein schnäpchen.

[goyauno]

hallo mrsun,

ich habe so ein Gefühl, dass der Deckel sehr bald gesprengt wird.

[mrsun]

Antwort auf Beitrag Nr.: 33.910.541 von goyauno am 17.04.08 17:40:19

hallo goyauno

Für heute nicht schlecht,aber ich glaube wir schließen so um 3,2$.
Solang wir über 3$ bleiben ein gutes Zeichen,denn es sind ein paar Gewinnmitnahmen zu erkennen.
Eine Tendenz ist klar zu erkennen,und die zeigt nach oben.
Die Infopipeline funzt,und die Angst nicht dabei zu sein wächst.

[mrsun]

ich liebe es mich zu irren,aber kann es sein daß es Menschen gibt,die schon wissen was Hruby am Mittwoch für Ergebnisse preiß gibt.
Wir werden´s sehen,hier nochmal die Meldung:

SIGA Technologies, Inc., a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, announced today that its Chief Scientific Officer, Dr. Dennis E. Hruby, is presenting a Distinguished Lecture at the Centers for Disease Control and Prevention (CDC) in Atlanta on Wednesday, April 23, 2008. Dr. Hruby’s presentation, entitled “Discovery and Development of a Smallpox Antiviral Drug,” outlines the progression of SIGA’s anti-orthopoxvirus drug, ST-246, from its discovery in the laboratory through SIGA’s recent filing with the U.S. Food and Drug Administration (FDA) in support of an Emergency Use Authorization (EUA) application for the drug.

Commenting on the CDC presentation, Dr. Hruby stated, “We look forward to having a platform such as this to provide an update on the progress we have made with our ST-246 antiviral. We have recently achieved several milestones that are of significant importance, including the submission of our application supporting an EUA, the completion of our multiple ascending dose human clinical trial and initiating the process of obtaining marketing authorization in Europe. The CDC has a very intimate understanding of the seriousness of the smallpox virus and the threat that it poses to global health safety. We think that this forum will provide those attending with a better understanding of how far we have come in the development of ST-246 and the drug’s capabilities in the event of a smallpox virus release.”

Dr. Hruby will also meet with CDC colleagues to discuss a series of smallpox virus challenge studies in nonhuman primates designed to further define the window of protective efficacy of ST-246. In the past, ST-246 has demonstrated significant antiviral activity against both the monkeypox virus and smallpox virus in primate models of disease.

Dr. Hruby specializes in virology and microbial pathogenesis research, and the use of viral and bacterial vectors to produce recombinant vaccines. He is a member of the American Society of Virology, the American Society for Microbiology and a fellow of the American Academy of Microbiology.

The upcoming smallpox virus challenge studies are of special interest to the CDC and SIGA due to the successful effort by SIGA at CDC’s request to help save the life of a 28-month toddler who had contracted a severe case of eczema vaccinatum (CID, 2008:46), which had arisen as a complication from smallpox vaccine administration. The FDA’s issuance of a compassionate emergency usage approval at CDC’s request allowed the child, who was near death and on the ninth day of hospitalization, to receive ST-246. The child’s prompt recovery suggests that the therapeutic window for ST-246 use may extend beyond the onset of disease symptoms.

[goyauno]

Antwort auf Beitrag Nr.: 33.923.129 von mrsun am 18.04.08 21:28:55

Hallo mrsun,

mir Sicherheit wissen sie mehr, ist auch jedesmal das gleiche Spiel.

Ich konnte nicht wiederstehen und habe mir noch schnell noch ein Shares genehmigt.

Bis Ende dieses Jahres kann ich ja ein großteil steuerfrei wieder verkaufen.

bis die Tage


goyauno

[mrsun]

Antwort auf Beitrag Nr.: 33.923.562 von goyauno am 18.04.08 22:16:52

hallo goyauno
Am Mittwoch muß etwas kommen,sonst seh ich hier wieder Abschläge.
Immerhin kommen wir von 1,8$,und stehn bei 3,6$.
Für Zocker sind das schlappe 100% auf die schnelle.
Wenn dem so sein soll,dann Kohle bereit halten und wieder rein unter 2$.Denn Aufzug fahren kann ich auch.
Also auf eine gute Woche und gute Nerven

[23_2011]

HIER IST MAL WIEDER WAS!!!!

GERADE GESEHEN !!!


http://biz.yahoo.com/pz/080521/143212.html


MFG

[mrsun]

schon gesehen??!!!
Time & Sales
Price Size Exch Time
t 3.57 300 NGS 16:22:16
3.01 5200 NGS 16:00:00
2.96 200 NDD 15:59:50
2.96 200 NGS 15:58:11
2.95 300 NDD 15:56:57
2.95 300 CBW 15:56:56
2.95 100 NGS 15:56:56
2.94 300 NGS 15:56:50
2.94 265 NGS 15:56:50
2.94 100 NGS 15:56:33
2.93 100 NDD 15:54:34
2.93 957 NDD 15:53:45
2.93 343 NGS 15:53:44
2.93 200 NGS 15:53:44
2.93 384 NDD 15:53:14
2.93 416 NGS 15:53:11

dazu eine meinung aus yahoo:

Monday is the deadline 30-May-08 05:19 pm So, Monday, 2 June, is the deadline for comments/rebuttals, etc. for the government's plan to finance Siga's manufacturing set-up for ST-246.

I'm surprised that I've not seen anymore discussion about this. Does anyone have an idea as to when agreement could be achieved on the amount of the grant? Seems I've seen 3 weeks to 3 months. Also, seems there is speculation that the amount could be between $20 and $50 million.

As a side note...I'm an engineer in the chemical industry, and I know that a medium size plant start-up will cost on the order of $100 million, depending. of course, on equipment needs. I'd say that $50 million is a reasonable target, more or less, for ST-246. This is a WAG, based solely on the efficacy of the drug (the amount needed to be manufactured for each pill). I don't know anything about cGMP, though.

Sentiment : Strong Buy

[mrsun]

SIGA rockt!!!!

SIGA Solicitation Number:
BAA-NIH-NIAID-DMID-08-20 Notice Type:
Award Notice Contract Award Date:
September 1, 2008
Contract Award Number:
HHSN272200800041C
Contract Award Dollar Amount:
$55,045,306
Contractor Awarded Name:
SIGA Technologies, Inc.
Contractor Awarded Address:
4575 SW Research Way

Corvallis, Oregon 97333
United States
Synopsis:
Added: Aug 29, 2008 1:48 pm
"ST-246 Smallpox Antiviral: Expanded Utility and Additional Indications"
Contracting Office Address:
Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Office of Acquisitions 6700 B Rockledge Room 3214 MSC7612, Bethesda, MD, 20892-7612, UNITED STATES
Place of Performance:
6700B Rockledge DriveRoom 3105, MSC 7612
Bethesda, MD
20892-7612

[goyauno]

Antwort auf Beitrag Nr.: 34.911.574 von mrsun am 29.08.08 22:27:10

Hi mrsun,

bin doch wirklich überrascht worden!!!

Unsere Geduld wurde doch sehr lange strapaziert.

Das war erst der Anfang.

gruss

goyauno

[mrsun]

Antwort auf Beitrag Nr.: 34.911.792 von goyauno am 29.08.08 22:48:50

Hallo goyauno

kann schon sein,denn anfang dieser woche kam diese meldung

Added: Aug 21, 2008 1:45 pm
This is a Notice of Intent to negotiate with only one source. The U.S. Government intends to acquire for the SNS 500,000 doses of a licensed anthrax vaccine with options to procure up to an additional 14,000,000 doses. Currently there is only one manufacturer who can supply FDA licensed anthrax vaccine: Emergent BioSolutions of Lansing, Michigan.



The Government intends to enter sole source negotiations with Emergent BioSolutions using the authority of 41 USC 253(c)(1). This notice of intent is not a request for proposal (RFP). The Government expects to make one award on or about 9/25/08. The determination by the Government not to compete the proposed contract under full and open competition procedures based upon responses to this notice is solely within the discretion of the Government.



Interested parties may identify their interest and capabilities in response to this notice of intent by submitting a capability statement by 9/5/08 to Michelle T. Gray, Contracting Officer, at [e-mail].



Any additional inquiries or comments to this announcement must reference the synopsis, RFP-DHHS-BARDA-08-26 and should be submitted to Michelle T. Gray.



This proposed acquisition is subject to the availability of funds.


Contracting Office Address:
Biomedical Advanced Research and Development Authority
330 Independence Avenue, SW, Rm G640
Washington, District of Columbia 20201
United States

Place of Performance:
TBD

United States

Primary Point of Contact.:
Michelle T. Gray,
Contracting Officer
[e-mail]
Phone: [phone]
Fax: [phone]

[goyauno]

Antwort auf Beitrag Nr.: 34.911.976 von mrsun am 29.08.08 23:02:38

Hi mrsun,

danke für die news.

Meines Erachtens wird dieser Auftrag die Zulassung seitens der FDA
positiv tangieren. Wobei die Zulassung für ST- 246 erst im kommenden Jahr vorgesehen ist.

gruss

goyauno

[mrsun]

Antwort auf Beitrag Nr.: 34.917.226 von goyauno am 30.08.08 12:20:54

Hallo goyauno
hab grad i-hub gelesen und fand das hier

SIGA,

I just spoke to David Burke of Siga Investor Relations.(1-212-896-1258)

He said that this 55 million dollars is for other indications for ST-246.
He said that this is a huge vote of confidence in the company's drug by the government.

He hopes that the company will issue a PR today on this award.

Manny


also warten wir ob heut noch was kommt

[goyauno]

Antwort auf Beitrag Nr.: 34.952.344 von mrsun am 02.09.08 20:41:02

Hallo mrsun,

die news sind da...........................

Press Release Source: SIGA Technologies, Inc.


SIGA Technologies Awarded $55 Million by Federal Government to Develop Broader Applications for Its Lead Drug Candidate ST-246
Wednesday September 3, 8:00 am ET


NEW YORK, Sept. 3, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NasdaqCM:SIGA - News), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced that it has been awarded a contract of $55 million from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), and The Office of the Biomedical Advance Research and Development Authority (BARDA), within the Department of Health and Human Services, to support development of additional formulations and smallpox-related indications for ST-246, SIGA's lead drug candidate. ST-246 is a potent, non-toxic inhibitor of orthopoxviruses that is in advanced development efforts to obtain regulatory approval.
ADVERTISEMENT


In contrast to SIGA's previously awarded and ongoing $16.5 million ST-246 development contract, this new funding enables the formulation and advanced development of a new ST-246 parenteral drug product as well as new ways to use the existing oral formulation of ST-246 to combat smallpox. Success would significantly enhance the utility of ST-246 and substantially expand the biodefense indications for SIGA's original oral formulation.

Commenting on the contract, Dr. Dennis E. Hruby, SIGA's Chief Scientific Officer and Principal Investigator on the award, stated, ``These funds will support all the studies needed to gain regulatory approval for these new indications. Formulation development, animal efficacy, human safety evaluations, and manufacturing are among the activities needed. We have already developed extensive evidence with respect to the safety and efficacy of ST-246 as a treatment for exposed individuals, and we are excited to see this project advance to include other indications and formulations.''

Commenting on the contract, SIGA's Chief Executive Officer Eric Rose stated, ``This new contract will broaden the use and utility of ST-246 as an orthopoxvirus (e.g., smallpox) countermeasure. It paves the way for ST-246 to provide protection to a much larger portion of the population in the event of a smallpox attack.''

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's Web site at http://www.siga.com/.

The SIGA Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4504

Forward-looking Statements

This press release contains or implies certain ``forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the continued development and possible eventual approval of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond SIGA's control. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (d) SIGA may not be able to secure funding from anticipated government contracts and grants, (e) SIGA may not be able to secure or enforce sufficient legal rights in its products, including sufficient patent protection for its products and (f) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.



Contact:
KCSA Strategic Communications
Todd Fromer
212-896-1215
[e-mail]
Marybeth Csaby
212-896-1236
[e-mail]
David Burke
212-896-1258
[e-mail]


--------------------------------------------------------------------------------
Source: SIGA Technologies, Inc.


Ich wünsche uns auch noch einen schönen Kursverlauf.

gruss

goyauno

[mrsun]

hallo goyauno,schon gesehen?

NIH Funds SIGA Lassa Antiviral Program
NEW YORK, Sept. 15, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that it has received the third year of grant funding for its ongoing Lassa fever antiviral research. This award provides an additional $3,655,000 from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), on top of the $2,089,000 in funding that SIGA has already received from this grant.

Lassa fever is found in West Africa and is endemic in certain areas of this region, where it can be a significant cause of morbidity and mortality. Overall, there are over 500,000 cases reported each year. (For more information on Lassa fever, please visit www.cdc.gov.)

Dr. Sean Amberg, Director of Anti-Infective Discovery at SIGA and Principal Investigator on the grant, stated, "We continue to make progress in our effort to develop ST-193, an antiviral intended for the prevention and treatment of Lassa fever, as well as other Category A arenaviruses such as Junin. The final year of funding from this grant will help to support enabling activities for an investigational new drug application. We believe ST-193 has the potential to be an important drug that one day will help treat many of those afflicted with, or are at risk of contracting, these serious diseases. ST-193 hopefully will also serve as another in our arsenal of tools against biowarfare threats."

Dr. Eric A. Rose, SIGA's Chief Executive Officer, added, "The additional funding received from NIAID affords us the ability to continue to explore the possibilities of ST-193 as a commercialized antiviral for Lassa fever. We believe this is a much needed drug given the severity of the disease and the large number of individuals it affects each year."

Dr. Rose continued, "We have in place an antiviral platform with several promising drugs in development, of which ST-193 and ST-246, our lead product candidate, are just two examples. While these drug candidates are in different developmental stages, results derived from the various sets of data have been encouraging."

SIGA's pipeline of drug candidates consists of antivirals to act against a number of Category A viruses. Included in this pipeline are ST-246 (orthopoxviruses), ST-193 (Old and New World arenaviruses), and ST-294 (New World arenaviruses), along with others in earlier stages of development.

[goyauno]

Antwort auf Beitrag Nr.: 35.117.636 von mrsun am 15.09.08 19:51:20

Hallo mrsun,

danke für die Infos..................

sieht doch klasse aus und sehr vielversprechen.

Noch mehr news..................................

Press Release Source: SIGA Technologies, Inc.


SIGA Technologies to Attend the HHS Public Health Emergency Medical Countermeasures Enterprise Stakeholders Workshop 2008 and BARDA Industry Day
Thursday September 18, 8:00 am ET


NEW YORK, Sept. 18, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NasdaqCM:SIGA - News), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and emerging human health threats, today announced that Dr. Dennis Hruby, SIGA's Chief Scientific Officer, will be attending The HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop 2008 and BARDA Industry Day on September 24th - 26th at the Crystal Gateway Marriott, Arlington, VA.
ADVERTISEMENT


Dr. Hruby will give a presentation discussing SIGA's Discovery and Development of Antiviral Drugs for Biodefense. Included will be a discussion on how SIGA has developed a novel approach to establish the infrastructure necessary to successfully advance new antiviral drugs from the discovery stage on through to licensure.

Commenting on the presentation, Dr. Hruby said, ``The approach that SIGA has taken to develop its antivirals for biodefense is one of collaboration with input and support from many sources including academic, federal, and private sector partners. The success of this model is evident and can best be demonstrated by the rapid progress of our lead antiviral against smallpox, ST-246.''

BARDA Industry day and PHEMCE Workshop provides a forum for a dynamic dialogue on the current state of medical countermeasure preparedness, PHEMCE initiatives in the past year, and plans for moving forward to enhance national capabilities to respond to a public health emergency. The event also provides unique opportunities for biotechnology and pharmaceutical industry representatives to showcase their latest breakthroughs targeting emerging bio-threats. More information on the event can be found at http://www.blsmeetings.net/phemc/workshopoverview.cfm.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's Web site at http://www.siga.com/.

The SIGA Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4504



Contact:
KCSA Strategic Communications
Todd Fromer
212-896-1215
[e-mail]
Marybeth Csaby
212-896-1236
[e-mail]
David Burke
212-896-1258
[e-mail]


--------------------------------------------------------------------------------
Source: SIGA Technologies, Inc.



gruss

goyauno

[mrsun]

Antwort auf Beitrag Nr.: 35.171.151 von goyauno am 18.09.08 16:55:57

hallo goyauno

siga rockt weiter,oder jetzt gehts erst richtig los

SIGA Technologies Receives Additional $20 Million From NIH for ST-246 Antiviral Therapeutic Development
NEW YORK, Sept. 18, 2008 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced that it has received an additional $20 million from the National Institute of Allergy and Infectious Disease (NIAID), a division of the National Institutes of Health (NIH), to accelerate development of ST-246 for a therapeutic indication.

The Office of the Biomedical Advance Research and Development Authority (BARDA), Department of Health and Human Services (HHS), has provided this funding to NIAID to advance research and development of biodefense products such as ST-246. This additional funding will be supplemental funding for SIGA's existing $16.5 million contract and will be used to accelerate process development related to large-scale manufacturing and packaging of the drug and commercial-scale validation.

Commenting on the contract, Dr. Dennis E. Hruby, SIGA's Chief Scientific Officer and Prinicpal Investigator on the award, stated, "Funding provided by this contract brings us one step closer to our goal of commercialization by allowing us to initiate commercial manufacturing of the drug in a timely manner and supporting the operating process. The support that we continue to receive from NIH for research and development of ST-246, we believe, speaks to the urgent need for a smallpox antiviral, as well as the continued success demonstrated by ST-246."

Dr. Eric Rose, SIGA's Chief Executive Officer, continued, "We have made considerable achievements thus far in our R&D efforts with ST-246, and are confident that we are on the right path to bring this drug to market to help prevent or contain the effects of any biological warfare attack using the smallpox virus in the United States or around the world, should the need arise."

[goyauno]

Antwort auf Beitrag Nr.: 35.174.474 von mrsun am 18.09.08 20:10:40

Hallo mrsun,

wir rocken natürlich mit, ein schöner Kursverlauf heute!

[Kleiner Chef]

Siga Technology: Vor Erschließung eines Mrd.-Marktes


A) Zuschüsse durch US-Regierung im Sept. von 80 Mill. Dollar erteilt:

- SIGA Technologies Receives Additional $20 Million From NIH for ST-246 Antiviral Therapeutic DevelopmentGlobeNewswire(Thu, Sep 18)

- NIH Funds SIGA Lassa Antiviral Program – Funds of 3.6 Mill Dollar

- NIH Funds SIGA Dengue Antiviral Program – Funds of 1 Mill. Dollar
Friday September 12, 8:30 am ET

- SIGA Technologies Awarded $55 Million by Federal Government to Develop Broader Applications for Its Lead Drug Candidate ST-246
Wednesday September 3, 8:00 am ET
(NasdaqCM:SIGA - News), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced that it has been awarded a contract of $55 million from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), and The Office of the Biomedical Advance Research and Development Authority (BARDA), within the Department of Health and Human Services, to support development of additional formulations and smallpox-related indications for ST-246, SIGA's lead drug candidate. ST-246 is a potent, non-toxic inhibitor of orthopoxviruses that is in advanced development efforts to obtain regulatory approval.
In contrast to SIGA's previously awarded and ongoing $16.5 million ST-246 development contract, this new funding enables the formulation and advanced development of a new ST-246 parenteral drug product as well as new ways to use the existing oral formulation of ST-246 to combat smallpox. Success would significantly enhance the utility of ST-246 and substantially expand the biodefense indications for SIGA's original oral formulation.

Commenting on the contract, Dr. Dennis E. Hruby, SIGA's Chief Scientific Officer and Principal Investigator on the award, stated, ``These funds will support all the studies needed to gain regulatory approval for these new indications. Formulation development, animal efficacy, human safety evaluations, and manufacturing are among the activities needed. We have already developed extensive evidence with respect to the safety and efficacy of ST-246 as a treatment for exposed individuals, and we are excited to see this project advance to include other indications and formulations.''
Commenting on the contract, SIGA's Chief Executive Officer Eric Rose stated, ``This new contract will broaden the use and utility of ST-246 as an orthopoxvirus (e.g., smallpox) countermeasure. It paves the way for ST-246 to provide protection to a much larger portion of the population in the event of a smallpox attack.''


B) Request for Project für ST 246 steht bevor mit Aussicht auf 3-stellige Mill. Aufträge

- Conference call zum Q2 2008: http://investor.siga.com/events.cfm

- Ein RFP ist das Mittel anhand dessen Barda die Notwendigkeit erklärt ein Produkt, Dienstleistung – also ST-246 – beziehen zu wollen ==>Ausschreibung. Normalerweise ist dem RFP ein RFI vorgeschaltet. Dies entfällt in diesem Falle. Das RFP durch Barda wird veröffentlicht ohne weitere Vorankündigung.

- Barda==> Biomedical Advanced Research and Development Authority
BARDA manages Project BioShield, which includes the procurement and advanced development of medical countermeasures for chemical, biological, radiological, and nuclear agents, as well as the advanced development and procurement of medical countermeasures for pandemic influenza and other emerging infectious diseases that fall outside the auspices of Project BioShield.


- 3-stelliger Mill. Auftrag als Ergebnis der Verhandlungen wahrscheinlich
„We believe that SIGA may begin selling its first product, the smallpox antiviral SIGA-246 and achieve EPS of $1.35 on revenues of $410 million in FY09.“ (http://adventfinancialinc.com/research/SIGA%20Update%2011.pd…

- ST 246 ==>Medikament gegen Pockeninfektionen hat den „Fast-Track-Status“ durch die FDA erhalten sowie den Orphan-Drug-Status. Dieses Medikament steht kurz davor für „Stockpiling“ und „Emergency Use“ genehmigt zu werden.

C) Siga ist bis zum Jahr 2010 durchfinanziert – Markteinführung gesichert

- Conference call zum Q2 2008 über die erteilten Zuschüsse:
Die vorgenannten Zuschüsse sichern Siga finanziell bis ins Jahr 2010 ab und stellt die Ausweitung der Researchstudien für die anderen Medikamente mit dem Ziel weitere Mrd.-Märkte zu adressieren, sicher.

- Grundlage vom Research- zum Kommerzialisierungsstatus geschaffen

Dr. Eric Rose, SIGA's Chairman and CEO, commented, ``During the recent quarter we continued to make important strides in the processes needed to produce ST-246 on a large scale. We continue to maintain a line of communication with BARDA, and are now anticipating a smallpox antiviral RFP. In addition, we have held our initial meeting with the Scientific Advice Working Party in Europe. Working with this team with respect to the quality, safety and efficacy of ST-246 will help to achieve a positive outcome and, hopefully, timely approval in the European Union. These efforts, coupled with gains made in our ability to manufacture this product on a commercial scale, give us great confidence that we have the right momentum needed in order to successfully bring ST-246 to market.“

``Our relationship with BARDA extends beyond the RFP process, and we continue to make progress in securing research funding from their research and development budget. We have multiple grant applications pending and believe there is a substantial likelihood that we will be awarded substantial funding.
In addition, MacAndrews & Forbes LLC, which has been a solid partner to SIGA over the past several years, provided us the option to access $8.5 million in capital during the next year if it becomes necessary. We have the resources we need to move ahead with our work on ST-246 and our other research and development projects.''


D) Fazit: Mrd-Markt wird von Siga kurzfristig mit ST 246 erschlossen

Siga war im Sommer genauso hoch bewertet wie aktuell nach der Vermeldung der Zuschüsse über insgesamt 80 Mill. Dollar. Insgesamt ist Siga bei ca. 35 Mill. ausstehenden Aktien mit 125 Mill. Dollar bewertet. Aussichtsreich wie ich meine bei den ausstehenden Mitteilungen von Barda mit der Wahrscheinlichkeit hieraus Aufträge im 3-stelligen Mill. Dollar Umfang zu erhalten.


Meinungen?

[mrsun]

soso,keiner mehr an Bord,war ja auch lange nichts los,doch wie wär´s damit

BARDA Issues a Presolicitation for Acquisition of a Smallpox Antiviral
SIGA to Host Conference Call Following Full Solicitation

NEW YORK, Feb. 11, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that the Department of Health and Human Services ("HHS") has issued a presolicitation to procure a smallpox antiviral drug that will be added to the Strategic National Stockpile ("SNS"). The request for proposal will seek to procure 1.7 million courses of treatment and may also seek offers to procure as many as 12 million courses.

The United States Government contemplates the award of a five-year, firm-fixed-price contract for medical countermeasures that can specifically provide treatment courses for symptomatic individuals exposed to smallpox.

A request for proposal is expected to be released sometime around February 24th and will call for a development level drug that is in the clinical study phase of the Investigational New Drug (IND) process as well as products that have already received approved therapeutic indications. The contract award resulting from this solicitation will have an estimated award date of September 2009. More information about the conditions set forth under this presolicitation can be found at: https://www.fbo.gov

Dr. Eric A. Rose, SIGA's Chief Executive Officer, commented, "This notice demonstrates a clear commitment by the United States Government to procure the medicines that will help defend the public against a smallpox bioterror attack. We believe that with our clinically advanced smallpox antiviral, we are in a good position to respond to the RFP when it is announced on or around February 24th. We look forward to working with HHS during this process."

The company intends to hold a conference call following the release of the full solicitation, which is expected on or about February 24, 2009. Details of the call will be released in a press release upon the announcement by HHS.

dem Markt scheint´s zu gefallen
lasst mal wieder was hören

[Kleiner Chef]

Antwort auf Beitrag Nr.: 36.559.870 von mrsun am 11.02.09 18:26:32

@mrsun

Sehr ruhig hier, sehe ich auch so. Dabei enthält obige Meldung einen weiteren Meilenstein im Hinblick auf den Auftragseingang von ST 246 für Siga mit: "The request for proposal will seek to procure 1.7 million courses of treatment and may also seek offers to procure as many as 12 million courses."

Nach dem Ausbruch im Chartverlauf, gehe ich nicht davon aus, daß das Ende des Aufwärtstrends bereits erreicht ist!

[mrsun]

Antwort auf Beitrag Nr.: 36.579.469 von Kleiner Chef am 14.02.09 12:12:38

hallo Kleiner Chef
zwei denker,eine meinung
8$ sind bis märz alle mal drin,aber da steckt noch viel
mehr drin.
aber schau dir mal an was bavarian nordic wieder macht.

schöne woche und viel glück

[goyauno]

Guten Abend,

doch, doch, immer noch mit am Bord, nur wie immer wenig Zeit.

Natürlich werden wir noch ganz andere Kurse sehen!!!!!!

Wer lange dabei war, und den Mut hatte zu halten, wird viel freude mit Siga haben.

Anbei ein ein sehr Aufschluss reiches interview aus dem Yahoo Bord.

CQ HOMELAND SECURITY
Jan. 5, 2009 – 4:13 p.m.
Director Expects ‘Banner Year’ at BARDA
By Matt Korade, CQ Staff
The threat of a bioterrorist attack has received renewed focus around the nation’s capital with
the release of the recent report of the congressionally mandated Commission on the Prevention
of WMD Proliferation and Terrorism.
While the commission’s report mentioned the proliferation of high-containment biodefense
research labs as a source of the threat, it gave the research, development and acquisition of
medical countermeasures to lethal pathogens less attention. CQ Homeland Security sat down
with one of the key government officials involved in that effort, Robin Robinson, the first
director of the Biomedical Advanced Research and Development Authority (BARDA), to
discuss the government’s progress in this key area of biodefense.
“We’re dedicated to the mission and we’ve brought in a total of 230 folks to work at BARDA,
many of whom are scientists that are from industry, and they have become dedicated to the
mission,” Robinson said.
Q: BARDA has been ramping up and you’ve been director since spring. What have been
your top priorities?
A: My top priorities have been to realign the CBRN [chemical biological, radiological, and
nuclear] medical countermeasure program to be similar to the pandemic influenza program we
have at BARDA, with a heavy emphasis on advance development of medical countermeasures,
so that we have real products that we are able to acquire in a relatively short period of time,
because we didn’t have the products that were far enough along in development to be able to use
the special reserve fund for <Project> <Bioshield>, to acquire products for the Strategic
National Stockpile.
Q: On the pace of the process in general, <Project> <Bioshield> (PL 108-276) was passed
in 2004 and the Pandemic and All-Hazards Preparedness Act (PL 109-417), which created
BARDA, was enacted in 2006. How would you characterize the countermeasure
development process so far?
A: Thus far for CBRN medical countermeasures, I think that we, as a young organization,
were trying to understand how to approach this and to rethink it. With the PAHPA [Pandemic
and All-Hazards Preparedness Act legislation in 2006, it gave us the authority to do advance
development. I think what was realized at that time was we did not have enough products in the
pipeline to move forward with Bioshield funding. Saying that, in 2008 we have really moved
quite aggressively forward with our advance development, and I think a good example of that
was the seven contracts that were awarded by BARDA in Sept. 2008 on acute radiation
syndrome illnesses, looking at seven different types of products that could be used to treat people
that were exposed to heavy loads of radiation, specifically for neutropenia illness . . . and that
momentum has carried forward. You’ll see in the early part of 2009 . . . more solicitations for
advance development, and we’re now seeing some products making it forward for consideration
for Bioshield funding in early 2009. So I think we’re now aligned the way we should be . . . and
are really minimizing our risk for using the Bioshield funding.
2009 should be a banner year. We can already see that things are going to happen going
forward, because we track these products, companies that are making them, where they are in
development. On the pandemic influenza side . . . what you’ll see very, very shortly is one of
the hallmarks of our program, cell-based influenza vaccine manufacture, which will be the actual
facilities in the United States . . . The other part of that is we have a solicitation out on the
street, [for] which we’ve already received proposals, and I’m very happy to say a large number
of proposals, for new influenza antiviral drugs, to develop these forward toward licensure. And I
think this is key in light of the fact that we’re seeing the human H1N1 virus . . . becoming
resistant to one of the neurominadase antiviral drugs that we have, the Tamiflu drug. So I think
the timing is very good, where we knew this could happen, and we’re already there, trying to
develop these new drugs. We will have these not only for seasonal purposes but also in case of a
pandemic, where we may have a virus that is resistant to what we have in the [national]
stockpile. . . . Fortunately we saw this occurring last year in northern part of Europe and it
moved to South America, in their flu season that just ended, and now we’re already seeing it in
our flu season in the U.S.
Q: The Center for Biosecurity at the University of Pittsburgh Medical Center put out an
analysis of how much it would cost to fund all of the countermeasures to a high degree of
success, and it turned out to be a lot of money. One of the questions that arises, particularly
around budget time, is can we convince the administration and Congress that the risktaking
kind of environment, if we want to make rapid progress, may really cost quite a bit?
In tough economic times, that information is not always welcome. Do you think there’s a
low risk-tolerance among members of Congress, and how can you overcome it, if so?
A: First I must say that the leadership in Congress, both from the Senate and the House side
have been very supportive of the bio-threat development of new products, and . . . that they
continue to be in the administration. And indications from the new administration also is that this
will be a prime initiative to continue forward, as these are really insurance policies that will have
to be deployed, because the bio-threats are not a situation or theoretical . . . they did happen in
2001 and 2002, and the level of threat has not waned, it’s still there. And they’re more
sophisticated than they ever were, so we have to complete the original mission and then also
enhance that effort to stay ahead of the game, so to speak.
Q: So the funding for countermeasures development in 2009 and into the future, has that
been discussed, do you expect it to increase dramatically? I know in 2009 it is expected to
go up by at least $2.2 billion based on the <Project> <Bioshield> authorization, and I also
think BARDA is getting a good amount of money this year.
A: We see that we have very good signs from Congress that the FY09 appropriations will be
what we asked for, and in FY10 we will be going back for the amount of money that we know
that we can execute and move forward with. I think part of it was two-fold: One is, how much
money do we actually have? And two is, I think they’ve been watching us to see how well we’ve
been doing, you know, can we manage this. They don’t want to throw money away, and I believe
that at this point, what they have told me is they have confidence in BARDA, they have
confidence in me and HHS, to execute the mission, and that we have a good path forward, and
just stay on that path and they will provide the appropriate funding as we go forward.
Q: And the Obama transition team, have you been in discussion with them about these
various issues?
A: The leaders at HHS . . . met with the transition team, some of the people were some of the
pioneers in bio-threat analysis and policy, and they understood what we were doing, they were
very complimentary in fact, and it will be a high priority for the new administration, and
Secretary [Tom] Daschle and President-elect Obama.
Q: I saw some information on your Web site that dealt with the number of
countermeasures that are under development or have been contracted out, etc., and I’m
wondering for which threats countermeasures had been successfully developed or are
under development. The one that springs to mind immediately is <anthrax>. I know there
were plans under the PHEMCE [Public Health Emergency Medical Countermeasures
Enterprise] strategic plan to have a second-generation rPA [recombinant protective
antigen] <anthrax> vaccine. How is that moving forward?
A: Specifically with the rPA next-generation <anthrax> vaccine, we are in contract
negotiations, and we hope to be able to award contracts when the protest which is public
knowledge, is lifted, which will be sometime in January.
Q: The rPA vaccine has had some difficulties in the past. Have those difficulties been
overcome?
A: We have studied this quite in depth, in fact, because of the stability problems with the rPA
product from VaxGen, and we feel very confident now that those problems that were
experienced in the past have been overcome; it was a formulation problem . . . and we feel
confident that there are several different candidates out there that will move very quickly
forward, and we’ll be able to provide a really good set of vaccines. Our approach again is not to
have one vaccine but several, so that we can have an infrastructure there and not just depend on
one company.
Q: In addition, in the BARDA roundtable there was talk about the RFI-RFP [request for
information and request for proposals] process, and this was something that some industry
folks talked about last year. They had mentioned that they thought the process was taking
too long, it wasn’t specific enough, and that there wasn’t enough transparency.
A: One of my main goals in 2009, going forward, is that it should not take any procurement
more than nine months, from the time we send the RFP out to the time we award contracts. And
our ultimate goal is to do it in six months, and we’ve been able to accomplish some of those at
the end of 2008. Nothing should go past nine months and we’re going to really work hard to do
that, and we’ve already made some changes to do that. RFIs signal to the industry and to the
public where we’re looking for capabilities. But I assure you, we have our annual stakeholders’
meeting, but we will have meetings on specific medical countermeasure products for specific
threats, say for <anthrax>, for <anthrax antitoxins, [and] we will be holding workshops
specific about that, inviting manufacturers, and industry players, and other stakeholders to come
to those meetings, smaller meetings, and to talk in very specific terms as to what our
requirements are, what our timelines are to go forward, so that you get input as to what they have
in development and how that relates to our requirements. And you’ll see much more . . .
satellite meetings . . . all across the country, so that we can communicate more effectively with
our stakeholders and partners to let them know where we are. Again the strategic plan will be the
roadmap going forward as we do these workshops on a regular basis.
Moving the process forward is just one aspect; smaller, very specific workshops is the second
[thing]; and then the third one is that I go out to industry all the time. I probably see as many as
20 companies a month, and I go out to probably two or three to talk to them about where they are
and so forth. The last [thing] is that we want to make these products better. We want to have
greater stability, greater effectiveness, so they have broader reach. And so we will have, starting
in 2009, an innovation piece: How can we make products or the manufacturing process for these
products better? Not to invent them, not to come up with new ones – there’s funding for that at
the NIH and other places, DARPA for example -- but [to] make these products better. For
example, if you have medication that’s provided by injection, can you provide it orally? Can you
make the product instead of a stability/shelf life of two years, maybe make it four, or six, or eight
years? Instead of having three doses, three injections, how about one injection? Those are very
meaningful things that not only drive down the cost but also make the product much better all the
way around. So we’re going to be driving hard on that, the innovation, in 2009.
Q: I know there’s the big project going on at Fort Detrick to build the biomedical
research center there, which should foment a lot of interagency discussion about what
countermeasures are needed and bring a lot of different stakeholders into the process. How
is that expected to help this countermeasures process?
A: The administration, the Homeland Security Council led by Dr. Bob Kadlec, introduced and
we adopted and have implemented an initiative called the one-portfolio approach, primarily with
the Department of Defense and HHS, but there are other players, including the Veterans
Administration, Homeland Security Department, and Department of Agriculture. That initiative
specifically coordinates the development of medical countermeasures for bio-threats, and
chemical, radiation and nuclear threats, for the U.S. governmentwide, and also the stockpiling of
those products, which we were doing already, but it was not on a very formal basis. . . . This
now formalizes that, that we work together, coordinating our research and development so that
we are synergistic as opposed to overlapping when it’s not really necessary [to do so], and then
building on what we’re doing, so that many of the products they have – [for example] a DARPA
[product] coming up through the pipeline can maybe make it through BARDA, in fact, for the
civilian population, or through other parts of the Department of Defense for the military
population. So we coordinate that, and then, again, [the process allows us] to increase the list of
products that we share in our stockpiles. That way we get a better price and have more leverage
with the manufacturers in our requirements. So I think we’re seeing a very big change, instead of
stovepipe silos everywhere.
Matt Korade can be reached at [e-mail].

mfg

goyauno

[mrsun]

Hallo Sigianer

Heute keine weltbewegende Meldung,verträglichkeit mit Acambis´
smallpox vaccine.
Wer aber aufgepasst hat kann mehr erkennen,siehe Auftrag Acambis
vom letzten Jahr

RNS Number:9020S
Acambis PLC
23 April 2008


$425m, ten-year ACAM2000(TM) smallpox vaccine contract awarded to Acambis by US
Government

Cambridge, UK and Cambridge, Massachusetts - 23 April 2008 - Acambis plc
(Acambis) (LSE: ACM) announces that it has been awarded a $425m (c. £212m),
ten-year contract by the US Government agency, the Centers for Disease Control
and Prevention (CDC), to provide it with a warm-base manufacturing capability
for Acambis' ACAM2000(TM) smallpox vaccine. Warm-base manufacturing entails the
maintenance of an ongoing production readiness capability through annual
production runs.

Under the terms of the contract, Acambis will:

•Establish a US-based manufacturing capability for ACAM2000(TM);
•Deliver against CDC orders for a minimum of nine million doses per annum
for the eight years from year three to year ten of the contract; and
•Undertake activities to maintain its product licence.

Acambis developed ACAM2000(TM) under a contract with the CDC and has already
delivered more than 195 million doses of this vaccine to the CDC for the US's
Strategic National Stockpile. Doses are also being supplied by the CDC to the
Department of Defense, which has transitioned over to ACAM2000(TM) for routine
vaccination of military, emergency-essential and equivalent civilian employees.

Acambis will establish a US-based manufacturing capability by transferring the
ACAM2000(TM) production process to Acambis' facilities in Canton, MA and
Rockville, MD. Previously, elements of the process were conducted outside the US
or by third-party contractors.

The CDC will procure at least nine million doses of ACAM2000(TM) a year in
contract years three to ten. The structure of the contract allows the CDC to
purchase up to 39 million doses in contract years five to ten, should the need
arise. This would increase the headline value of the contract to around $660m.
For the dose-delivery activities, Acambis will receive payment on a fixed-price
basis.

In addition, Acambis will undertake licence maintenance activities throughout
the life of the contract on a cost-plus-fixed-fee basis. In the initial years,
this includes conducting a Phase 4 study in US military personnel, establishing
an enhanced surveillance programme and myocarditis registry to monitor the
safety profile of the vaccine, and undertaking a bridging trial to support a
licence amendment for transfer of bulk production to its Canton, MA facility.

Of the $425m (c. £212m) revenues, approximately two-thirds relates to the
delivery of doses in contract years three to ten, and one-third to licence
maintenance activities.

Ian Garland, Chief Executive Officer of Acambis, said:

"We are delighted to be awarded this contract by the CDC, which marks the
achievement of one of Acambis' major corporate goals. It is highly satisfying to
know that, following eight years' collaboration with the CDC to develop
ACAM2000(TM), this core part of the US Government's defence against smallpox has
been secured by Acambis for the long term."


-ends-

[goyauno]

Guten Tag, die news sind da.............

und das ist erst der Anfang.

Press Release Source: SIGA Technologies, Inc.
SIGA to Respond to Barda's Request for Proposal Seeking 1.7 Million Courses of Smallpox Antiviral
Company to Hold Conference Call Today At 10:00 am EDT
Thursday March 12, 2009, 9:36 am EDT
Buzz up! Print Related:SIGA Technologies Inc.
NEW YORK, March 12, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NasdaqCM:SIGA - News), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced its intent to respond to the government's Request for Proposal (RFP) with respect to the procurement of 1.7 million courses of medical countermeasures that can specifically provide treatment courses for symptomatic individuals exposed to smallpox. The RFP indicates that up to 12 million courses may be procured. SIGA believes its smallpox antiviral drug candidate ST-246(r) is strongly and uniquely positioned to meet the RFP's specifications.

Related Quotes
Symbol Price Change
SIGA 5.20 +0.46


{"s" : "siga","k" : "c10,l10,p20,t10","o" : "","j" : ""} The Biomedical Advance Research and Development Authority (BARDA), an office within the Department of Health and Human Services (HHS) and the agency responsible for the RFP, has indicated that awards under this proposal would be granted in September 2009 to a single vendor. The RFP calls for a response via a statement of intent which is due by April 10, 2009, with the full proposal due by April 30, 2009. BARDA will hold a preproposal conference on or about March 31, 2009 to further discuss the RFP and help guide those companies that expect to respond.

The United States Government contemplates the award of a five-year, firm-fixed-price contract for a drug product on a sliding scale for volumes up to 2 million courses and multiple breakpoints up to 12 million. The antiviral would be required to have at least a 36-month shelf-life.

There are also clearly stated optional interests in the RFP for a ``warm production'' capacity; an intravenous formulation; an oral suspension for both children and elderly adults; and pursuit of post-exposure prophylaxis.

In addition, BARDA would also monitor the antiviral as it moves along the FDA approval path and would require the company awarded the contract to implement an FDA Phase IV monitoring plan. The RFP also notes that the company awarded the contract would also receive funds for non-fixed pricing for factors like physical and informational security of the company and its suppliers.

Among the requirements in the RFP are that the purchased drug must have shown satisfactory results following both variola and lethal monkeypox challenges in non-human primates. SIGA believes that it is the only company that can meet this requirement.

Any award on the RFP would be subject to negotiation of final contract terms and specifications. Once final negotiations are completed, BARDA will issue a formal Notification of Award. It is anticipated that the RFP award will provide a commitment to purchase additional amounts of the antiviral following the initial procurement of 1.7 million courses.

Dr. Eric A. Rose, SIGA's Chief Executive Officer, commented, ``Release of this RFP is a transformational step for SIGA that we view as firm confirmation that our future as a company is in plain sight and within our grasp. We will be working diligently over the next few weeks to make our view a reality. We anticipate that this is the beginning of what we hope will be the first of several government contracts for the purchase of multiple formulations of ST-246(r), our smallpox antiviral, for multiple indications. Finding an antiviral for smallpox has been a high priority for the U.S. government in its effort to defend the country and the world against the mortality, morbidity, and potentially devastating social and economic consequences of a smallpox bioterror attack.

``SIGA will continue to pursue full FDA approval for ST-246(r) even as it responds to the Bioshield RFP. Full approval, if received, would open the door for stockpiling of ST-246(r) by corporations for employee use and should ease the path to international approvals and sales.''

Dr. Dennis E. Hruby, SIGA's Chief Scientific Officer, stated, ``The years we have spent developing ST-246(r) have been well-worth the effort. The support that we have received from BARDA, the NIH and the military has been instrumental in the advancement of ST-246(r). We will continue to collaborate with the U.S. government to develop ST-246(r) for use as a prophylaxis and in creating additional formulations. We will also continue to develop our pipeline of drug candidates, as we believe ST-246(r) is just the beginning of what we can accomplish in the development of agents to defend against serious viral pathogens like Dengue and Lassa fevers.''

The RFP was issued under Project BioShield, a program administered by BARDA that is intended to encourage the development and procurement of medicines that can protect the population of the United States against chemical, biological, radiological and nuclear attacks. Project Bioshield permits BARDA to purchase both approved drugs and drugs that are within eight years of FDA approval. Smallpox has long been considered one of the leading biowarfare agents even though it has been eradicated from the natural environment, and there is no approved antiviral available against smallpox. SIGA's ST-246(r) has proven effective against orthopox virus infections, including smallpox, in several animal models, and has also done well in all human safety trials to date. SIGA believes that ST-246(r) is the most advanced smallpox antiviral in development.

Conference Call:

Participants should call 877-741-4248 (United States/Canada) or 719-325-4750 (International) and request the SIGA Technologies call or utilize the confirmation code 4232923. A live broadcast of the conference call will also be available via the Internet at http://www.SIGA.com. During the call, there will be a question-and-answer session open to analysts and institutional investors.

If you are unable to participate, an audio replay of the call will be available beginning two hours after the call and will be available until 11:59 p.m. on Tuesday, March 24, 2009, by dialing 888-203-1112 (domestic) or 719-457-0820 (international) using replay pass code 4232923. The webcast of the event will also be archived on the Company's website for one year.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's Web site at http://www.siga.com/.

The SIGA Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4504

Forward-looking Statements

This press release contains or implies certain ``forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the continued development and possible eventual approval of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond SIGA's control. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (i) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (ii) SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (iii) SIGA may not be able to obtain anticipated funding for its development projects or other needed funding, (iv) SIGA may not be able to secure funding from anticipated government contracts and grants, (v) SIGA may not be able to secure or enforce sufficient legal rights in its products, including sufficient patent protection for its products, (vi) regulatory approval for SIGA's products may require further or additional testing that will delay or prevent approval, (vii) the Biomedical Advanced Research & Development Authority may not complete the procurement set forth in its solicitation for the acquisition of a smallpox antiviral for the strategic national stockpile, or may complete it on different terms; (viii) SIGA's proposed drug candidate for responding to any governmental solicitation for purchase may not meet the requirements of the solicitation; (ix) the volatile and competitive nature of the biotechnology industry may hamper SIGA's efforts, (x) changes in domestic and foreign economic and market conditions may adversely affect SIGA's ability to advance its research or its products, and (xi) changing federal, state and foreign regulation on SIGA's businesses may adversely affect SIGA's ability to advance its research or its products. More detailed information about SIGA and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2008, and in other documents that SIGA has filed with the Commission. SIGA urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov. Interested parties may also obtain those documents free of charge from SIGA. Forward-looking statements speak only as to the date they are made, and, except for any obligation under the U.S. federal securities laws, SIGA undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.

Contact:
KCSA Strategic Communications
Todd Fromer
212-896-1215
[e-mail]
Marybeth Csaby
212-896-1236

[Kleiner Chef]

Siga: Die Story zur Erschließung eines Mrd. Marktes wird rund!


- Final FDA Study for ST 246 starts in June 2009
- This study will enroll ~112 male and female subjects to whom either ST-246 (400 or 600mg) or placebo will be given for 14 days. SIGA will be assessing the safety, tolerability and pharmacokinetics of ST-246.
- The study will be finished in December 2009

Quelle und weitere Infos:

http://clinicaltrials.gov/ct2/show/NCT00907803?term=siga&ran…

[goyauno]

Antwort auf Beitrag Nr.: 37.260.071 von Kleiner Chef am 27.05.09 10:19:44

Und noch ein neues 52 Wochen hoch..............

Und die pipeline von Siga sieht sehr gut aus.

mfg